



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 261/14, 261/08, 413/12, 417/12, 413/14, A61K 31/42</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/47880 (43) International Publication Date: 29 October 1998 (29.10.98)</p>
<p>(21) International Application Number: PCT/JP98/01770 (22) International Filing Date: 17 April 1998 (17.04.98) (30) Priority Data: 9/118871 21 April 1997 (21.04.97) JP 9/367154 24 December 1997 (24.12.97) JP (71) Applicant: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP/JP); 2-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8510 (JP). (72) Inventors: NAKATSUKA, Masashi; 3-2-4-807, Yamazaki, Shimamotocho, Mishima-gun, Osaka 618-0001 (JP). UENO, Yoshihide; 2-3-37-112, Matsuzakicho, Abeno-ku, Osaka-shi, Osaka 545-0053 (JP). OKADA, Shin-ichiro; 2-17-18, Okutenjincho, Takatsuki-shi, Osaka 569-1118 (JP). NISHIKAKU, Fumio; 1-21, Sakuragaoka 5-chome, Itami-shi, Hyogo 664-0897 (JP). (74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Ohtemachi Building, 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo 100-0004 (JP).</p>		<p>(81) Designated States: CN, ID, KR, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: ISOXAZOLE DERIVATIVES</p>		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(1)</p> </div> <div style="text-align: center;">  <p>(a)</p> </div> </div>		
<p>(57) Abstract</p> <p>An isoxazole derivative represented by formula (1): [wherein D is a hydrogen atom, a halogen atom, a hydroxyl group or the like; one of A and B is a group represented by formula (a): (wherein E is a single bond or an alkylene group, one of the two broken lines represents a double bond together with the solid line, while the other represents a single bond together with the other solid line. R¹ is bonded to the nitrogen atom bonded through the single bond represented by the broken line and the solid line, and R¹, R², R³ and R⁴ are independently a hydrogen atom, a halogen atom, a hydroxyl group or the like); and the other of A and B is a group represented by the formula: -J-G (wherein G is a substituted or unsubstituted aryl group or the like, and J is -C(R⁸R⁹)- or -C(=CR⁸R⁹)- (wherein R⁸ and R⁹ are independently a hydrogen atom, a substituted or unsubstituted lower alkoxy group, or the like))] or a pharmaceutically acceptable salt thereof is useful as, for example, a therapeutic drug for autoimmune diseases, inflammatory diseases, etc.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

ISOXAZOLE DERIVATIVES

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U. S. Provisional Application No. 60/048,757 filed on June 3, 1997.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to isoxazole derivatives useful as, for example, therapeutic drugs
5 for autoimmune diseases, inflammatory diseases, etc.

Description of the Related Art

Acidic nonsteroidal anti-inflammatory drugs or steroidal drugs have been used as therapeutic drugs for inflammatory diseases but are limited in their use
10 because of their side effects. In addition, treatments using such drugs, despite their ability to ameliorate symptoms cannot remove the fundamental cause of the diseases. With the progress of elucidation of the pathophysiology of autoimmune diseases such as rheumatoid
15 arthritis accompanied by serious inflammation, it has been suggested that an immune system disorders are deeply concerned in the onset of inflammation, its progression and maintenance of a chronic state. For these reasons,

drugs capable of modifying the diseases by acting on the immune system, such as gold compounds and D-penicillamine have been noted as drugs for causal treatment. They, however, are not always satisfactory because of their
5 side effects and deficiency in lasting efficacy.

On the other hand, isoxazole derivatives having various biological activities have been reported. For example, Japanese Patent Unexamined Publication No. 63-152368 reports aralkyl 5-membered
10 heterocyclic compounds including isoxazole derivatives, as therapeutic drugs for autoimmune diseases, inflammation, allergy, asthma, etc. German Patent No. 2847792 reports quinolylylguanidine derivatives including isoxazole derivatives, as anti-inflammatory, analgesic
15 and antipyretic drugs. J. Med. Chem. 21, 773(1978) reports that N-cyano-N'-isoxazolylylguanidine derivatives are effective as hypotensive drugs.


Therapeutic drugs for autoimmune diseases should be clearly effective against chronic inflammation
20 which induces tissue destruction. Moreover, it is important for them to have inhibitory effect on an immune system disorders responsible for the diseases, as a drug for radical treatment. In addition, the therapeutic drugs for the diseases should have little
25 adverse side effect because they often require long-term administration.

The present invention is intended to provide a compound useful as a therapeutic or prophylactic drug

for solving the above-mentioned problems, and consequently found that isoxazole derivatives have marked immunomodulating and anti-chronic-inflammatory effects and have little side effect, whereby the present
5 invention has been accomplished.

That is, the present invention is as follows.

[1] An isoxazole derivative represented by the formula 1:




wherein D is a hydrogen atom, a halogen atom, a
10 hydroxyl group, a mercapto group, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxyl-amino group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a
15 sulfo group, $-R^5$, $-OR^5$, $-CO_2R^6$, $-SR^7$, $-(CO)SR^7$, $-(CS)OR^7$ or $-CS_2R^7$ wherein R^5 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a
20 substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, or an acyl group, R^6 is a substituted or unsubstituted alkyl group, a

substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, or an acyl group,

5 R^6 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and R^7 is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group;

one of A and B is a group represented by the formula:



wherein E is a single bond or an alkylene group;

15 one of the two broken lines represents a double bond together with the solid line, while the other represents a single bond together with the other solid line. R^1 is bonded to the nitrogen atom bonded through the single bond represented by the broken line

20 and the solid line; and

R^1 , R^2 , R^3 and R^4 are independently a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted

or unsubstituted hydroxylamino group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a sulfo group, a protecting group for NH group, $-R^5$, $-OR^5$, $-CO_2R^6$, $-SR^7$,
5 $-(CO)SR^7$, $-(CS)OR^7$ or $-CS_2R^7$ wherein R^5 , R^6 and R^7 are as defined above, any two of R^1 , R^2 , R^3 and R^4 may be taken together with the nitrogen atom(s) to form a substituted or unsubstituted heterocyclic ring; and the formula: $-NR^3R^4$ may be a group represented by the
10 following formula: $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined in (1) or (2)

(1) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms;
 $-(CH_2)_n-COCH_3$ wherein n represents an integer of 1 to 3;
15 $-(CH_2)_n-CO_2R^{32}$ wherein n is as defined above and R^{32} represents an alkyl group having 1 to 3 carbon atoms;
 $-(CH_2)_n-CONR^{33}R^{34}$ wherein n is as defined above and R^{33} and R^{34} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms; $-(CH_2)_m-OR^{35}$ wherein m
20 represents 2 or 3 and R^{35} represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms or $-(CH_2)_m-OR^{36}$ wherein m is as defined above and R^{36} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; $-(CH_2)_m-NR^{37}R^{38}$ wherein m is as defined above and
25 R^{37} and R^{38} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms, or when taken together with the nitrogen atom, represent pyrrolidine, piperidine, azepane, morpholine or N-methylpiperazine

wherein said pyrrolidine, piperidine, azepane, morpholine and N-methylpiperazine may be substituted with one or two methyl groups; a phenyl group; a pyridyl group; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} represent independently hydrogen atoms, alkyl groups having 1 to 3 carbon atoms, phenyl groups or pyridyl groups;

(2) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; and the other of A and B is a group represented by the formula: $-J-G$

wherein G is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; J is $-C(R^8R^9)-$ or $-C(=CR^8R^9)-$ wherein R^8 and R^9 are independently a hydrogen atom, a substituted or unsubstituted lower alkoxy group, or a substituted or unsubstituted lower alkyl group; R^8 and R^9 may be taken together with the carbon atom to form a substituted or

unsubstituted hydrocarbon ring, a substituted or unsubstituted 1,3-dioxane, or a substituted or unsubstituted 1,3-dioxolane, or a pharmaceutically acceptable salt thereof.

5 [2] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to [1], wherein E is a single bond or a lower alkylene.

[3] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to [1] or [2], wherein
10 D is a hydrogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted carbamoyl group, -R⁵ or -CO₂R⁶ wherein R⁵ and R⁶ are as defined above.

15 [4] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to [3], wherein D is a hydrogen atom, a carboxyl group, -R⁵ or -CO₂R⁶ wherein R⁵ and R⁶ are as defined above.

[5] An isoxazole derivative or a pharmaceutically
20 acceptable salt thereof according to any of [1] to [4], wherein R¹, R², R³ and R⁴ are independently a hydrogen atom, a hydroxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxyl-amino group, a substituted or unsubstituted alkoxy
25 group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or

unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; and the formula: $-NR^3R^4$ may be a group represented by the following formula:

- 5 $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined above; or any two of R^1 , R^2 , R^3 and R^4 may be taken together with the nitrogen atom(s) to form a substituted or unsubstituted heterocyclic ring.


[6] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to [5], wherein R^1 , R^2 , R^3 and R^4 are independently a hydrogen atom, a hydroxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, or a substituted or unsubstituted cycloalkyl group; and the formula: $-NR^3R^4$ may be a group represented by the following formula:

- 20 $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined above; or any two of R^1 , R^2 , R^3 and R^4 may be taken together with the nitrogen atom(s) to form a substituted or unsubstituted heterocyclic ring.

[7] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to any of [1] to [6], wherein G is a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, a substituted or unsubstituted furyl, a substituted or

unsubstituted thienyl, a substituted or unsubstituted
indolyl, a substituted or unsubstituted isothiazolyl, a
substituted or unsubstituted benzothienyl, a substituted
or unsubstituted isobenzofuranyl, a substituted or
5 unsubstituted pyrrolyl, a substituted or unsubstituted
benzofuryl, a substituted or unsubstituted imidazolyl, a
substituted or unsubstituted pyrazolyl, a substituted or
unsubstituted isoxazolyl, a substituted or unsubstituted
isothiazolyl, a substituted or unsubstituted thiazolyl, a
10 substituted or unsubstituted oxazolyl, a substituted or
unsubstituted benzimidazolyl, a substituted or unsub-
stituted benzothiazolyl, a substituted or unsubstituted
benzoxazolyl, a substituted or unsubstituted pyridyl, a
substituted or unsubstituted pyrazinyl, a substituted or
15 unsubstituted pyrimidinyl, a substituted or unsub-
stituted pyridazinyl, a substituted or unsubstituted
triazinyl, a substituted or unsubstituted quinolyl, a
substituted or unsubstituted isoquinolyl, a substituted
or unsubstituted quinazolinyl, a substituted or
20 unsubstituted quinoxalinyl, a substituted or
unsubstituted 2,3-dihydrobenzo[1,4]dioxinyl, or a
substituted or unsubstituted carbazolyl.

[8] An isoxazole derivative or a pharmaceutically
acceptable salt thereof according to [1], which is
25 represented by the formula:



- wherein G¹ represents phenyl, biphenyl-4-yl, 3-benzoylphenyl, 4-benzoylphenyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-indol-2-yl, 1-methyl-1H-indol-3-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, quinolyl, isoquinolyl, phen-ylpyridyl, phenylpyrimidinyl, phenylpyridazinyl or phen-ylpyrazinyl wherein said phenyl, biphenyl-4-yl, 3-benzoylphenyl, 4-benzoylphenyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-indol-2-yl, 1-methyl-1H-indol-3-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, quinolyl, isoquinolyl, phenylpyridyl, phenylpyrimidinyl, phenylpyridazinyl and phenylpyrazinyl may be substituted with one or two groups arbitrarily selected from the group consisting of fluorine atom, chlorine atom, bromine atom, acetyl, cyano, -CO₂R²⁹ wherein R²⁹ represents an alkyl group having 1 to 3 carbon atoms and -CONR³⁰R³¹ wherein R³⁰ and R³¹ represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms;
- R²³ and R²⁴ represent independently hydrogen atoms, alkyl groups having 1 to 4 carbon atoms, methoxy or ethoxy, or when taken together, form a methylene group; and the formula: =C(NR²⁵R²⁶)NR²⁷R²⁸ is as defined in the

following (1), (2) or (3):

(1) R^{25} and R^{26} are as defined in the following (a) or (b) and R^{27} and R^{28} are as defined in the following (c) or (d):

- 5 (a) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms; $-(CH_2)_n-COCH_3$ wherein n is as defined above; $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above; $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined;
- 10 $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above; $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above; a phenyl group; a pyridyl group; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a
- 15 pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;
- 20 (b) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing group may be substituted with one or two substituents arbitrarily
- 25 selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;
- (c) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms;


$-(CH_2)_n-COCH_3$ wherein n is as defined above; $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above; $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above; $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above; $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above; a phenyl group; a pyridyl group; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

(d) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

(2) when taken together, R^{26} and R^{27} form with the two nitrogen atoms and the one carbon atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group,

alkoxy group and oxo group; and R^{25} and R^{28} represent independently hydrogen atoms, alkyl groups having 1 to 3 carbon atoms, acetyl or $-(CH_2)_m-OR^{36}$ wherein m and R^{36} are as defined above;

- 5 (3) the formula: $=C(NR^{25}R^{26})NR^{27}R^{28}$ is a group represented by the following formula:




- wherein R^{41} and R^{42} are as defined in the following (a') or (b'); and R^{43} and R^{44} are as defined in the following
10 (c') or (d'):

- (a') each represents independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein
15 n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a tetrazolyl group, a benzyl group, a
20 pyridylmethyl group, a pyrimidinylmethyl group, a pyridazinylmethyl group, a pyrazinylmethyl group, a tetrazolylmethyl group, a hydroxyl group, an alkoxy group having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

- 25 (b') when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group

may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

- 5 (c') each represents independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n, R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ 10 wherein m and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m, R^{37} and R^{38} are as defined above, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a tetrazolyl group, a benzyl group, a pyridylmethyl group, a 15 pyrimidinylmethyl group, a pyridazinylmethyl group, a pyrazinylmethyl group, a tetrazolylmethyl group, a hydroxyl group, an alkoxy group having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above; (d') when taken together, they form with the 20 nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino 25 group, hydroxyl group, alkoxy group and oxo group; or represented by the formula:



wherein G^1 , R^{23} and R^{24} are as defined above; the formula:
 $-N(R^{45})C(NR^{46}R^{47})=NR^{48}$ is as defined in the following (1')
 or (2'):

(1') R^{45} represents an alkyl group having 1 to 3
 5 carbon atoms or an acetyl group; R^{48} represents a
 hydrogen atom, an alkyl group having 1 to 3 carbon atoms
 or an acetyl group; and R^{46} and R^{47} are as defined in the
 following (a") or (b"):

(a") each represents independently a hydrogen
 10 atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-$
 $COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein
 n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein
 n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m
 and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37}
 15 and R^{38} are as defined above, a phenyl group, a pyridyl
 group, a pyrimidinyl group, a pyridazinyl group, a pyra-
 zinyl group, a tetrazolyl group, a benzyl group, a
 pyridylmethyl group, a pyrimidinylmethyl group, a
 pyridazinylmethyl group, a pyrazinylmethyl group, a
 20 tetrazolylmethyl group, a hydroxyl group, an alkoxy group
 having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40}
 are as defined above;


(b") when taken together, they form with the

nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents

5 arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

(2') when taken together, R^{45} and R^{46} form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; and R^{47} and R^{48} represent independently alkyl groups having 1 to 3 carbon atoms, acetyl groups or $-(CH_2)_m-OR^{36}$ wherein m and R^{36} are as defined above;

[9] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to 20 [1], which is represented by the formula:



wherein G^2 represents 2-fluoro-biphenyl-4-yl, 2'-fluoro-

biphenyl-4-yl or 3-benzoyl-phenyl; R^{49} represents methyl; R^{50} represents hydrogen, methyl, methoxy or ethoxy; and the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is as defined in the following (1"), (2") or (3"):

- 5 (1") R^{51} and R^{52} are as defined in the following (a'"), (b'") or (c'") and R^{53} and R^{54} are as defined in the following (d'"), (e'") or (f'"):

(a'") each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

- 10 (b'") one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n, R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as
15 defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m, R^{37} and R^{38} are as defined above;

- (c'") when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine,
20 piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position
25 with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which

may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups;


(d'") each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(e'") one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m is as defined above and R^{35} is as defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above;

(f'") when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-


2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups;

10 (2") the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is a group represented by the following formula:



wherein R^{55} represents an alkyl group having 1 to 3 carbon atom, acetyl or $-(CH_2)_m-OR^{56}$ wherein m is as defined above and R^{56} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms;

(3") the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is a group represented by the following formula:



wherein R^{57} and R^{58} are as defined in the following (a""), (b""), (c""), (d""), (e""), (f""), (g""), (h""), (i""), (j""), (k""), (l""), (m""), (n""), (o""), (p""), (q""), (r""), (s""), (t""), (u""), (v""), (w""), (x""), (y""), (z""), (aa""), (ab""), (ac""), (ad""), (ae""), (af""), (ag""), (ah""), (ai""), (aj""), (ak""), (al""), (am""), (an""), (ao""), (ap""), (aq""), (ar""), (as""), (at""), (au""), (av""), (aw""), (ax""), (ay""), (az""), (ba""), (bb""), (bc""), (bd""), (be""), (bf""), (bg""), (bh""), (bi""), (bj""), (bk""), (bl""), (bm""), (bn""), (bo""), (bp""), (bq""), (br""), (bs""), (bt""), (bu""), (bv""), (bw""), (bx""), (by""), (bz""), (ca""), (cb""), (cc""), (cd""), (ce""), (cf""), (cg""), (ch""), (ci""), (cj""), (ck""), (cl""), (cm""), (cn""), (co""), (cp""), (cq""), (cr""), (cs""), (ct""), (cu""), (cv""), (cw""), (cx""), (cy""), (cz""), (da""), (db""), (dc""), (dd""), (de""), (df""), (dg""), (dh""), (di""), (dj""), (dk""), (dl""), (dm""), (dn""), (do""), (dp""), (dq""), (dr""), (ds""), (dt""), (du""), (dv""), (dw""), (dx""), (dy""), (dz""), (ea""), (eb""), (ec""), (ed""), (ee""), (ef""), (eg""), (eh""), (ei""), (ej""), (ek""), (el""), (em""), (en""), (eo""), (ep""), (eq""), (er""), (es""), (et""), (eu""), (ev""), (ew""), (ex""), (ey""), (ez""), (fa""), (fb""), (fc""), (fd""), (fe""), (ff""), (fg""), (fh""), (fi""), (fj""), (fk""), (fl""), (fm""), (fn""), (fo""), (fp""), (fq""), (fr""), (fs""), (ft""), (fu""), (fv""), (fw""), (fx""), (fy""), (fz""), (ga""), (gb""), (gc""), (gd""), (ge""), (gf""), (gg""), (gh""), (gi""), (gj""), (gk""), (gl""), (gm""), (gn""), (go""), (gp""), (gq""), (gr""), (gs""), (gt""), (gu""), (gv""), (gw""), (gx""), (gy""), (gz""), (ha""), (hb""), (hc""), (hd""), (he""), (hf""), (hg""), (hh""), (hi""), (hj""), (hk""), (hl""), (hm""), (hn""), (ho""), (hp""), (hq""), (hr""), (hs""), (ht""), (hu""), (hv""), (hw""), (hx""), (hy""), (hz""), (ia""), (ib""), (ic""), (id""), (ie""), (if""), (ig""), (ih""), (ii""), (ij""), (ik""), (il""), (im""), (in""), (io""), (ip""), (iq""), (ir""), (is""), (it""), (iu""), (iv""), (iw""), (ix""), (iy""), (iz""), (ja""), (jb""), (jc""), (jd""), (je""), (jf""), (jg""), (jh""), (ji""), (jj""), (jk""), (jl""), (jm""), (jn""), (jo""), (jp""), (jq""), (jr""), (js""), (jt""), (ju""), (jv""), (jw""), (jx""), (jy""), (jz""), (ka""), (kb""), (kc""), (kd""), (ke""), (kf""), (kg""), (kh""), (ki""), (kj""), (kk""), (kl""), (km""), (kn""), (ko""), (kp""), (kq""), (kr""), (ks""), (kt""), (ku""), (kv""), (kw""), (kx""), (ky""), (kz""), (la""), (lb""), (lc""), (ld""), (le""), (lf""), (lg""), (lh""), (li""), (lj""), (lk""), (ll""), (lm""), (ln""), (lo""), (lp""), (lq""), (lr""), (ls""), (lt""), (lu""), (lv""), (lw""), (lx""), (ly""), (lz""), (ma""), (mb""), (mc""), (md""), (me""), (mf""), (mg""), (mh""), (mi""), (mj""), (mk""), (ml""), (mm""), (mn""), (mo""), (mp""), (mq""), (mr""), (ms""), (mt""), (mu""), (mv""), (mw""), (mx""), (my""), (mz""), (na""), (nb""), (nc""), (nd""), (ne""), (nf""), (ng""), (nh""), (ni""), (nj""), (nk""), (nl""), (nm""), (nn""), (no""), (np""), (nq""), (nr""), (ns""), (nt""), (nu""), (nv""), (nw""), (nx""), (ny""), (nz""), (oa""), (ob""), (oc""), (od""), (oe""), (of""), (og""), (oh""), (oi""), (oj""), (ok""), (ol""), (om""), (on""), (oo""), (op""), (oq""), (or""), (os""), (ot""), (ou""), (ov""), (ow""), (ox""), (oy""), (oz""), (pa""), (pb""), (pc""), (pd""), (pe""), (pf""), (pg""), (ph""), (pi""), (pj""), (pk""), (pl""), (pm""), (pn""), (po""), (pp""), (pq""), (pr""), (ps""), (pt""), (pu""), (pv""), (pw""), (px""), (py""), (pz""), (qa""), (qb""), (qc""), (qd""), (qe""), (qf""), (qg""), (qh""), (qi""), (qj""), (qk""), (ql""), (qm""), (qn""), (qo""), (qp""), (qq""), (qr""), (qs""), (qt""), (qu""), (qv""), (qw""), (qx""), (qy""), (qz""), (ra""), (rb""), (rc""), (rd""), (re""), (rf""), (rg""), (rh""), (ri""), (rj""), (rk""), (rl""), (rm""), (rn""), (ro""), (rp""), (rq""), (rr""), (rs""), (rt""), (ru""), (rv""), (rw""), (rx""), (ry""), (rz""), (sa""), (sb""), (sc""), (sd""), (se""), (sf""), (sg""), (sh""), (si""), (sj""), (sk""), (sl""), (sm""), (sn""), (so""), (sp""), (sq""), (sr""), (ss""), (st""), (su""), (sv""), (sw""), (sx""), (sy""), (sz""), (ta""), (tb""), (tc""), (td""), (te""), (tf""), (tg""), (th""), (ti""), (tj""), (tk""), (tl""), (tm""), (tn""), (to""), (tp""), (tq""), (tr""), (ts""), (tt""), (tu""), (tv""), (tw""), (tx""), (ty""), (tz""), (ua""), (ub""), (uc""), (ud""), (ue""), (uf""), (ug""), (uh""), (ui""), (uj""), (uk""), (ul""), (um""), (un""), (uo""), (up""), (uq""), (ur""), (us""), (ut""), (uu""), (uv""), (uw""), (ux""), (uy""), (uz""), (va""), (vb""), (vc""), (vd""), (ve""), (vf""), (vg""), (vh""), (vi""), (vj""), (vk""), (vl""), (vm""), (vn""), (vo""), (vp""), (vq""), (vr""), (vs""), (vt""), (vu""), (vv""), (vw""), (vx""), (vy""), (vz""), (wa""), (wb""), (wc""), (wd""), (we""), (wf""), (wg""), (wh""), (wi""), (wj""), (wk""), (wl""), (wm""), (wn""), (wo""), (wp""), (wq""), (wr""), (ws""), (wt""), (wu""), (wv""), (ww""), (wx""), (wy""), (wz""), (xa""), (xb""), (xc""), (xd""), (xe""), (xf""), (xg""), (xh""), (xi""), (xj""), (xk""), (xl""), (xm""), (xn""), (xo""), (xp""), (xq""), (xr""), (xs""), (xt""), (xu""), (xv""), (xw""), (xx""), (xy""), (xz""), (ya""), (yb""), (yc""), (yd""), (ye""), (yf""), (yg""), (yh""), (yi""), (yj""), (yk""), (yl""), (ym""), (yn""), (yo""), (yp""), (yq""), (yr""), (ys""), (yt""), (yu""), (yv""), (yw""), (yx""), (yy""), (yz""), (za""), (zb""), (zc""), (zd""), (ze""), (zf""), (zg""), (zh""), (zi""), (zj""), (zk""), (zl""), (zm""), (zn""), (zo""), (zp""), (zq""), (zr""), (zs""), (zt""), (zu""), (zv""), (zw""), (zx""), (zy""), (zz""); and R^{59} and R^{60} are as defined in the following (d""), (e""), (f"");

(a"") each represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(b"") one of them represents a hydrogen atom

and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as
5 defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above;

(c'') when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine,
10 piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine or piperidine substituted in the 4-position
15 with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group
20 having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1
25 to 3 carbon atoms, may be substituted with one or two methyl groups;


(d'') each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(e'') one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n, R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m, R^{37} and R^{38} are as defined above;

(f'') when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups.

[10] An isoxazole derivative or a pharmaceutically

acceptable salt thereof according to [1], which is represented by the formula:




wherein G^2 , R^{49} and R^{50} are as defined above; the formula: $=C(NR^{61}R^{62})NR^{63}R^{64}$ is as defined in the following (1''),

5 (2'') or (3''):

(1'') R^{63} and R^{64} both represent hydrogen atoms; and R^{61} and R^{62} are as defined in the following (a'), (b') or (c'):

- (a') each represents independently a hydrogen
 10 atom or an alkyl group having 1 to 3 carbon atoms;
- (b') one of them represents a hydrogen atom and the other represents $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_m-OR^{65}$ wherein m is 2 or 3 and R^{65} represents a hydrogen atom or an alkyl group having 1
 15 to 3 carbon atoms, 2-hydroxyethyl or 3-hydroxypropyl; or $-(CH_2)_m-NR^{66}R^{67}$ wherein m is as defined above and R^{66} and R^{67} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms or, when taken together, form with the nitrogen atom pyrrolidine, piperidine,
 20 morpholine, or N-methylpiperazine wherein said pyrrolidine, piperidine, morpholine and N-methylpiperazine may be substituted with one or two methyl groups;

(c^v) when taken together, they form with the nitrogen atom pyrrolidine, piperidine, morpholine or N-methylpiperazine wherein said pyrrolidine, piperidine, morpholine and N-methylpiperazine may be substituted with
 5 one or two methyl groups;
 (2'") the formula: $=C(NR^{61}R^{62})NR^{63}R^{64}$ is a group represented by the following formula:



wherein R⁶⁸ represents an alkyl group having 1 to 3 carbon atoms, 2-hydroxyethyl or 3-hydroxypropyl.
 10 (3'") when taken together, R⁶¹ and R⁶² form morpholine with the nitrogen atom; and when taken together, R⁶³ and R⁶⁴ form amino-morpholin-4-yl-methylene.
 [11] An isoxazole derivative or a pharmaceutically acceptable salt thereof according to [1], which is
 15 selected from the group consisting of the following compounds:

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;
 [(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 20 isoxazol-5-ylimino)-(4-methyl-piperazin-1-yl)-methyl]-
 amine;
 N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 isoxazol-5-yl)-N'-(2-morpholin-4-yl-ethyl)-guanidine;
 ((3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-

ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

[{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

5 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(({3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

10 [{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

15 ((3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

[{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

20 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;

25 [3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;

N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-

yl)-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-
isoxazol-3-yl]-1-methyl-ethyl)-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-
5 methyleneamino]-isoxazol-3-yl]-1-methyl-ethyl)-phenyl}-
phenyl-methane;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine.

[12] A pharmaceutical composition comprising as an
10 active ingredient an isoxazole derivative or a
pharmaceutically acceptable salt thereof according to any
one of [1] to [11], together with a pharmaceutically
acceptable carrier.

[13] A pharmaceutical composition according to [12],
15 which is for the treatment or prophylaxis of autoimmune
diseases.

[14] A pharmaceutical composition according to [12],
which is for the treatment or prophylaxis of inflammatory
diseases.

20 [15] A pharmaceutical composition according to [12],
which is an antirheumatic drug.

[16] A pharmaceutical composition according to [12],
which is an anti-inflammatory drug.

[17] A method for treating or preventing autoimmune
25 diseases or inflammatory diseases, which comprises
administering an isoxazole derivative or a
pharmaceutically acceptable salt according to any one of
[1] to [11] in an effectively amount to a human body.

[18] Use of an isoxazole derivative or a
pharmaceutically acceptable salt according to any one of
[1] to [11] in the manufacture of a medicament for the
treatment or prophylaxis of autoimmune diseases or
5 inflammatory diseases.

BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 is a graph showing the results of test
of the compounds of this invention using experimental
allergic encephalomyelitis mice which are animal models
10 of multiple sclerosis.

DETAILED DESCRIPTION OF THE INVENTION

The aryl group includes, for example, aryl
groups of 6 to 14 carbon atoms. Specific examples
thereof are phenyl, 1-naphthyl, 2-naphthyl, phenanthryl,
15 anthryl, etc. Preferable examples thereof are phenyl,
1-naphthyl and 2-naphthyl.

The heterocyclic group includes, for example,
5- to 7-membered monocyclic to tricyclic saturated or
unsaturated heterocyclic groups containing 1 to 6
20 nitrogen atoms, oxygen atoms and/or sulfur atoms.

Specific examples of the saturated hetero-
cyclic groups are monocyclic to tricyclic 5-membered
saturated heterocyclic groups such as tetrahydrofuryl,
pyrrolidinyl, pyrazolidinyl, imidazolidinyl, etc.;
25 monocyclic to tricyclic 6-membered saturated heterocyclic
groups such as piperidinyl, morpholinyl, thia-

morpholinyl, piperazinyl, hexahydro-pyrimidinyl, etc.; and monocyclic to tricyclic 7-membered saturated heterocyclic groups such as azepanyl, etc.

Specific examples of the unsaturated hetero-
5 cyclic groups are monocyclic to tricyclic 5-membered unsaturated heterocyclic groups such as furyl, thienyl, indolyl, isothiazolyl, benzothienyl, isobenzofuranyl, pyrrolyl, benzofuryl, imidazolyl, 4,5-dihydro-1H-imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,
10 thiazolyl, oxazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, carbazolyl etc.; monocyclic to tricyclic 6-membered unsaturated heterocyclic groups such as pyridyl, pyrazinyl, pyrimidinyl, 1,4,5,6-tetrahydro-pyrimidinyl, 3,6-dihydro-2H-[1,3,5]oxadiazinyl,
15 pyridazinyl, triazinyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, chromenyl, 2,3-dihydrobenzo[1,4]dioxinyl, etc.; and monocyclic to tricyclic 7-membered unsaturated heterocyclic groups such as 4,5,6,7-tetrahydro-1H-[1,3]diazepinyl, etc.

20 As the substituent of each of the substituted aryl group and the substituted heterocyclic group, there may be exemplified any substituents in the following groups a) to g), and each of the substituted aryl group and the substituted heterocyclic group may optionally
25 have one or more of these substituents.

a) Halogen atoms, nitro group, cyano group, azide group, mercapto group, substituted or unsubstituted amino groups, substituted or unsubstituted

hydroxylamino groups, substituted or unsubstituted lower alkoxyamino groups, hydroxyl group, acyl groups, acyloxy groups, carboxyl group, substituted or unsubstituted carbamoyl groups, substituted or unsubstituted

5 carbamoyloxy groups, sulfo group, and substituted or unsubstituted sulfamoyl groups.

b) $-R^{10}$, $-OR^{10}$, $-CO_2R^{10}$, $-SO_3R^{10}$, $-SR^{10}$, $-OCH_2R^{10}$ and $-SCH_2R^{10}$ wherein R^{10} is a phenyl group or a monocyclic heterocyclic group, wherein said phenyl group

10 and monocyclic heterocyclic group may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms, lower alkyl groups, lower haloalkyl groups, cyano group, nitro group, azide group, hydroxyl group, lower alkoxy groups, lower

15 haloalkoxy groups, substituted or unsubstituted amino groups, substituted or unsubstituted carbamoyl groups, carboxyl group, lower alkylcarbonyl groups, lower alkoxy carbonyl groups, lower alkylthio groups, lower alkylsulfinyl groups, lower alkylsulfonyl groups, etc.

20 c) Alkyl groups, alkoxy groups, alkoxy-carbonyl groups, alkoxy(thiocarbonyl) groups, alkylthio groups, (alkylthio)thiocarbonyl groups, (alkylthio)-carbonyl groups, alkylcarbonyl groups, alkylthioyl groups, alkylsulfinyl groups, alkylsulfonyl groups,

25 alkylcarbonyloxy groups, alkylthioxyloxy groups and alkylsulfonyloxy groups, each of which groups may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms;

nitro group; cyano group; mercapto group; oxo group;
thioxo group; substituted or unsubstituted amino groups;
hydroxyl group; acyl groups; acyloxy groups; carboxyl
group; substituted or unsubstituted carbamoyl groups;
5 substituted or unsubstituted carbamoyloxy groups; sulfo
group; substituted or unsubstituted sulfamoyl groups;
-R¹⁰; -OR¹⁰; -SR¹⁰; -OCH₂R¹⁰; -SCH₂R¹⁰ wherein R¹⁰ is as
defined above;

lower cycloalkyl groups which may be
10 substituted by at least one member optionally selected
from the group consisting of, for example, halogen atoms,
lower alkyl groups, lower haloalkyl groups, substituted
or unsubstituted amino groups, hydroxyl group, lower
alkoxy groups, lower haloalkoxy groups, etc.;
15 lower alkoxy groups; lower alkoxycarbonyl
groups; and lower alkylthio groups, wherein said lower
alkoxy groups, lower alkoxycarbonyl groups and lower
alkylthio groups may be substituted by at least one
member optionally selected from the group consisting of,
20 for example, halogen atoms, lower cycloalkyl groups,
monocyclic heterocyclic groups, phenyl group, cyano
group, nitro group, hydroxyl group, lower alkoxy groups,
lower haloalkoxy groups, substituted or unsubstituted
amino groups, substituted or unsubstituted carbamoyl
25 groups, carboxyl group, lower alkylcarbonyl groups, lower
alkoxycarbonyl groups, lower alkylthio groups, lower
alkylsulfinyl groups and lower alkylsulfonyl groups, etc.

d) Alkenyl groups, which may be substituted by

- at least one member optionally selected from the group consisting of, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, substituted or unsubstituted amino groups, hydroxyl
- 5 group, lower alkoxy groups, lower haloalkoxy groups, lower alkoxy carbonyl groups, lower alkylthio groups, acyl groups, acyloxy groups, carboxyl group, substituted or unsubstituted carbamoyl groups, $-R^{10}$, $-OR^{10}$, $-SR^{10}$, $-OCH_2R^{10}$ and $-SCH_2R^{10}$ wherein R^{10} is as defined above, etc.
- 10 e) Alkynyl groups, which may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, substituted or unsubstituted amino groups, hydroxyl
- 15 group, lower alkoxy groups, lower haloalkoxy groups, lower alkoxy carbonyl groups, lower alkylthio groups, acyl groups, acyloxy groups, carboxyl group, substituted or unsubstituted carbamoyl groups, $-R^{10}$, $-OR^{10}$, $-SR^{10}$, $-OCH_2R^{10}$ and $-SCH_2R^{10}$ wherein R^{10} is as defined above, etc.
- 20 f) Alkenyloxy groups, alkenyloxycarbonyl groups, alkenylcarbonyl groups, alkenylcarbonyloxy groups, ~~alkynyloxy groups and alkynyloxycarbonyl groups,~~ each of which groups may be substituted by at least one member optionally selected from the group consisting of,
- 25 for example, halogen atoms, oxo group, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, acyl groups, acyloxy groups, lower alkylthio groups, carboxyl group,

substituted or unsubstituted carbamoyl groups, lower alkoxycarbonyl groups, phenyl group, etc.

- g) Lower cycloalkyl groups, lower cycloalkyloxy groups, lower cycloalkylcarbonyl groups, lower cycloalkylcarbonyloxy groups, lower cycloalkyloxy carbonyl groups, lower cycloalkenyl groups, lower cycloalkenyloxy groups, lower cycloalkenylcarbonyl groups, lower cycloalkenylcarbonyloxy groups and lower cycloalkenyloxycarbonyl groups, each of which groups may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, lower alkyl groups, lower haloalkyl groups, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, acyl groups, acyloxy groups, lower alkylthio groups, carboxyl groups, substituted or unsubstituted carbamoyl groups, lower alkoxycarbonyl groups, etc.

- Specific examples of the substituent of the substituted aryl group and substituted heterocyclic group are methyl, 2-methyl-1-propyl, hexyl, 2-methyl-2-propyl, 2-propyl, phenyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, 6,6,6-trifluorohexyl, hydroxymethyl, hydroxyethyl, methoxymethyl, hexyloxymethyl, cyclopropylmethoxymethyl, acetoxymethyl, N,N-dimethylcarbamoyloxymethyl, methanesulfonyloxymethyl, N,N-dimethylsulfamoyloxymethyl, 2-(1-pyrrolidinyl)ethoxymethyl, 2-methoxyethyl, carboxymethyl,

methoxycarbonylmethyl, carbamoylmethyl, amidinomethyl, methylthiomethyl, cyanomethyl, aminomethyl, aminoethyl, N-acetylaminomethyl, ethenyl, 2-propenyl, ethynyl, 2-propynyl, 2-methoxycarbonylethenyl, fluoro, chloro, 5 bromo, nitro, cyano, hydroxyl, amino, N,N-dimethylamino, mercapto, sulfo, carboxyl, amidino, methoxy, cyclopropylmethoxy, 2-(1-pyrrolidinyl)ethoxy, methoxycarbonylmethoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-methoxyethoxy, 4,4,5,5,5-pentafluoropentoxy, 2- 10 methanesulfinylethoxy, phenoxy, benzyloxy, 4-methoxybenzyloxy, methoxycarbonyloxy, 1-pyrrolidinyl, 3-hydroxy-1-pyrrolidinyl, acetylamino, N-acetyl-N-methylamino, N-methanesulfonylamino, N-methanesulfonyl-N-methylamino, methoxycarbonyl, 2-methyl-2-propoxy- 15 carbonyl, 2,2,2-trifluoroethoxycarbonyl, carbamoyl, N,N-dimethylcarbamoyl, 2-thiazolidinyl, 2-oxazolidinyl, 5-tetrazolyl, methanesulfinyl, sulfamoyl, N,N-dimethylsulfamoyl, acetyl, benzoyl, pivaloyl, trifluoroacetyl, formyl, ethylenedioxymethyl, imino, methoxyimino, etc. 20 Of these substituents, specific examples of preferable substituent are methyl, 2-methyl-1-propyl, hexyl, 2-methyl-2-propyl, 2-propyl, phenyl, trifluoro-methyl, 2,2,2-trifluoroethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, cyclopropylmethoxymethyl, acetoxy- 25 methyl, N,N-dimethylcarbamoyloxymethyl, methanesulfonyloxymethyl, N,N-dimethylsulfamoyloxymethyl, 2-(1-pyrrolidinyl)ethoxymethyl, 2-methoxyethyl, carboxymethyl, methoxycarbonylmethyl, carbamoylmethyl, amidino-

methyl, methylthiomethyl, cyanomethyl, aminomethyl, aminoethyl, N-acetylaminomethyl, fluoro, chloro, bromo, nitro, cyano, hydroxyl, amino, N,N-dimethylamino, methoxy, 2-(1-pyrrolidinyl)ethoxy, methoxycarbonyl-
5 methoxy, 2-acetoxyethoxy, 2-hydroxyethoxy, 2-methoxy-ethoxy, 2-methanesulfinylethoxy, 1-pyrrolidinyl, 3-hydroxy-1-pyrrolidinyl, acetylamino, N-acetyl-N-methylamino, N-methanesulfonylamino, N-methanesulfonyl-N-methylamino, methoxycarbonyl, 2-methyl-2-propoxy-
10 carbonyl, 2,2,2-trifluoroethoxycarbonyl, carbamoyl, N,N-dimethylcarbamoyl, methanesulfinyl, acetyl, benzoyl, pivaloyl, trifluoroacetyl, etc.

The number of substituents of each of the aryl group and the heterocyclic group is preferably 1, 2 or
15 3. As each of the aryl group and the heterocyclic group, an unsubstituted one is also preferable.

The alkyl group includes, for example, linear or branched alkyl groups of 1 to 10 carbon atoms. Specific examples thereof are methyl, ethyl, propyl,
20 1-methylethyl, butyl, 1-methylpropyl, 2-methyl-1-propyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-methylbutyl, 3-methylbutyl, hexyl, 2-methylpentyl, 3,3-dimethylbutyl, heptyl, 1-ethylpentyl, 5-methylhexyl, octyl, 1,5-dimethylhexyl, 2-ethylhexyl,
25 nonyl, decyl, etc. The lower alkyl group includes alkyl groups of 1 to 6 carbon atoms.

As the substituent of the substituted alkyl group, there may be exemplified any substituents in the

following groups a) to d), and the substituted alkyl group may optionally have one or more of these substituents.

a) Halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, substituted or unsubstituted amino groups, substituted or unsubstituted hydroxylamino groups, substituted or unsubstituted lower alkoxyamino groups, hydroxyl group, acyl groups, acyloxy groups, carboxyl group, substituted or unsubstituted carbamoyl groups, substituted or unsubstituted carbamoyloxy groups, sulfo group, and substituted or unsubstituted sulfamoyl groups.

b) Lower cycloalkyl groups, lower cycloalkyloxy groups, lower cycloalkylcarbonyl groups, lower cycloalkylcarbonyloxy groups, lower cycloalkyloxy-carbonyl groups, lower cycloalkenyl groups, lower cycloalkenyloxy groups, lower cycloalkenylcarbonyl groups, lower cycloalkenylcarbonyloxy groups and lower cycloalkenyloxy-carbonyl groups, each of which group may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms, ~~nitro group, cyano group, mercapto-group, oxo group,~~ thioxo group, lower alkyl groups, lower haloalkyl groups, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, acyl groups, acyloxy groups, lower alkylthio groups, carboxyl groups, substituted or unsubstituted carbamoyl groups, lower alkoxy-carbonyl groups, etc.

c) Alkoxy groups, alkoxycarbonyl groups, alkoxy(thiocarbonyl) groups, alkylthio groups, (alkylthio)thiocarbonyl groups, (alkylthio)carbonyl groups, alkylcarbonyl groups, alkylthioyl groups, alkylsulfinyl groups, alkylsulfonyl groups, alkylcarbonyloxy groups, alkylthioxyloxy groups and alkylsulfonyloxy groups, each of which groups may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms; nitro group; cyano group; mercapto group; oxo group; thioxo group; substituted or unsubstituted amino groups; hydroxyl group; acyl groups; acyloxy groups; carboxyl group; substituted or unsubstituted carbamoyl groups; substituted or unsubstituted carbamoyloxy groups; sulfo group; substituted or unsubstituted sulfamoyl groups; $-R^{10}$; $-OR^{10}$; $-SR^{10}$; $-OCH_2R^{10}$; $-SCH_2R^{10}$ wherein R^{10} is as defined above;

lower cycloalkyl groups which may be substituted by at least one member optionally selected from the group consisting of, for example, halogen atoms, lower alkyl groups, lower haloalkyl groups, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, etc.;

lower alkoxy groups; lower alkoxycarbonyl groups; and lower alkylthio groups, wherein said lower alkoxy groups, lower alkoxycarbonyl group and lower alkylthio groups may be substituted by at least one member optionally selected from the group consisting of,

for example, halogen atoms, lower cycloalkyl groups, monocyclic heterocyclic groups, phenyl group, cyano group, nitro group, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, substituted or unsubstituted

5 amino groups, substituted or unsubstituted carbamoyl groups, carboxyl group, lower alkylcarbonyl groups, lower alkoxy carbonyl groups, lower alkylthio groups, lower alkylsulfinyl groups and lower alkylsulfonyl groups, etc.

- d) $-R^{10}$, $-OR^{10}$, $-SR^{10}$, $-OCH_2R^{10}$ and
- 10 $-SCH_2R^{10}$ wherein R^{10} is as defined above.

Specific examples of the substituted alkyl group are trifluoromethyl, 2-nitroethyl, 2-cyanopropyl, 4-mercaptobutyl, 3-oxobutyl, 2-piperidinoethyl, 2-hydroxyethyl, 3-methoxypropyl, ethoxycarbonylmethyl,

15 cyclopropylmethyl, cyclohexylmethyl, 6-cyclohexylhexyl, 3-cyclohexenylbutyl, 2-phenylbutyl, benzyl, 2-naphthylmethyl, phenethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-quinolylmethyl, 3-quinolylmethyl, 3-thienylpropyl, hydroxymethyl, hydroxyethyl, aminomethyl,

20 aminoethyl, carboxymethyl, ethoxycarbonylmethyl, carbamoylmethyl, etc.

~~The lower haloalkyl group represents a lower~~
alkyl group substituted by 1 to 5 halogen atoms.

The alkoxy group represents to an oxy group

25 having an alkyl group bonded thereto. Specific examples thereof are methoxy, ethoxy, propoxy, 2-propoxy, butoxy, 1,1-dimethylethoxy, pentoxy, hexoxy, etc. As the substituent of the substituted alkoxy group, there may

be exemplified the same substituents as those exemplified above as the substituent of the substituted alkyl group. Specific examples of the substituted alkoxy group are cyclopropylmethoxy, trifluoromethoxy, 2-
5 pyrrolidinoethoxy, benzyloxy, 2-pyridylmethoxy, etc.

The haloalkoxy group represents an alkoxy group substituted by 1 to 5 halogen atoms.

The alkoxycarbonyl group represents a carbonyl group having an alkoxy group bonded thereto. Specific
10 examples thereof are methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 2-propoxycarbonyl, etc. As the substituent of the substituted alkoxycarbonyl group, there may be exemplified the same substituents as those exemplified above as the substituent of the substituted
15 alkyl group.

The alkenyl group includes linear or branched alkenyl groups of 2 to 10 carbon atoms having 1 to 3 double bonds. Specific examples thereof are ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-
20 butenyl, 3-butenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, 2-heptenyl, 1-octenyl, 2-octenyl, 1,3-octadienyl, 2-nonenyl, 1,3-nonadienyl, 2-decenyl, etc. Preferable examples of the alkenyl group are, for
25 example, ethenyl, 1-propenyl and 1-butenyl. The lower alkenyl group includes alkenyl groups of 2 to 6 carbon atoms.

The substituent of the substituted alkenyl

group includes, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, 5 lower alkoxycarbonyl groups, lower alkylthio groups, acyl groups, acyloxy groups, carboxyl group, substituted or unsubstituted carbamoyl groups, $-R^{10}$, $-OR^{10}$, $-SR^{10}$, $-OCH_2R^{10}$, $-SCH_2R^{10}$ wherein R^{10} is as defined above etc.

The alkenyloxy group represents an oxy group 10 having an alkenyl group bonded thereto.

The alkynyl group includes linear or branched alkynyl groups of 2 to 10 carbon atoms having 1 to 3 triple bonds. Specific examples thereof are ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 15 1-pentylnyl, 2-pentylnyl, 4-pentylnyl, 1-octynyl, 6-methyl-1-heptylnyl, 2-decylnyl, etc. Preferable examples of the alkynyl group are, for example, 1-propynyl, 1-butylnyl, etc. The lower alkynyl group includes alkynyl groups of 2 to 6 carbon atoms.

20 The substituent of the substituted alkynyl group includes, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, 25 acyl groups, acyloxy groups, lower alkylthio groups, carboxyl group, substituted or unsubstituted carbamoyl groups, lower alkoxycarbonyl groups, $-R^{10}$, $-OR^{10}$, $-SR^{10}$, $-OCH_2R^{10}$, $-SCH_2R^{10}$ wherein R^{10} is as defined above, etc.

The alkynyloxy group represents an oxy group having an alkynyl group bonded thereto.

The cycloalkyl group includes, for example, cycloalkyl groups of 3 to 10 carbon atoms. Specific
5 examples thereof are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. The lower cycloalkyl group includes cycloalkyl groups of 3 to 6 carbon atoms. The cycloalkyloxy group represents an oxy group having a cycloalkyl group bonded thereto.

10 The cycloalkenyl group includes, for example, cycloalkenyl groups of 3 to 10 carbon atoms. Specific examples thereof are cyclohexenyl, etc. The lower cycloalkenyl group includes cycloalkenyl groups of 3 to 6 carbon atoms. The cycloalkenyloxy group refers to an
15 oxy group having a cycloalkenyl group bonded thereto.

The substituent of each of the substituted cycloalkyl group and the substituted cycloalkenyl group includes, for example, halogen atoms, nitro group, cyano group, mercapto group, oxo group, thioxo group, lower
20 alkyl groups, lower haloalkyl groups, substituted or unsubstituted amino groups, hydroxyl group, lower alkoxy groups, lower haloalkoxy groups, acyl groups, acyloxy groups, lower alkylthio groups, carboxyl group, substituted or unsubstituted carbamoyl groups, lower
25 alkoxycarbonyl groups, etc.

The acyl group includes, for example, acyl groups of the formula: $-Z-R^{11}$ wherein Z is $-CO-$, $-CS-$, $-SO-$ or $-SO_2-$, and R^{11} is a substituted or unsubstituted

alkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heterocyclic group. Specific examples of the acyl group are formyl, acetyl, propanoyl, 2-propanoyl, pivaloyl, valeryl, pivaloyl, 5 trifluoroacetyl, benzoyl, naphthoyl, nicotinoyl, methanesulfonyl, trifluoromethanesulfonyl, p-toluene-sulfonyl, etc. Preferable examples of the acyl group are acetyl group, etc. The acyloxy group represents an oxy group having an acyl group bonded thereto.

10 The substituent of the substituted carbamoyl group includes, for example, alkyl groups which may be substituted by an aryl group or a heterocyclic group, aryl groups, heterocyclic groups, etc. The substituted carbamoyl group may have a plurality of the same or 15 different substituents independently introduced thereinto. Specific examples of the substituted carbamoyl group are ethylcarbamoyl, dimethylcarbamoyl, phenylcarbamoyl, 2-pyridylcarbamoyl, benzylcarbamoyl, (3-pyridylmethyl)carbamoyl, etc.

20 The substituent of the substituted sulfamoyl group includes, for example, alkyl groups, aryl groups, heterocyclic groups, etc. The substituted sulfamoyl group may have a plurality of the same or different substituents independently introduced thereinto. 25 Specific examples of the substituted sulfamoyl group are ethylsulfamoyl, dimethylsulfamoyl, phenylsulfamoyl, 2-pyridylsulfamoyl, etc.

 The substituent of the substituted amino group

includes, for example, acyl groups, alkyl groups, etc. The substituted amino group may have a plurality of the same or different substituents independently introduced thereinto. Specific examples of the substituted amino
5 group are acetamide, propionamide, butylamide, 2-butylamide, methylamino, 2-methyl-1-propylamino, diethylamino, etc.

The substituent of the substituted hydroxylamino group may be on either the nitrogen atom or the
10 oxygen atom. As the substituent, there may be exemplified the same substituents as those exemplified above as the substituent of the substituted amino group.

The halogen atom includes, for example, fluorine atom, chlorine atom, bromine atom, iodine
15 atom, etc.

The alkylene group includes, for example, linear or branched alkylene groups of 1 to 10 carbon atoms. Specific examples thereof are methylene, ethylene, trimethylene, tetramethylene, pentamethylene,
20 hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, methylmethylene, ethylmethylene, dimethylmethylene, 1,1-dimethylethylene,
1,2-dimethylethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 1,2-dimethyltri-
25 methylene, 1,3-dimethyltrimethylene, 2,2-dimethyltrimethylene, 1-ethyltrimethylene, 2-ethyltrimethylene, 1,1-diethyltrimethylene, 1,2-diethyltrimethylene, 1,3-diethyltrimethylene, 2,2-diethyltrimethylene, etc.

The lower alkylene group include, for example, linear or branched alkylene groups of 1 to 6 carbon atoms.

As the protecting group for NH group, various conventional protecting groups may be used, though preferable examples thereof are carbamate type protecting groups such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl and the like, amide type protecting groups such as acetyl, benzoyl and the like, benzyl, nitro, p-toluenesulfonyl, methane-sulfonyl, etc.

In the substituted or unsubstituted heterocyclic ring which any two of R^1 , R^2 , R^3 and R^4 form when taken together with the nitrogen atom(s), the heterocyclic ring includes, for example, 5- to 7-membered monocyclic or bicyclic saturated or unsaturated heterocyclic rings containing 1 to 6 nitrogen atoms, oxygen atoms and/or sulfur atoms which contains at least one nitrogen atom. Specific examples thereof are pyrrolidine, imidazolidine, 4,5-dihydro-1H-imidazole, piperidine, piperidin-4-one, piperazine, morpholine, thiamorpholine, 1,4,5,6-tetrahydro-pyrimidine, hexahydropyrimidine, 3,6-dihydro-2H-[1,3,5]oxadiazine, etc. As the substituent of the substituted heterocyclic ring, there may be exemplified the same substituents as those exemplified above as the substituent of the substituted heterocyclic group.

The substituted or unsubstituted hydro-

carbon ring which R⁸ and R⁹ form when taken together with the carbon atom, includes, for example, substituted or unsubstituted cycloalkane rings of 3 to 8 carbon atoms or substituted or unsubstituted cycloalkene rings of 3 to 8 carbon atoms. Specific examples of the cycloalkane rings or cycloalkene rings are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, etc. As the substituent of the substituted hydrocarbon ring, there may be exemplified the same substituents as those exemplified above as the substituent of the substituted cycloalkyl group.

When the isoxazole derivative of the formula 1 has a polar functional group introduced into the isoxazole ring, this compound possesses improved pharmacokinetics, has little side effect and may be administered for a long period of time.


The present invention includes all stereoisomers, optical isomers, tautomers and the like of the isoxazole derivative of the formula 1. The present invention also includes solvates (e.g. hydrates and the like) and all crystal forms of the isoxazole derivative of the formula 1 or a pharmaceutically acceptable salt thereof.

The pharmaceutically acceptable salt of the isoxazole derivative of the formula 1 includes acid addition salts and base addition salts. The acid addition salts include, for example, salts with

inorganic acids, such as hydrochloride, hydrobromide, sulfate, hydroiodate, nitrate, phosphate, etc.; and salts with organic acids, such as citrate, oxalate, acetate, formate, propionate, benzoate, trifluoro-
 5 acetate, fumarate, maleate, tartrate, aspartate, glutamate, methanesulfonate, benzenesulfonate, camphorsulfonate, etc. The base addition salts include salts with inorganic bases, such as sodium salt, potassium salt, calcium salt, magnesium salt, ammonium
 10 salt, etc.; and salts with organic bases, such as triethylammonium salt, triethanol ammonium salt, pyridinium salt, diisopropylammonium salt, etc.

The isoxazole derivative of the formula 1 may be produced, for example, by any of the five processes
 15 described below. Although an explanation is given in the following reaction formulas by taking the case where A and B have one of the two combinations of meanings defined above, the derivative in which A and B have the other combination of meanings may be produced in the
 20 same manner.

Process 1




wherein D, E, J, G, R¹, R², R³, R⁴ and the broken lines are as defined above.

An isoxazole derivative (1a) of the present invention may be produced by reacting a compound of the formula 2a with a guanidine derivative of the formula 3 in an inert solvent at a reaction temperature of 0 - 25°C under conditions of Mitsunobu reaction using a trialkylphosphine and an azodicarboxylic acid ester (Chem. Lett., 1994, 539; Tetrahedron Lett., 35, 977(1994)). The trialkylphosphine includes, for example, triphenylphosphine, tributylphosphine, etc. The azodicarboxylic acid ester includes, for example, diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1'-(azodicarbonyl)dipiperidine, N,N,N',N'-tetramethyl-azodicarboxamide and N,N,N',N'-tetraisopropylazodicarboxamide, etc. Preferable examples of the solvent are tetrahydrofuran, benzene, toluene, etc.

When R¹, R², R³ or R⁴ is a protecting group for NH group in the compound of the formula 1a, deprotection may be carried out if desired. This deprotection may be carried out according to a conventional method, for example, the method described in "Protective Groups in Organic Synthesis" (2nd Edition, T.W. Greene and P.G.M. Wuts, John Wiley and Sons, inc., New York (1991), p 315-362). As the protecting group for NH group, various conventional protecting groups may be used. Preferable examples thereof are carbamate type protecting groups such as methoxycarbonyl,

ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl and the like, amide type protecting groups such as N-acetyl, N-benzoyl and the like, benzyl, nitro, p-toluenesulfonyl, methanesulfonyl, etc.

- 5 1) Process for producing a compound of the formula 2a
wherein E is an alkylene (a compound of the formula
2a¹)



wherein D, J and G are as defined above, E¹ is a single bond or an alkylene group, and R¹² is a lower alkyl


10 group.

A compound of the formula 5a may be produced by reacting an ester derivative of β-diketone of the formula 4 with hydroxyamine or hydroxylamine hydrochloride in an inert solvent according to a conventional isoxazole synthesis process (for example, A.R. Katritzky et al., "Comprehensive Heterocyclic Chemistry", Vol. 6, Pergamon Press Ltd., New York (1984), p 61). In this case, a compound of the formula 5b is also produced in some cases, but it is also possible to produce only one of the compound of the formula 5a and the compound of the formula 5b by controlling the reaction conditions

(for example, F. Lepage et al., Eur. J. Med. Chem., 27, 581(1992); and the above reference, A.R. Katritzky et al., "Comprehensive Heterocyclic Chemistry", Vol. 6, Pergamon Press Ltd., New York (1984), p 62).

- 5 A compound of the formula $2a^1$ may be produced by treating the compound of the formula 5a with a reducing agent in an inert solvent. The reducing agent includes, for example, lithium aluminum hydride, etc. The solvent includes tetrahydrofuran, etc. The reaction
10 temperature is preferably about 0°C.

2) Process for producing a compound of the formula 2a
wherein E is a single bond (a compound of the
formula $2a^2$)



wherein D, J and G are as defined above.


- 15 An amine of the formula 7a may be produced by reacting an acynitrile of the formula 6 with hydroxyl-
amine hydrochloride according to a conventional method
(for example, Japanese Patent Unexamined Publication No. 63-152368).

- 20 Then, a compound of the formula $2a^2$ may be produced by hydrolyzing the amine of the formula 7a with an acid according to a conventional method (for example, Japanese Patent Unexamined Publication No. 62-84064).

The compound of the formula $2a^2$ may be produced also by reacting a Meldrum's acid derivative of the formula 8 with hydroxylamine hydrochloride according to a conventional method (for example,

5 Japanese Patent Unexamined Publication No. 52-106466).

3) Process for producing a compound of the formula $2b$ wherein E is a single bond (a compound of the formula $2b^2$)



wherein D, J, G and R^{12} are as defined above.

10 An amine of the formula 7b may be produced by treating an acyl nitrile of the formula 6 with hydrogen chloride gas in methanol and reacting the treated acyl nitrile with hydroxylamine hydrochloride, according to a conventional method (for example, Japanese Patent


15 Unexamined Publication No. 54-3062).

Using the amine of the formula 7b, a compound of the formula $2b^2$ may be produced by the same process as for the production of the compound of the formula $2a^2$ from the amine of the formula 7a.

20 The compound of the formula $2b^2$ may be produced also by reacting a β -keto ester of the formula 9 with hydroxylamine hydrochloride according to a

conventional method (for example, N. Jacobsen et al.,
Can. J. Chem., 62, 1940(1984)).

Process 2



- 5 wherein D, E, J, G and the broken lines are as defined
above, and R¹³, R¹⁴, R¹⁵ and R¹⁶ are independently a
hydrogen atom, a halogen atom, a hydroxyl group, a
mercapto group, a nitro group, a cyano group, a carboxyl
group, a substituted or unsubstituted amino group, a
10 substituted or unsubstituted hydroxylamino group, a
substituted or unsubstituted carbamoyl group, a
substituted or unsubstituted sulfamoyl group, a sulfo
group, a protecting group for NH group, -R⁵, -OR⁵,
-CO₂R⁶, -SR⁷, -(CO)SR⁷, -(CS)OR⁷ or -CS₂R⁷ wherein R⁵,
15 R⁶ and R⁷ are as defined above.


A compound of the formula 1a¹ may be produced
by reacting a pseudothioureia derivative of the formula
10a with an amine of the formula 11 at a reaction
temperature of 20 - 140°C optionally in the presence of
20 an additive optionally in an inert solvent. The
additive includes, for example, ammonium acetate, sodium

acetate, acetic acid, oxalic acid, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, 1,8-diazabicyclo[5.4.0]undec-7-ene, triethylamine and mixtures thereof, etc. Preferable examples of the
5 solvent are water, methanol, ethanol, isopropanol, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, pyridine, toluene, chloroform, methylene chloride and mixtures thereof, etc.

The compound of the formula 1a¹ may be
10 produced also by reacting the compound of the formula 10a with the amine of the formula 11 in the presence of silver nitrate and a base in an inert solvent at a reaction temperature of -10°C to 50°C according to the method of Web et al. using silver nitrate as an additive
15 (J. Org. Chem., 56, 3009(1991)). The base includes, for example, triethylamine, etc. Preferable examples of the solvent are acetonitrile, etc.

When R¹³, R¹⁴, R¹⁵ or R¹⁶ is a protecting group for NH group in the compound of the formula 1a¹,
20 deprotection may be carried out in the same manner as above if desired.

The starting compounds in the production
process described above are per se well-known compounds, or compounds producible by well-known synthetic
25 processes. For example, the compound of the formula 10a may be produced by the following process:




wherein D, E, J, G, R¹³, R¹⁴ and the broken lines are as defined above, and one of R¹⁷ and R¹⁸ is a hydrogen atom, while the other is a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a sulfo group, a protecting group for NH group, -R⁵, -OR⁵, -CO₂R⁶, -SR⁷, -(CO)SR⁷, -(CS)OR⁷ or -CS₂R⁷ wherein R⁵, R⁶ and R⁷ are as defined above.

The compound of the formula 10a may be produced by reacting a methyl halide with a thiourea derivative of the formula 12a which is well-known or is producible by a well-known synthetic process (for example, Japanese Patent Unexamined Publication No. 63-152368), in an inert solvent in the presence of a base at a reaction temperature of 40 - 80°C. The methyl halide includes, for example, methyl iodide, etc. The base includes, for example, potassium carbonate, sodium carbonate, an aqueous potassium hydroxide solution, an aqueous sodium hydroxide solution, etc. The solvent includes, for example, methanol, ethanol,

tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, etc.

Process 3



wherein D, E, J, G, R¹³, R¹⁴, R¹⁵ and R¹⁶ are as defined above.

- 5 A compound of the formula 1a² may be produced by reacting a compound of the formula 13a with a pseudo-thiourea derivative of the formula 14 in the presence of a base in an inert solvent at a reaction temperature of 20 - 100°C. The base includes, for example, 1,8-
- 10 diazabicyclo[5.4.0]undec-7-ene, triethylamine, etc. Preferable examples of the solvent are pyridine, acetonitrile, N,N-dimethylformamide, etc.


- The compound of the formula 1a² may be produced also by carrying out the reaction in the presence of
- 15 silver nitrate and a base in an inert solvent at a reaction temperature of -10°C to 50°C according to the above-mentioned method of Web et al. using silver nitrate (J. Org. Chem., 56, 3009(1991)). The base includes, for example, triethylamine, etc. Preferable
- 20 examples of the solvent are acetonitrile, etc.

When R¹³, R¹⁴, R¹⁵ or R¹⁶ is a protecting

group for NH group in the compound of the formula 1a², deprotection may be carried out in the same manner as above if desired.

The compound of the formula 13a may be produced, for example, by subjecting a compound of the formula 2a to halogenation, conversion to azide, etc. (for example, the process of Y. Pei et al. (Tetrahedron Lett., 34, 7509(1993)). If necessary, a substituent may be introduced into the amino group (for example, R.C. Larock, "Comprehensive Organic Transformations", VCH Publishers, Inc., New York(1989), p 397).

Process 4



wherein D, E, J, G, R¹³, R¹⁵ and R¹⁶ are as defined above, R¹⁹ is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and L¹ and L² are


independently a halogen atom or a methylthio group.

A compound of the formula $1a^3$ may be obtained by reacting a compound of the formula 13a with a methylenesulfonamide derivative of the formula 15 (for example Chem. Ber., 99, 2900(1966)) in an inert solvent at a reaction temperature of -20°C to 80°C and then with an amine of the formula 11. Preferable examples of the solvent are acetonitrile, diethyl ether, tetrahydrofuran, 1,4-dioxane, benzene, toluene, methylene chloride, carbon tetrachloride, etc.

When E is a single bond, the compound of the formula 15 is preferably a compound in which both L^1 and L^2 are chlorine atoms.

When R^{13} , R^{15} or R^{16} is a protecting group for NH group in the compound of the formula $1a^3$, deprotection may be carried out in the same manner as above if desired. It is also possible to remove the group represented by $-\text{SO}_2\text{R}^{19}$, in the same manner as above if desired.

20 Process 5




wherein D, E, J, G, R^{13} , R^{15} and R^{16} are as defined above.

A compound of the formula $1a^4$ may be obtained

by reacting a compound of the formula 13a with a cyanoamido derivative of the formula 16 (for example, commercially available cyanomorpholine) in an inert solvent in the presence of a base at a temperature of 20°C to 130°C. Examples of the base are sodium hydride, potassium carbonate, sodium amide, lithium amide, etc. Preferable examples of the solvent are N,N-dimethylformamide, tetrahydrofuran, toluene, acetonitrile, tert-butanol, etc.

When R^{13} , R^{15} or R^{16} is a protecting group for NH group in the compound of the formula 1a⁴, deprotection may be carried out in the same manner as above if desired.

The compound represented by the formula 20a which becomes the starting compound in the above-mentioned method can also be produced as follows:



wherein G and J are as defined above; and R^{20} represents -CO_2R^{21} or -SO_2R^{21} in which R^{21} represents a lower alkyl group or an aryl group.

The compound of the formula 19 can be obtained by activating the carboxyl group of the compound of the

formula 17, reacting it with the compound of the formula 18 which is, if necessary, treated with a base, in an inert solvent at a reaction temperature of -78 to 30°C and subsequently removing the group represented by R²⁰.

5 Preferable examples of the inert solvent include tetrahydrofuran, methylene chloride, toluene and the like.

 The method of activating the carboxyl group can be carried out by effecting the reaction in the inert
10 solvent, if necessary, in the presence of an additive. As the activating agent, the additive and the reaction conditions, there can be used those which are usually used, and there are mentioned, for example, those stated in "Reactivity and Structure Concepts in Organic
15 Chemistry, Vol. 21; The Practice of Peptide Synthesis" (M. Bodanszky and A. Bodanszky, Springer-Verlag, Berlin (1984), pp. 87-150). Preferable activating agents are, for example, 1,1'-carbonyldiimidazole, isobutyl chloroformate, n-butyl chloroformate and the like.

20 Preferable additives are, for example, triethylamine, 4-(dimethylamino)pyridine, N-methylmorpholine and the like.

Preferable solvents are, for example, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, toluene and the like.

25 Preferable examples of the compound of the formula 18 are isopropyl cyanoacetate, tert-butyl cyanoacetate, methylsulfonylacetonitrile, phenylsulfonylacetonitrile and the like. Preferable examples

of the base with which the compound of the formula 18 is, if necessary, treated are 4-(dimethyl-amino)pyridine, lithium diisopropylamide, magnesium ethoxide and the like, and more preferable examples are sodium hydride,
5 lithium amide and the like.

As a method of removing the group represented by R^{20} , a conventional method can be used. When R^{20} is $-CO_2R^{21}$, the method can be carried out, for example, by subjecting the compound to acid treatment at a reaction
10 temperature of 0 to 100°C in the inert solvent.

Preferable examples of the acid are hydrochloric acid, sulfuric acid, trifluoroacetic acid and the like.

Preferable examples of the inert solvent are tetrahydrofuran, methylene chloride, toluene and the like. When
15 R^{20} is $-SO_2R^{21}$, the method can be carried out according to the known method (for example, K.C. Santhosh et al., J. Chem. Soc., Chem. Commun., 1992, 224; R. Giovannini et al., Synlett, 1995, 973).

The amine of the formula 20a can be produced by
20 reacting the compound of the formula 19 with hydroxylamine according to the known method (for example, Japanese Patent Unexamined Publication No. 63-152,368).

The compound of the formula 20a can be produced directly from the compound of the formula 17 without
25 isolating the compound of the formula 19. That is to say, by allowing the compound of the formula 19 as produced to react with hydroxylamine in a water-soluble solvent having, if necessary, added thereto water or a

buffer solution at a reaction temperature of 20 to 100°C, the amine of the formula 20a can be produced directly from the compound of the formula 17. Preferable examples of the water-soluble solvent are ethanol, isopropanol, 5 tert-butanol, N,N-dimethylformamide and the like. Preferable examples of the buffer solution are phosphate buffer solution, acetate buffer solution and the like.

According to the above method, when there is an asymmetric carbon atom in the J position, it is possible 10 to produce the amine of the formula 20a while keeping its optical purity.

As a process for producing an isoxazole derivative of the formula 1 wherein any two of R¹, R², R³ and R⁴ are taken together with the nitrogen atom(s) 15 to form a heterocyclic ring, there are, for example, a process using a starting material having said ring structure, according to any of the above-mentioned process 1 to 5, and a process of carrying out ring closure of a substituent in the middle or the final step 20 of any of the above-mentioned production processes [for example, condensation reaction of a carboxyl group with a NH group (for instance, J. Gen. Chem. U.S.S.R., 18, 2023(1948), and ring-closing reaction using the following reagents for reaction]. The reagents for reaction 25 used in the ring-closing reaction include 1,3-dibromopropane (J. Chem. Soc. Chem. Commun., 1992, 507), 1,4-diaminobutane (J. Am. Chem. Soc., 70, 430(1948)), bis-chloromethyl-methyl-amine (European Patent No. 428941),

paraformaldehyde (European Patent No. 580553), butyl-
amine and formaldehyde (J. Org. Chem., 25, 147(1960)),
glyoxal (Tetrahedron Lett., 32, 5325(1991)), acrylic
esters (Heterocycles, 20, 1769(1983)), benzylidene-
5 acetone (J. Heterocycl. Chem., 21, 65(1984)), epibromo-
hydrin (Can. J. Chem., 53, 894(1975)), etc.

As a process for producing an isoxazole
derivative of the formula 1 wherein J represents
-C(=CR⁸R⁹)- wherein R⁸ and R⁹ are as defined above, there
10 is, for example, a process which comprises treating an
isoxazole derivative of the formula 1 wherein J
represents -C(R^{8a}R^{9a})- wherein R^{8a} represents a lower
alkoxyl group and R^{9a} represents a lower alkyl group,
with an acid such as trifluoroacetic acid in an inert
15 solvent such as methylene chloride.

As a process for producing an isoxazole
derivative of the formula 1 wherein each of R⁸ and R⁹
represents a substituted or unsubstituted lower alkyl
group, or R⁸ and R⁹ are bound to each other and taken
20 together with a carbon atom to form a substituted or
unsubstituted 1,3-dioxane or a substituted or
unsubstituted 1,3-dioxolane, there is, for example, a
process which comprises reacting an ester of 2-
ketoalkanoic acid with an alcohol, an trialkyl orthformate
25 or its derivative, ethyleneglycol or its derivative, or
1,3-propanediol or its derivative in the presence of an
acid (for example, "Protective Groups in Organic
Synthesis", 2nd Edition, T.W.Greene and P.G.M.Wuts, John

Wiley and Sons, inc., New York (1991), p. 185-195);
converting the reaction product into the compound of the
formula 6 according to a known method (for example,
Japanese Patent Unexamined Publication No. 63-152308);
5 and further converting the resulted product into the
objective compound according to the Process 1 or 2 as
stated hereinbefore.

The isoxazole derivative of the formula 1
wherein D represents an alkoxycarbonyl group may be
10 subjected to hydrolysis followed by decarboxylation to
form an isoxazole derivative of the formula 1 wherein D
represents a hydrogen atom.

The isoxazole derivative of the formula 1
having at least one asymmetric center in the molecule may
15 be produced by using the corresponding starting compound
having the asymmetric center, or introducing the
asymmetric center thereinto in the steps for producing
the objective compound. For example, when producing the
optical isomer of the isoxazole derivative, the isomer
20 may be produced by using the corresponding optically
active starting material, or making optical resolution in
the steps for producing the objective compound.

When used as a medicine, the isoxazole
derivative or pharmaceutically acceptable salt
25 thereof of the present invention may be administered
orally or parenterally (for example, intravenously,
subcutaneously, intramuscularly, locally, rectally,
percutaneously, or through nose). Pharmaceutical forms

for the oral administration include, for example, tablets, capsules, pills, granules, powders, solutions, syrups, suspensions, etc. Pharmaceutical forms for the parenteral administration include, for example, aqueous
5 or oily preparations for injection, ointments, creams, lotions, aerosols, suppositories, patches, etc. These preparations are prepared by conventional techniques and may contain conventional acceptable carriers, excipients, binders, stabilizers, etc. When said isoxazole
10 derivative or salt thereof is used in the form of an injection, there may be added a buffer, a solubilizer, a tonicity agent and the like which are acceptable.

Although dose and frequency of administrations of the isoxazole derivative or pharmaceutically
15 acceptable salt thereof of the present invention are varied depending on symptom, age, body weight and administration route, the isoxazole derivative or salt thereof may be administered to an adult usually in a dose of approximately 1 - 2,000 mg, preferably 10 - 500
20 mg, in terms of the compound of the present invention as active ingredient, per day in one portion or several portions.

Specific examples of compounds included in the present invention are the compounds described below.
25 These compounds, however, are for exemplification, and the present invention is not limited to them.

N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;

N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-N,N-dimethyl-guanidine;

N'-(2-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-ethyl)-N,N-dimethyl-guanidine;

5 N'-(3-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-propyl)-N,N-dimethyl-guanidine;

N'-(2-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-ethyl)-N,N-dimethyl-guanidine;

10 N'-(3-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-propyl)-N,N-dimethyl-guanidine;

N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-5-yl)-N,N-dimethyl-guanidine;

N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;

15 N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-3-yl)-N,N-dimethyl-guanidine;

N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;

20 5-(N',N'-Dimethyl-guanidino)-3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic acid;

5-(N',N'-Dimethyl-guanidinomethyl)-3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic
acid;

25 3-(N',N'-Dimethyl-guanidino)-5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic acid;

3-(N',N'-Dimethyl-guanidinomethyl)-5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic
acid;

- {5-(N',N'-Dimethyl-guanidino)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;
- {5-(N',N'-Dimethyl-guanidinomethyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;
- 5 {3-(N',N'-Dimethyl-guanidino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;
- {3-(N',N'-Dimethyl-guanidinomethyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;
- 10 N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-hydroxymethyl-isoxazol-5-yl)-N,N-dimethyl-guanidine;
- N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-hydroxymethyl-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;
- N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-hydroxymethyl-isoxazol-3-yl)-N,N-dimethyl-guanidine;
- 15 N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-hydroxymethyl-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;
- N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-N,N-dimethyl-guanidine;
- 20 N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;
- N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-yl)-N,N-dimethyl-guanidine;
- 25 N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;
- N'-(3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-yl)-N,N-dimethyl-guanidine;

N' - [3 - (2-Fluoro-biphenyl-4-ylmethyl) - isoxazol-5-ylmethyl] - N,N-dimethyl-guanidine;

N' - [5 - (2-Fluoro-biphenyl-4-ylmethyl) - isoxazol-3-yl] - N,N-dimethyl-guanidine;

5 N' - [5 - (2-Fluoro-biphenyl-4-ylmethyl) - isoxazol-3-ylmethyl] - N,N-dimethyl-guanidine;

N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - cyclopropyl] - isoxazol-5-yl} - N,N-dimethyl-guanidine;

10 N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - cyclopropyl] - isoxazol-5-ylmethyl} - N,N-dimethyl-guanidine;

N' - {5 - [1 - (2-Fluoro-biphenyl-4-yl) - cyclopropyl] - isoxazol-3-yl} - N,N-dimethyl-guanidine;

N' - {5 - [1 - (2-Fluoro-biphenyl-4-yl) - cyclopropyl] - isoxazol-3-ylmethyl} - N,N-dimethyl-guanidine;

15 N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - vinyl] - isoxazol-5-yl} - N,N-dimethyl-guanidine;

N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - vinyl] - isoxazol-5-ylmethyl} - N,N-dimethyl-guanidine;

20 N' - {5 - [1 - (2-Fluoro-biphenyl-4-yl) - vinyl] - isoxazol-3-yl} - N,N-dimethyl-guanidine;

N' - {5 - [1 - (2-Fluoro-biphenyl-4-yl) - vinyl] - isoxazol-3-ylmethyl} - N,N-dimethyl-guanidine;

N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - 2-methylpropenyl] - isoxazol-5-yl} - N,N-dimethyl-guanidine;

25 N' - {3 - [1 - (2-Fluoro-biphenyl-4-yl) - 2-methylpropenyl] - isoxazol-5-ylmethyl} - N,N-dimethyl-guanidine;

N' - {5 - [1 - (2-Fluoro-biphenyl-4-yl) - 2-methylpropenyl] - isoxazol-3-yl} - N,N-dimethyl-guanidine;

N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-propenyl]-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;

N'-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-N,N-dimethyl-guanidine;

5 N'-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;

N'-(5-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-3-yl)-N,N-dimethyl-guanidine;

10 N'-(5-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;

N'-(3-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-5-yl)-N,N-dimethyl-guanidine;

N'-(3-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;

15 N'-(5-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-3-yl)-N,N-dimethyl-guanidine;

N'-(5-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;

20 N'-(3-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-yl)-N,N-dimethyl-guaniline;

N'-(3-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-ylmethyl)-N,N-dimethyl-guanidine;

N'-(5-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-3-yl)-N,N-dimethyl-guanidine;

25 N'-(5-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-3-ylmethyl)-N,N-dimethyl-guanidine;

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino)-piperidin-1-yl-methyl)-amine;

- ((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino)-piperidin-1-yl-methyl)-amine;
- ((2-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-ethylimino)-piperidin-1-yl-methyl)-amine;
- 5 ((3-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-propylimino)-piperidin-1-yl-methyl)-amine;
- ((2-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-ethylimino)-piperidin-1-yl-methyl)-amine;
- 10 ((3-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-propylimino)-piperidin-1-yl-methyl)-amine;
- ((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-methyl-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine;
- 15 ((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-methyl-isoxazol-5-ylmethylimino)-piperidin-1-yl-methyl)-amine;
- ((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-methyl-isoxazol-3-ylimino)-piperidin-1-yl-methyl)-amine;
- 20 ((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-methyl-isoxazol-3-ylmethylimino)-piperidin-1-yl-methyl)-amine;
- 5-(Amino-piperidin-1-yl-methyleneamino)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic
- 25 acid;
- 5-(Amino-piperidin-1-yl-methyleneamino-methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic acid;

3-(Amino-piperidin-1-yl-methyleneamino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic acid;

5 3-(Amino-piperidin-1-yl-methyleneamino-methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic acid;

{5-(Amino-piperidin-1-yl-methyleneamino)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;

10 {5-(Amino-piperidin-1-yl-methyleneamino-methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;

{3-(Amino-piperidin-1-yl-methyleneamino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;

15 {3-(Amino-piperidin-1-yl-methyleneamino-methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic acid;

{5-(Amino-piperidin-1-yl-methyleneamino)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-methanol;

~~{5-(Amino-piperidin-1-yl-methyleneamino-methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-methanol;~~

25 {3-(Amino-piperidin-1-yl-methyleneamino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-methanol;

{3-(Amino-piperidin-1-yl-methyleneamino-

methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-methanol;

((3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine;

5 ((3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylmethylimino)-piperidin-1-yl-methyl)-amine;

((5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-ylimino)-piperidin-1-yl-methyl)-amine;

10 ((5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-ylmethylimino)-piperidin-1-yl-methyl)-amine;

[[3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-ylimino]-piperidin-1-yl-methyl)-amine;

15 [[3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-ylmethylimino]-piperidin-1-yl-methyl)-amine;

[[5-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-3-ylimino]-piperidin-1-yl-methyl)-amine;

20 [[5-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-3-ylmethylimino]-piperidin-1-yl-methyl)-amine;

((3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine;

((3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-5-ylmethylimino)-piperidin-1-yl-methyl)-amine;

25 ((5-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-3-ylimino)-piperidin-1-yl-methyl)-amine;

((5-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-3-ylmethylimino)-piperidin-1-yl-methyl)-amine;

- ({3-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-
isoxazol-5-ylimino}-piperidin-1-yl-methyl)-amine;
- ({3-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-
isoxazol-5-ylmethyylimino}-piperidin-1-yl-methyl)-amine;
- 5 ({5-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-
isoxazol-3-ylimino}-piperidin-1-yl-methyl)-amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-
isoxazol-3-ylmethyylimino}-piperidin-1-yl-methyl)-amine;
- ({3-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-
10 propenyl]-isoxazol-5-ylimino}-piperidin-1-yl-methyl)-
amine;
- ({3-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-
propenyl]-isoxazol-5-ylmethyylimino}-piperidin-1-yl-
methyl)-amine;
- 15 ({5-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-
propenyl]-isoxazol-3-ylimino}-piperidin-1-yl-methyl)-
amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-
propenyl]-isoxazol-3-ylmethyylimino}-piperidin-1-yl-
20 methyl)-amine;
- (3-{1-[5-(Amino-piperidin-1-yl-methylene-
amino)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;
- (3-{1-[5-(Amino-piperidin-1-yl-methyleneamino-
methyl)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;
- 25 (3-{1-[3-(Amino-piperidin-1-yl-methylene-
amino)-isoxazol-5-yl]-ethyl}-phenyl)-phenyl-methanone;
- (3-{1-[3-(Amino-piperidin-1-yl-methyleneamino-
methyl)-isoxazol-5-yl]-ethyl}-phenyl)-phenyl-methanone;

- ({ 3 - [1 - (4 - Isobutyl - phenyl) - ethyl] - isoxazol - 5 -
ylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 3 - [1 - (4 - Isobutyl - phenyl) - ethyl] - isoxazol - 5 -
ylmethylimino } - piperidin - 1 - yl - methyl) - amine ;
- 5 ({ 5 - [1 - (4 - Isobutyl - phenyl) - ethyl] - isoxazol - 3 -
ylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 5 - [1 - (4 - Isobutyl - phenyl) - ethyl] - isoxazol - 3 -
ylmethylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 3 - [1 - (6 - Methoxy - naphthalen - 2 - yl) - ethyl] -
10 isoxazol - 5 - ylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 3 - [1 - (6 - Methoxy - naphthalen - 2 - yl) - ethyl] -
isoxazol - 5 - ylmethylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 5 - [1 - (6 - Methoxy - naphthalen - 2 - yl) - ethyl] -
isoxazol - 3 - ylimino } - piperidin - 1 - yl - methyl) - amine ;
- 15 ({ 5 - [1 - (6 - Methoxy - naphthalen - 2 - yl) - ethyl] -
isoxazol - 3 - ylmethylimino } - piperidin - 1 - yl - methyl) - amine ;
- ({ 3 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -
isoxazol - 5 - ylmethylimino } - morpholin - 4 - yl - methyl) - amine ;
- ({ 5 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -
20 isoxazol - 3 - ylimino } - morpholin - 4 - yl - methyl) - amine ;
- [(2 - { 3 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -
isoxazol - 5 - yl } - ethylimino) - morpholin - 4 - yl - methyl] - amine ;
- [(3 - { 3 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -
isoxazol - 5 - yl } - propylimino) - morpholin - 4 - yl - methyl] -
25 amine ;
- [(2 - { 5 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -
isoxazol - 3 - yl } - ethylimino) - morpholin - 4 - yl - methyl] - amine ;
- [(3 - { 5 - [1 - (2 - Fluoro - biphenyl - 4 - yl) - ethyl] -

isoxazol-3-yl}-propylimino)-morpholin-4-yl-methyl]-
amine;

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

5 ((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-5-ylmethylimino)-morpholin-4-yl-methyl)-
amine;

((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-3-ylimino)-morpholin-4-yl-methyl)-amine;

10 ((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-4-
methyl-isoxazol-3-ylmethylimino)-morpholin-4-yl-methyl)-
amine;

5-(Amino-morpholin-4-yl-methyleneamino)-3-[1-
(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic
15 acid;

5-(Amino-morpholin-4-yl-methyleneamino-
methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-
4-carboxylic acid;

3-(Amino-morpholin-4-yl-methyleneamino)-5-[1-
20 (2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-4-carboxylic
acid;

3-(Amino-morpholin-4-yl-methyleneamino-
methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole-
4-carboxylic acid;

25 {5-(Amino-morpholin-4-yl-methyleneamino)-3-[1-
(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl}-acetic
acid;

{5-(Amino-morpholin-4-yl-methyleneamino-

methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-acetic acid;

 {3-(Amino-morpholin-4-yl-methyleneamino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-acetic
5 acid;

 {3-(Amino-morpholin-4-yl-methyleneamino-methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-acetic acid;

 {5-(Amino-morpholin-4-yl-methyleneamino)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-methanol;
10

 {5-(Amino-morpholin-4-yl-methyleneamino-methyl)-3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-methanol;

 {3-(Amino-morpholin-4-yl-methyleneamino)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-methanol;
15

 {3-(Amino-morpholin-4-yl-methyleneamino-methyl)-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-4-yl)-methanol;

 ({3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylmethylimino)-morpholin-4-yl-methyl)-amine;
20

 ({5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-ylimino)-morpholin-4-yl-methyl)-amine;

 ({5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-3-ylmethylimino)-morpholin-4-yl-methyl)-amine;
25

 ({3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-ylmethylimino)-morpholin-4-yl-methyl)-amine;

- {[5-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-3-ylimino]-morpholin-4-yl-methyl}-amine;
- {[5-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-3-ylmethylimino]-morpholin-4-yl-methyl}-amine;
- 5 ({3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-5-ylmethylimino}-morpholin-4-yl-methyl)-amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-3-ylimino}-morpholin-4-yl-methyl)-amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-3-ylmethylimino}-morpholin-4-yl-methyl)-amine;
- 10 ({3-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;
- ({3-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-isoxazol-5-ylmethylimino}-morpholin-4-yl-methyl)-amine;
- 15 ({5-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-isoxazol-3-ylimino}-morpholin-4-yl-methyl)-amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-isoxazol-3-ylmethylimino}-morpholin-4-yl-methyl)-amine;
- ({3-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-propenyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;
- 20 ({3-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-propenyl]-isoxazol-5-ylmethylimino}-morpholin-4-yl-methyl)-amine;
- 25 ({5-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-propenyl]-isoxazol-3-ylimino}-morpholin-4-yl-methyl)-amine;
- ({5-[1-(2-Fluoro-biphenyl-4-yl)-2-methyl-

propenyl]-isoxazol-3-ylmethylimino}-morpholin-4-yl-methyl)-amine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino-methyl)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;

5 (3-{1-[3-(Amino-morpholin-4-yl-methylene-amino)-isoxazol-5-yl]-ethyl}-phenyl)-phenyl-methanone;

(3-{1-[3-(Amino-morpholin-4-yl-methyleneamino-methyl)-isoxazol-5-yl]-ethyl}-phenyl)-phenyl-methanone;

10 ({3-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-5-ylmethylimino}-morpholin-4-yl-methyl)-amine;

((5-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-3-ylimino)-morpholin-4-yl-methyl)-amine;

((5-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-3-ylmethylimino)-morpholin-4-yl-methyl)-amine;

15 ((3-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-ylmethylimino)-morpholin-4-yl-methyl)-amine;

((5-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-3-ylimino)-morpholin-4-yl-methyl)-amine;

20 ((5-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-3-ylmethylimino)-morpholin-4-yl-methyl)-amine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-guanidine;

25 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-N'-methyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-N'-methyl-guanidine;

N-Ethyl-N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-guanidine;

N-Ethyl-N'-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-guanidine;

5 N-Ethyl-N'-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-guanidine;

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-N'-phenyl-guanidine;

10 N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-N'-phenyl-guanidine;

N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N'-phenyl-guanidine;

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-p-toluyyl-guanidine;

15 N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-N'-p-toluyyl-guanidine;

N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-N'-p-toluyyl-guanidine;

20 N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N'-p-toluyyl-guanidine;

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(4-methoxy-phenyl)-guanidine;

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-N'-(4-methoxy-phenyl)-guanidine;

25 N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-N'-(4-methoxy-phenyl)-guanidine;

N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N'-(4-methoxy-phenyl)-guanidine;

N-Benzyl-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine;

N-Benzyl-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-guanidine;

5 N-Benzyl-N'-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-guanidine;

N-Benzyl-N'-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-guanidine;

10 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-phenethyl-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-N'-phenethyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-N'-phenethyl-guanidine;

15 N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N'-phenethyl-guanidine;

N-(2-Amino-ethyl)-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine;

20 N-(2-Amino-ethyl)-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-guanidine;

N-(2-Amino-ethyl)-N'-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-guanidine;

N-(2-Amino-ethyl)-N'-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-guanidine;

25 [{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperidin-1-yl)-methyl]-amine;

[{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-

isoxazol-5-ylmethylimino)-(4-methyl-piperidin-1-yl)-
methyl]-amine;

5 [[5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino)-(4-methyl-piperidin-1-yl)-methyl]-
amine;

 [[5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethylimino)-(4-methyl-piperidin-1-yl)-
methyl]-amine;

10 ((2,6-Dimethyl-piperidin-1-yl)-{3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-
methyl)-amine;

 ((2,6-Dimethyl-piperidin-1-yl)-{3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-
methyl)-amine;

15 ((2,6-Dimethyl-piperidin-1-yl)-{5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-
methyl)-amine;

 ((2,6-Dimethyl-piperidin-1-yl)-{5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-
20 methyl)-amine;

 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylmethylimino}-methyl)-piperidin-4-ol;

 1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylimino}-methyl)-piperidin-4-ol;

25 1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylmethylimino}-methyl)-piperidin-4-ol;

 [[3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino)-(4-methoxy-piperidin-1-yl)-methyl]-

amine;

[{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethylimino}-(4-methoxy-piperidin-1-yl)-
methyl]-amine;

5 [{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino}-(4-methoxy-piperidin-1-yl)-methyl]-
amine;

[{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethylimino}-(4-methoxy-piperidin-1-yl)-
10 methyl]-amine;

((4-Amino-piperidin-1-yl)-(3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-amine;

((4-Amino-piperidin-1-yl)-(3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino)-methyl)-
15 amine;

((4-Amino-piperidin-1-yl)-(5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino)-methyl)-amine;

((4-Amino-piperidin-1-yl)-(5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-
20 amine;

((4-Dimethylamino-piperidin-1-yl)-(3-[1-(2-
~~fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-~~
methyl)-amine;

((4-Dimethylamino-piperidin-1-yl)-(3-[1-(2-
25 fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino)-
methyl)-amine;

((4-Dimethylamino-piperidin-1-yl)-(5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino)-

methyl)-amine;

((4-Dimethylamino-piperidin-1-yl)-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-amine;

5 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-piperidine-4-carboxylic acid;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino)-methyl)-piperidine-4-
10 carboxylic acid;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino)-methyl)-piperidine-4-carboxylic acid;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-piperidine-4-
15 carboxylic acid;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-piperidine-4-carboxamide;

20 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino)-methyl)-piperidine-4-carboxamide;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino)-methyl)-piperidine-4-
25 carboxamide;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-piperidine-4-carboxamide;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidine-3-carboxylic acid;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-methyl)-piperidine-3-carboxylic acid;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-methyl)-piperidine-3-carboxylic acid;

10 1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-methyl)-piperidine-3-carboxylic acid;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidine-3-

15 carboxamide;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-methyl)-piperidine-3-carboxamide;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-methyl)-piperidine-3-carboxamide;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-methyl)-piperidine-3-carboxamide;

25 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-methyl)-piperidin-4-one;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-

ethyl]-isoxazol-3-ylimino)-methyl)-piperidin-4-one;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-piperidin-4-one;

5 ((3,5-Dimethyl-morpholin-4-yl)-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-amine;

((3,5-Dimethyl-morpholin-4-yl)-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-methyl)-amine;

10 ((3,5-Dimethyl-morpholin-4-yl)-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-methyl)-amine;

((3,5-Dimethyl-morpholin-4-yl)-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-methyl)-amine;

((2,6-Dimethyl-morpholin-4-yl)-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-amine;

20 ((2,6-Dimethyl-morpholin-4-yl)-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethylimino}-methyl)-amine;

((2,6-Dimethyl-morpholin-4-yl)-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-methyl)-amine;

25 ((2,6-Dimethyl-morpholin-4-yl)-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-methyl)-amine;

- (({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethylimino}-thiamorpholin-4-yl-methyl)-
amine;
- 5 (({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino}-thiamorpholin-4-yl-methyl)-amine;
- (({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethylimino}-thiamorpholin-4-yl-methyl)-
amine;
- 10 (({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethylimino}-piperazin-1-yl-methyl)-amine;
- (({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino}-piperazin-1-yl-methyl)-amine;
- (({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethylimino}-piperazin-1-yl-methyl)-amine;
- 15 [({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethylimino}-(4-methyl-piperazin-1-yl)-
methyl)-amine;
- [({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino}-(4-methyl-piperazin-1-yl)-methyl)-
20 amine;
- [({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethylimino}-(4-methyl-piperazin-1-yl)-
methyl)-amine;
- 25 2-[4-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-yl]-
ethanol;
- 2-[4-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylmethylimino}-methyl)-piperazin-1-

yl]-ethanol;

2-[4-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylimino}-methyl)-piperazin-1-yl]-
ethanol;

5 2-[4-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylmethyylimino}-methyl)-piperazin-1-
yl]-ethanol;

10 ([4-(2-Amino-ethyl)-piperazin-1-yl]-{3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-
methyl)-amine;

10 ([4-(2-Amino-ethyl)-piperazin-1-yl]-{3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyylimino}-
methyl)-amine;

15 ([4-(2-Amino-ethyl)-piperazin-1-yl]-{5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylimino}-
methyl)-amine;

15 ([4-(2-Amino-ethyl)-piperazin-1-yl]-{5-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyylimino}-
methyl)-amine;

20 1-[4-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-yl]-
ethanone;

25 1-[4-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylmethyylimino}-methyl)-piperazin-1-
yl]-ethanone;

1-[4-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylimino}-methyl)-piperazin-1-yl]-
ethanone;

1-[4-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-methyl)-piperazin-1-yl]-ethanone;

(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-guanidino)-acetic acid;

(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-guanidino)-acetic acid;

(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-guanidino)-acetic acid;

10 (N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N-methyl-guanidino)-acetic acid;

(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-N-methyl-guanidino)-acetic acid;

15 (N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-N-methyl-guanidino)-acetic acid;

(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N-methyl-guanidino)-acetic acid;

Ethyl (N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-guanidino)-acetate;

20 Ethyl (N'-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-guanidino)-acetate;

Ethyl (N'-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-guanidino)-acetate;

25 2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidino)-acetamide;

2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-guanidino)-acetamide;

2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-

- isoxazol-3-yl}-guanidino)-acetamide;
2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-guanidino)-acetamide;
2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-yl}-guanidino)-propionic acid;
2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl)-guanidino)-propionic acid;
2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-guanidino)-propionic acid;
10 2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-guanidino)-propionic acid;
2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-guanidino)-succinic acid;
2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
15 isoxazol-5-ylmethyl)-guanidino)-succinic acid;
2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-guanidino)-succinic acid;
2-(N'-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-guanidino)-succinic acid;
20 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylimino)-methyl)-pyrrolidine-2-
carboxylic acid;
1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylmethyylimino)-methyl)-pyrrolidine-2-
25 carboxylic acid;
1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylimino)-methyl)-pyrrolidine-2-
carboxylic acid;

1-(Amino-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-methyl)-pyrrolidine-2-carboxylic acid;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N',N"-dimethyl-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-N',N"-dimethyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-N',N"-dimethyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N',N"-dimethyl-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-methyl-N"-phenyl-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-N'-methyl-N"-phenyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-N'-methyl-N"-phenyl-guanidine;

N-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N'-methyl-N"-phenyl-guanidine;

N"-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N,N,N',N'-tetramethyl-guanidine;

N"-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-N,N,N',N'-tetramethyl-guanidine;

N"-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-N,N,N',N'-tetramethyl-guanidine;

N"-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N,N,N',N'-tetramethyl-guanidine;

(Di-piperidin-1-yl-methylene)-{3-[1-(2-fluoro-

- biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;
(Di-piperidin-1-yl-methylene)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-amine;
(Di-piperidin-1-yl-methylene)-{5-[1-(2-fluoro-
5 biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-amine;
(Di-piperidin-1-yl-methylene)-{5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-amine;
(Di-morpholin-4-yl-methylene)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;
10 (Di-morphilin-4-yl-methylene)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-amine;
(Di-morphilin-4-yl-methylene)-{5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-amine;
(Di-morphilin-4-yl-methylene)-{5-[1-(2-fluoro-
15 biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-amine;
(Di-piperazin-4-yl-methylene)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;
(Di-piperazin-4-yl-methylene)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-amine;
20 (Di-piperazin-4-yl-methylene)-{5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-amine;
(Di-piperazin-4-yl-methylene)-{5-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-amine;
(4,5-Dihydro-1H-imidazol-2-yl)-{3-[1-(2-
25 fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;
(4,5-Dihydro-1H-imidazol-2-yl)-{3-[1-(2-
fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-amine;
(4,5-Dihydro-1H-imidazol-2-yl)-{5-[1-(2-

- fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-amine;
(4,5-Dihydro-1H-imidazol-2-yl)-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-amine;
1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-yl)-4,5-dihydro-1H-imidazol-2-ylamine;
1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl)-4,5-dihydro-1H-imidazol-2-ylamine;
1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-4,5-dihydro-1H-imidazol-2-ylamine;
10 1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-4,5-dihydro-1H-imidazol-2-ylamine;
(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-
5-yl)-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine;
(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-
15 5-ylmethyl)-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine;
(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-
3-yl)-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine;
(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-
3-ylmethyl)-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine;
20 1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-1,4,5,6-tetrahydro-pyrimidin-2-ylamine;
1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl)-1,4,5,6-tetrahydro-pyrimidin-2-
ylamine;
25 1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-1,4,5,6-tetrahydro-pyrimidin-2-ylamine;
1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-1,4,5,6-tetrahydro-pyrimidin-2-

ylamine;

(3,6-Dihydro-2H-[1,3,5]oxadiazin-4-yl)-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-amine;

(3,6-Dihydro-2H-[1,3,5]oxadiazin-4-yl)-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-amine;

(3,6-Dihydro-2H-[1,3,5]oxadiazin-4-yl)-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl)-amine;

(3,6-Dihydro-2H-[1,3,5]oxadiazin-4-yl)-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-amine;

3-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-3,6-dihydro-2H-[1,3,5]oxadiazin-4-ylamine;

3-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl}-3,6-dihydro-2H-[1,3,5]oxadiazin-4-ylamine;

3-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-yl}-3,6-dihydro-2H-[1,3,5]oxadiazin-4-

ylamine;

3-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-3,6-dihydro-2H-[1,3,5]oxadiazin-4-

ylamine;

(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-(1,4,5,6-tetrahydro-[1,3,5]triazin-2-yl)-amine;

(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylmethyl)-(1,4,5,6-tetrahydro-[1,3,5]triazin-

2-yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-(1,4,5,6-tetrahydro-[1,3,5]triazin-2-yl)-
amine;

5 {5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-(1,4,5,6-tetrahydro-[1,3,5]triazin-
2-yl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-(5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
10 triazin-2-yl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl}-(5-methyl-1,4,5,6-tetrahydro-
[1,3,5]triazin-2-yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
15 isoxazol-3-yl}-(5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
triazin-2-yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-(5-methyl-1,4,5,6-tetrahydro-
[1,3,5]triazin-2-yl)-amine;

20 1-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-1,4,5,6-tetrahydro-[1,3,5]triazin-2-
ylamine;

1-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl}-1,4,5,6-tetrahydro-[1,3,5]triazin-2-
25 ylamine;

1-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-1,4,5,6-tetrahydro-[1,3,5]triazin-2-
ylamine;

1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-1,4,5,6-tetrahydro-[1,3,5]triazin-2-
ylamine;

1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-yl)-5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
triazin-2-ylamine;

1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
triazin-2-ylamine;

10 1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
triazin-2-ylamine;

1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-5-methyl-1,4,5,6-tetrahydro-[1,3,5]-
15 triazin-2-ylamine;

2-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylamino)-1,4,5,6-tetrahydro-pyrimidin-5-ol;

2-((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl)-amino)-1,4,5,6-tetrahydro-
20 pyrimidin-5-ol;

2-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylamino)-1,4,5,6-tetrahydro-pyrimidin-5-ol;

2-((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl)-amino)-1,4,5,6-tetrahydro-
25 pyrimidin-5-ol;

(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-(5-methoxy-1,4,5,6-tetrahydro-pyrimidin-2-
yl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl}-(5-methoxy-1,4,5,6-tetrahydro-
pyrimidin-2-yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-3-yl}-(5-methoxy-1,4,5,6-tetrahydro-pyrimidin-2-
yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-(5-methoxy-1,4,5,6-tetrahydro-
pyrimidin-2-yl)-amine;

10 2-Amino-1-(3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-yl)-1,4,5,6-tetrahydro-pyrimidin-5-ol;

2-Amino-1-(3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylmethyl)-1,4,5,6-tetrahydro-
pyrimidin-5-ol;

15 2-Amino-1-(5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-yl)-1,4,5,6-tetrahydro-pyrimidin-5-ol;

2-Amino-1-(5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylmethyl)-1,4,5,6-tetrahydro-
pyrimidin-5-ol;

20 1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-5-methoxy-1,4,5,6-tetrahydro-pyrimidin-2-
ylamine;

1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl)-5-methoxy-1,4,5,6-tetrahydro-
25 pyrimidin-2-ylamine;

1-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl)-5-methoxy-1,4,5,6-tetrahydro-pyrimidin-2-
ylamine;

1-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-5-methoxy-1,4,5,6-tetrahydro-
pyrimidin-2-ylamine;

5 {3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-(4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-
yl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylmethyl}-(4,5,6,7-tetrahydro-1H-[1,3]-
diazepin-2-yl)-amine;

10 {5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-(4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-
yl)-amine;

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-(4,5,6,7-tetrahydro-1H-[1,3]-
15 diazepin-2-yl)-amine;

1-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-
ylamine;

1-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
20 isoxazol-5-ylmethyl}-4,5,6,7-tetrahydro-1H-[1,3]-
diazepin-2-ylamine;

1-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-
ylamine;

25 1-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-4,5,6,7-tetrahydro-1H-[1,3]-
diazepin-2-ylamine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-

- isoxazol-5-ylmethylimino}-pyrrolidin-1-yl-methyl)-amine;
({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylimino}-pyrrolidin-1-yl-methyl)-amine;
({5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-3-ylmethylimino}-pyrrolidin-1-yl-methyl)-amine;
(Azepan-1-yl-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylimino}-methyl)-amine;
({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-ylimino}-thiazolidin-3-yl-methyl)-amine;
10 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-methyl)-piperidin-2-one;
N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;
Ethyl 3-(N'-(3-[1-(2-fluoro-biphenyl-4-yl)-
15 ethyl]-isoxazol-5-yl)-guanidino)-propionate;
2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;
3-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-guanidino)-N,N-dimethyl-propionamide;
20 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine;
N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;
N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
25 isoxazol-5-yl}-N'-(2-piperidin-1-yl-ethyl)-guanidine;
N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-
guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(3-morpholin-4-yl-propyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-[2-(2-methoxy-ethoxy)-ethyl]-guanidine;

5 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-[2-(3-hydroxy-propoxy)-ethyl]-
guanidine;

2-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-1-(2-methoxy-ethyl)-imidazolidin-4-
10 one;

N-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-methylamino-methyl)-N'-methyl-
guanidine;

N'-(Dimethylamino-{3-[1-(2-fluoro-biphenyl-4-
15 yl)-ethyl]-isoxazol-5-ylimino}-methyl)-N,N-dimethyl-
guanidine;

[{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-
methylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

20 N-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-(2-morpholin-4-yl-ethylamino)-
methyl)-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-(2-hydroxy-ethylamino)-methyl)-N'-(2-
25 hydroxy-ethyl)-guanidine;

N-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-[2-(2-hydroxy-ethoxy)-ethylamino]-
methyl)-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

- [Bis-(4-methyl-piperazin-1-yl)-methylene]-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-amine;
- N-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N',N''-bis-(2-morpholin-4-yl-ethyl)-
- 5 guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N',N''-bis-(2-hydroxy-ethyl)-guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N',N''-bis-[2-(2-hydroxy-ethoxy)-ethyl]-
- 10 guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(methylamino)-guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(dimethylamino)-guanidine;
- 15 N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(pyridin-2-yl-amino)-guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-pyridin-2-yl-guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-pyridin-4-yl-guanidine;
- 20 isoxazol-5-yl)-N'-pyrimidin-2-yl-guanidine;
- N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(1H-tetrazol-5-yl)-guanidine;
- 25 [{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-(1-oxo-[1,4]thiazinan-4-yl)-methyl]-amine;
- ((1,1-Dioxo-[1,4]thiazinan-4-yl)-(3-[1-(2-

fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-
amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-
5-yl}-(imino-morpholin-4-yl-methyl)-methyl-amine;

5 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-yl}-N'-methyl-guanidine;

N-Ethyl-N'-(3-[1-(2-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-yl)-guanidine;

N,N-Diethyl-N'-(3-[1-(2-fluoro-biphenyl-4-yl)-
10 1-methyl-ethyl]-isoxazol-5-yl)-guanidine;

{{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-pyrrolidin-1-yl-methyl)-amine;

(Azepan-1-yl-{3-[1-(2-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-ylimino}-methyl)-amine;

15 [{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-
methyl]-amine;

{{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-thiazolidin-3-yl-methyl)-

20 amine;

[{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-(4-methyl-piperidin-1-yl)-
methyl]-amine;

((2,6-Dimethyl-morpholin-4-yl)-(3-[1-(2-fluoro-
25 biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-
methyl)-amine;

((4-Dimethylamino-piperidin-1-yl)-(3-[1-(2-
fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-

ylimino}-methyl)-amine;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-one;

5 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-2-one;

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-ol;

10 [{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methoxy-piperidin-1-yl)-methyl]-amine;

15 amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-[1,4]thiazinan-4-yl-methyl)-

1-[4-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-yl]-ethanone;

20 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;

Ethyl (N'-(3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-acetate;

Ethyl 3-(N'-(3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-propionate;

25 2-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;

3-(N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-

propionamide;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-methoxy-ethyl)-guanidine;

N-(2-Dimethylamino-ethyl)-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-piperidin-1-yl-ethyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(3-morpholin-4-yl-propyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-

ethyl]-isoxazol-5-yl}-N'-[2-(2-methoxy-ethoxy)-ethyl]-
guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-yl}-N'-[2-(3-hydroxy-propoxy)-ethyl]-
5 guanidine;

2-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-1-methyl-imidazolidin-4-one;

2-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-1-(2-hydroxy-ethyl)-
10 imidazolidin-4-one;

2-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-1-(2-methoxy-ethyl)-
imidazolidin-4-one;

N-({3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
15 ethyl]-isoxazol-5-ylimino)-methylamino-methyl)-N'-methyl-
guanidine;

N'-(Dimethylamino-{3-[1-(2-fluoro-biphenyl-4-
yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-methyl)-N,N-
dimethyl-guanidine;

20 [({3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methylimino)-
morpholin-4-yl-methyl]-amine;

[({3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino)-(4-methyl-piperazin-1-yl)-
25 methylimino)-(4-methyl-piperazin-1-yl)-methyl]-amine;

N-({3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino)-(2-morpholin-4-yl-ethylamino)-
methyl)-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-{{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(2-hydroxy-ethylamino)-methyl}-N'-(2-hydroxy-ethyl)-guanidine;

N-{{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-[2-(2-hydroxy-ethoxy)-ethylamino]-methyl}-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-dimethyl-guanidine;

10 N"-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N,N,N',N'-tetramethyl-guanidine;

(Di-morpholin-4-yl-methylene)-{3-[1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-amine;

[Bis-(4-methyl-piperazin-1-yl)-methylene]-{3-
15 [1-(2-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-amine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-morpholin-4-yl-ethyl)-guanidine;

20 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-methyl-guanidine;

N'-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-

isoxazol-5-yl}-N,N-dimethyl-guanidine;

N-Ethyl-N'-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine;

N,N-Diethyl-N'-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine;

((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-pyrrolidin-1-yl-methyl)-amine

((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine;

(Azepan-1-yl-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-amine;

[(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-(4-methyl-piperazin-1-yl)-methyl]-amine;

((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-thiazolidin-3-yl-methyl)-amine;

[(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-(4-methyl-piperidin-1-yl)-methyl]-amine;

((2,6-Dimethyl-morpholin-4-yl)-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-amine;

((4-Dimethylamino-piperidin-1-yl)-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-

amine;

1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-one;

1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-

- ethyl]-isoxazol-5-ylimino)-methyl)-piperidin-2-one;
1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-ylimino)-methyl)-piperidin-4-ol;
[{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-ylimino)-(4-methoxy-piperidin-1-yl)-methyl]-
amine;
({3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino)-[1,4]thiazinan-4-yl-methyl)-amine;
1-[4-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-
10 ethyl]-isoxazol-5-ylimino)-methyl)-piperazin-1-yl]-
ethanone;
N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;
Ethyl (N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-
15 ethyl]-isoxazol-5-yl)-guanidino)-acetate;
Ethyl 3-(N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-yl)-guanidino)-propionate;
2-(N'-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;
20 3-(N'-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-guanidino)-N,N-dimethyl-propionamide;
N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine;
N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
25 isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine
N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}-N'-(2-methoxy-ethyl)-guanidine;
N-(2-Dimethylamino-ethyl)-N'-(3-[1-(2'-fluoro-

- biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-yl)-N'-(2-piperidin-1-yl-ethyl)-guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-(2-morpholin-4-yl-ethyl)-guanidine
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-
10 guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-(3-morpholin-4-yl-propyl)-guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;
15 N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-[2-(2-methoxy-ethoxy)-ethyl]-guanidine;
N-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-N'-[2-(3-hydroxy-propoxy)-ethyl]-
guanidine;
20 2-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino)-1-methyl-imidazolidin-4-one;
~~2-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-~~
isoxazol-5-ylimino)-1-(2-hydroxy-ethyl)-imidazolidin-4-
one;
25 2-(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino)-1-(2-methoxy-ethyl)-imidazolidin-4-
one;
N-((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-

isoxazol-5-ylimino)-methylamino-methyl)-N'-methyl-guanidine;

N'-(Dimethylamino-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-N,N-dimethyl-

5 guanidine;

[{(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methylimino)-morpholin-4-yl-methyl]-amine;

[{(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-(4-methyl-piperazin-1-yl)-methylimino)-(4-methyl-piperazin-1-yl)-methyl]-amine;

N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-(2-morpholin-4-yl-ethylamino)-methyl]-N'-(2-morpholin-4-yl-ethyl)-guanidine;

15 N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-(2-hydroxy-ethylamino)-methyl]-N'-(2-hydroxy-ethyl)-guanidine;

N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-[2-(2-hydroxy-ethoxy)-ethylamino]-

20 methyl]-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N',N'-dimethyl-guanidine

N"-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N,N,N',N'-tetramethyl-guanidine;

25 (Di-morpholin-4-yl-methylene)-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;

[Bis-(4-methyl-piperazin-1-yl)-methylene]-{3-[1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-amine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-morpholin-4-yl-ethyl)-guanidine;

5 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N',N"-bis-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

10 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-methyl-guanidine;

N'-(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-N,N-dimethyl-guanidine;

N-Ethyl-N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidine;

15 N,N-Diethyl-N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidine;

(({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-pyrrolidin-1-yl-methyl)-amine;

20 ethyl]-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine;

(Azepan-1-yl-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-methyl)-amine;

(({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

25 [{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

(({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-

ethyl]-isoxazol-5-ylimino}-thiazolidin-3-yl-methyl)-
amine;

5 [{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-(4-methyl-piperidin-1-yl)-
methyl]-amine;

 ((2,6-Dimethyl-morpholin-4-yl)-(3-[1-(2'-
fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-
ylimino)-methyl)-amine;

10 ((4-Dimethylamino-piperidin-1-yl)-(3-[1-(2'-
fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-
ylimino)-methyl)-amine;

 1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-
one;

15 1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-2-
one;

 1-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-ol;

20 [{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-(4-methoxy-piperidin-1-yl)-
methyl]-amine;

 ({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-
ethyl]-isoxazol-5-ylimino}-[1,4]thiazinan-4-yl-methyl)-
25 amine;

 1-[4-(Amino-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-
methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-
yl]-ethanone;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;

Ethyl (N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-acetate;

5 Ethyl 3-(N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-propionate;

2-(N'-(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;

3-(N'-(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-
10 propionamide;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine;
15

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-methoxy-ethyl)-guanidine;

N-(2-Dimethylamino-ethyl)-N'-(3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidine;

20 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-piperidin-1-yl-ethyl)-
25 guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-guanidine;

5 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(3-morpholin-4-yl-propyl)-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

10 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(2-methoxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-[2-(3-hydroxy-propoxy)-ethyl]-
15 guanidine;

2-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-1-methyl-imidazolidin-4-one;

2-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-1-(2-hydroxy-ethyl)-
20 imidazolidin-4-one;

2-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-1-(2-methoxy-ethyl)-
imidazolidin-4-one;

N-({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methylamino-methyl)-N'-methyl-
25 guanidine;

N'-(Dimethylamino-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-N,N-

dimethyl-guanidine;

[{(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methylimino)-morpholin-4-yl-methyl]-amine;

5 [[(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-(4-methyl-piperazin-1-yl)-methylimino)-(4-methyl-piperazin-1-yl)-methyl]-amine;

N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-(2-morpholin-4-yl-ethylamino)-methyl]-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-(2-hydroxy-ethylamino)-methyl]-N'-(2-hydroxy-ethyl)-guanidine;

15 N-[(3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-[2-(2-hydroxy-ethoxy)-ethylamino]-methyl]-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-dimethyl-guanidine;

20 N"-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N,N,N',N'-tetramethyl-guanidine;

(Di-morpholin-4-yl-methylene)-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-amine;

[Bis-(4-methyl-piperazin-1-yl)-methylene]-{3-[1-(2'-fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-amine;

25 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-morpholin-4-yl-ethyl)-

guanidine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-hydroxy-ethyl)-guanidine;

5 N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-methyl-guanidine;

10 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-ethyl-guanidine;

N'-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-N,N-diethyl-guanidine;

(3-{1-[5-(Amino-pyrrolidin-1-yl-methyleneamino)]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

(3-{1-[5-(Amino-azepan-1-yl-methyleneamino)]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-methylenemaino]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

20 (3-{1-[5-(Amino-thiazolidin-3-yl-methyleneamino)]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

25 [3-(1-{5-[Amino-(4-methyl-piperidin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(2,6-dimethyl-morpholin-4-yl)-

methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;

[3-(1-{5-[Amino-(4-dimethylamino-piperidin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-

5 methanone;

1-(Amino-{3-[1-(3-benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-one;

1-(Amino-{3-[1-(3-benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-2-one;

10 [3-(1-{5-[Amino-(4-hydroxy-piperidin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;

[3-(1-{5-[Amino-(4-methoxy-piperidin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-

15 methanone;

(3-{1-[5-(Amino-[1,4]thiazinan-4-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl)-phenyl-methanone;

20 1-[4-(Amino-{3-[1-(3-benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-yl]-ethanone;

N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;

Ethyl (N'-(3-[1-(3-benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-guanidino)-acetate;

25 Ethyl 3-(N'-(3-[1-(3-benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-guanidino)-propionate;

2-(N'-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;

- 3-(N'-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-propionamide;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine;
- 5 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-methoxy-ethyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-dimethylamino-ethyl)-guanidine;
- 10 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-piperidin-1-yl-ethyl)-guanidine;
- 15 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(3-morpholin-4-yl-propyl)-guanidine;
- 20 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-(2-hydroxy-ethoxy)-ethyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-[2-(2-methoxy-ethoxy)-ethyl]-guanidine;
- 25 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-[2-(3-hydroxy-propoxy)-ethyl]-guanidine;
- 2-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino}-1-methyl-imidazolidin-4-one;

- 2-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-1-(2-hydroxy-ethyl)-imidazolidin-4-one;
- 2-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-1-(2-methoxy-ethyl)-imidazolidin-4-one;
- 5 N-((3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-methylamino-methyl)-N'-methyl-guanidine;
- N'-((3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-dimethylamino-methyl)-N,N-dimethyl-guanidine;
- [3-(1-{5-[(Amino-morpholin-4-yl-methyleneamino)-morpholin-4-yl-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;
- 10 [3-(1-{5-[[Amino-(4-methyl-piperazin-1-yl)-methyleneamino]-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;
- 15 methanone;
- N-[(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-(2-morpholin-4-yl-ethylamino)-methyl]-N'-(2-morpholin-4-yl-ethyl)-guanidine;
- N-[(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-ylimino)-2-(hydroxy-ethylamino)-methyl]-N'-(2-hydroxy-ethyl)-guanidine;
- 20 ylimino)-[2-(2-hydroxy-ethoxy)-ethylamino]-methyl)-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;
- 25 N-(3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-N',N"-dimethyl-guanidine;
- N"-[3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl)-N,N,N',N'-tetramethyl-guanidine;

- (3-{1-[5-(Di-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;
- [3-(1-{5-[Bis-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-
- 5 methanone;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-morpholin-4-yl-ethyl)-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-hydroxy-ethyl)-guanidine;
- 10 N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N',N"-bis-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;
- N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-methyl-guanidine;
- N'-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N,N-dimethyl-guanidine;
- 15 isoxazol-5-yl}-N'-ethyl-guanidine;
- N'-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N,N-diethyl-guanidine;
- 20 (3-{1-[5-(Amino-pyrrolidin-1-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone;
- (3-{1-[5-(Amino-piperidin-1-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone;
- 25 (3-{1-[5-(Amino-azepan-1-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone;
- (3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-
methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-
phenyl-methanone;

(3-{1-[5-(Amino-thiazolidin-3-yl-
5 methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-
phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperidin-1-yl)-
methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-
phenyl-methanone;

10 [3-(1-{5-[Amino-(2,6-dimethyl-morpholin-4-yl)-
methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-
phenyl-methanone;

[3-(1-{5-[Amino-(4-dimethylamino-piperidin-1-
yl)-methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-
15 phenyl]-phenyl-methanone;

1-(Amino-{3-[1-(3-benzoyl-phenyl)-1-methyl-
ethyl]-isoxazol-5-ylimino)-methyl)-piperidin-4-one;

1-(Amino-{3-[1-(3-benzoyl-phenyl)-1-methyl-
ethyl]-isoxazol-5-ylimino)-methyl)-piperidin-2-one;

20 [3-(1-{5-[Amino-(4-hydroxy-piperidin-1-yl)-
methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-
phenyl-methanone;

[3-(1-{5-[Amino-(4-methoxy-piperidin-1-yl)-
methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-
25 phenyl-methanone;

(3-{1-[5-(Amino-[1,4]thiazinan-4-yl-
methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-
phenyl-methanone;

1-[4-(Amino-{3-[1-(3-benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-ylimino}-methyl)-piperazin-1-yl]-ethanone;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-oxo-propyl)-guanidine;

Ethyl (N'-(3-[1-(3-benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-acetate;

Ethyl 3-(N'-(3-[1-(3-benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-propionate;

2-(N'-(3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-acetamide;

3-(N'-(3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl)-guanidino)-N,N-dimethyl-propionamide;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(3-hydroxy-propyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-methoxy-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-dimethylamino-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-pyrrolidin-1-yl-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-piperidin-1-yl-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-

isoxazol-5-yl)-N'-[2-(4-methyl-piperazin-1-yl)-ethyl]-
guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-yl)-N'-(3-morpholin-4-yl-propyl)-guanidine;

5 N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-yl)-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-yl)-N'-[2-(2-methoxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
10 isoxazol-5-yl)-N'-[2-(3-hydroxy-propoxy)-ethyl]-
guanidine;

2-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-ylimino)-1-methyl-imidazolidin-4-one;

2-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
15 isoxazol-5-ylimino)-1-(2-hydroxy-ethyl)-imidazolidin-4-
one;

2-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-ylimino)-1-(2-methoxy-ethyl)-imidazolin-4-one;

N-({3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
20 isoxazol-5-ylimino)-methylamino-methyl)-N'-methyl-
guanidine;

N'-({3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-
isoxazol-5-ylimino)-dimethylamino-methyl)-N,N-dimethyl-
guanidine;

25 [3-(1-{5-[(Amino-morpholin-4-yl-
methyleneamino)-morpholin-4-yl-methyleneamino]-isoxazol-
3-yl)-1-methyl-ethyl)-phenyl]-phenyl-methanone;

[3-(1-{5-[[Amino-(4-methyl-piperazin-1-yl)-

methyleneamino]-(4-methyl-piperazin-1-yl)-methylene-amino]-isoxazol-3-yl)-1-methyl-ethyl)-phenyl]-phenyl-methane;

5 N-[[3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-ylimino]-(2-morpholin-4-yl-ethylamino)-methyl]-N'-(2-morpholin-4-yl-ethyl)-guanidine;

N-[[3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-ylimino]-(2-hydroxy-ethylamino)-methyl]-N'-(2-hydroxy-ethyl)-guanidine;

10 N-[[3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-ylimino]-[2-(2-hydroxy-ethoxy)-ethylamino]-methyl]-N'-[2-(2-hydroxy-ethoxy)-ethyl]-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-dimethyl-guanidine;

15 N"-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N,N,N',N'-tetramethyl-guanidine;

(3-{1-[5-(Di-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl)-phenyl)-phenyl-methanone;

20 [3-(1-{5-[Bis-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl)-1-methyl-ethyl)-phenyl]-phenyl-methanone;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-morpholin-4-yl-ethyl)-guanidine;

25 N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-(2-hydroxy-ethyl)-guanidine;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N',N"-bis-[2-(2-hydroxy-ethoxy)-ethyl]-

guanidine;

((3-[1-Ethoxy-1-(2'-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-1-ethoxy-ethyl}-phenyl)-phenyl-methanone;

((3-[(2-Fluoro-biphenyl-4-yl)-dimethoxy-methyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

5 ((3-(1-Biphenyl-4-yl-vinyl)-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

10 ((3-[1-(1-Methyl-1H-indol-2-yl)-vinyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine;

(Morpholin-4-yl-(3-[1-(6-phenyl-pyridazin-3-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-amine;

(Morpholin-4-yl-(3-[1-(5-phenyl-pyrimidin-2-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-amine;

15 (Morpholin-4-yl-(3-[1-(4-phenyl-pyrimidin-2-yl)-ethyl]-isoxazol-5-ylimino)-methyl)-amine;

(Morpholin-4-yl-[3-(1-quinolin-6-yl-ethyl)-isoxazol-5-ylimino]-methyl)-amine;

20 N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-pyridin-3-ylmethyl-guanidine

EXAMPLES

The present invention is explained below with examples and reference examples but is, of course, not
25 limited by them.


In the examples and the like, the meanings of the abbreviations used are as follows:

121

Boc : tert-butoxycarbonyl
 Tos : p-toluenesulfonyl
 Me : methyl
 Et : ethyl
 5 Prⁿ : n-propyl
 Bu^t : tert-butyl
 Ph : phenyl
 Ac : Acetyl
 TFA : Trifluoroacetic acid
 10 TMS : Trimethylsilyl

Example 1

N'-(tert-Butoxycarbonyl)-N''-(3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N,N-dimethyl-
guanidine



15 The compound (2.10 g) obtained in Reference
 Example 2 was dissolved in acetonitrile (100 ml),
 followed by adding thereto triethylamine (1.77 g), and a
 40% aqueous dimethylamine solution (1.04 g) was added
 dropwise under ice-cooling. Then, a solution of silver
 20 nitrate (1.33 g) in acetonitrile (20 ml) was added
 dropwise over a period of 30 minutes, and the resulting

mixture was stirred at room temperature for 18 hours.
The insoluble materials were filtered off and washed
with acetonitrile, after which the mother liquor was
concentrated under reduced pressure and the residue was
5 purified by a silica gel column chromatography to obtain
the desired compound (1.76 g).

Melting point 108 - 111°C (decomp.).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.43(s, 9H), 1.66(d, 3H, J=7.1Hz), 3.07(s,
10 6H), 4.16(q, 1H, J=7.1Hz), 5.24(s, 1H),
6.74(s, 1H), 7.07-7.17(m, 2H), 7.32-7.54(m,
6H).

IR (KBr) [cm⁻¹]: 3383, 2975, 1733, 1614, 1482,
1403.

15 MS (FD) [m/e]: 452 (M⁺).


Elementary analysis;

Calculated: C 66.35, H 6.46, N 12.38

Found : C 66.22, H 6.45, N 12.46

Example 2

20 N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N"-ethyl-guanidine



123

The desired compound was obtained by the same procedure as in Example 1.

Melting point 87 - 92°C


¹H-NMR (270 MHz, CDCl₃) δ ppm:

5 1.21(t, 3H, J=7.3Hz), 1.49(s, 9H), 1.67(d, 3H, J=7.3Hz), 3.40(m, 2H), 4.14(q, 1H, J=7.3Hz), 5.32(s, 1H), 7.07-7.17(m, 2H), 7.31-7.54(m, 6H), 7.94(br, 1H), 8.48(br, 1H).

IR (KBr) [cm⁻¹]: 3410, 3340, 2980, 1730, 1628,
10 1603, 1556, 1445, 1240, 1152.

Example 3

(tert-Butoxycarbonyl)-((3-((1-(2-fluoro-biphenyl-4-yl)-ethyl)-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine



15 The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (270 MHz, CDCl₃) δ ppm:


 1.42(s, 9H), 1.65(br-s, 6H), 1.66(d, 3H, J=6.3Hz), 3.40-3.60(br, 4H), 4.15(q, 1H, J=6.3Hz),
20 5.24(s, 1H), 6.60-6.80(br, 1H), 7.06-7.17(m, 2H), 7.32-7.54(m, 6H).

124

IR (KBr) [cm^{-1}]: 3390, 2940, 1726, 1600, 1483,
1435, 1365, 1152.

Example 4

(tert-Butoxycarbonyl)-({3-[1-(2-fluoro-
5 biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-
yl-methyl)-amine



The desired compound was obtained by the same
procedure as in Example 1.

Melting point 152 - 153°C.

10 $^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

1.44(s, 9H), 1.67(d, 3H, $J=7.2\text{Hz}$), 3.57(m,
4H), 3.75(m, 4H), 4.16(q, 1H, $J=7.2\text{Hz}$), 5.28(s,
1H), 6.86(s, 1H), 7.06-7.16(m, 2H), 7.32-
7.53(m, 6H).

15 IR (KBr) [cm^{-1}]: 3374, 2976, 1726, 1609, 1482,
1431, 1115.

MS (FD) [m/e]: 495 ($M+1$).


Elementary analysis;

Calculated: C 65.57, H 6.32, N 11.33

20 Found : C 65.45, H 6.39, N 11.36

Example 5

tert-Butyl (N'-(tert-butoxycarbonyl)-N''-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidino)-acetate



5 The desired compound was obtained by the same procedure as in Example 1.

 Melting point 101.5 - 103.5°C.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

 1.48(s, 9H), 1.50(s, 9H), 1.66(d, 3H,
10 J=7.3Hz), 4.03(d, 2H, J=4.6Hz), 4.14(q, 1H,
 J=7.3Hz), 5.31(s, 1H), 7.06-7.16(m, 2H), 7.32-
 7.54(m, 6H), 8.50-8.52(br-m, 2H).

 IR (KBr) [cm⁻¹]: 3407, 3351, 2980, 1743, 1643,
 1560, 1485, 1452.

15 MS (FD) [m/e]: 538 (M⁺).


 Elementary analysis;

 Calculated: C 64.67, H 6.55, N 10.40

 Found : C 64.36, H 6.57, N 10.35

Example 6

20 tert-Butyl (N'-(tert-butoxycarbonyl)-N''-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N-methyl-

guanidino)-acetate

The desired compound was obtained by the same procedure as in Example 1.

Melting point 190 - 198°C (decomp.).

5 ¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.42(s, 9H), 1.47(s, 9H), 1.65(d, 3H,
J=7.2Hz), 3.12(s, 3H), 4.00(s, 2H), 4.12(q,
1H, J=7.2Hz), 5.29(s, 1H), 6.87(br-s, 1H),
7.06-7.16(m, 2H), 7.32-7.54(m, 6H).

10 IR (KBr) [cm⁻¹]: 3388, 2984, 1744, 1733, 1608,
1483, 1413.

MS (FD) [m/e]: 552 (M⁺).

Elementary analysis;


Calculated: C 65.20, H 6.75, N 10.14

15 Found : C 64.90, H 6.74, N 9.93

Example 7

Ethyl (N'-(tert-butoxycarbonyl)-N"-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidino)-acetate

127



The desired compound was obtained by the same procedure as in Example 1.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.28(t, 3H, J=7.1Hz), 1.50(s, 9H), 1.66(d, 3H, J=7.3Hz), 4.12(d, 2H, J=5.0Hz), 4.16(q, 1H, J=7.3Hz), 4.23(q, 2H, J=7.1Hz), 5.33(s, 1H), 7.07-7.16(m, 2H), 7.35-7.54(m, 6H), 8.54(br-m, 2H).

IR (neat) [cm⁻¹]: 3398, 2981, 1732, 1634, 1608, 1557, 1486, 1455.

Example 8

N'-Benzoyl-N-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N-methyl-N"-propyl-guanidine



The desired compound was obtained by the same procedure as in Example 1.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

128

0.90(t, 3H, J=7.3Hz), 1.56(sext., 2H,
J=7.3Hz), 1.70(d, 3H, J=7.3Hz), 2.85-2.97(m,
2H), 3.51(s, 3H), 4.21(q, 1H, J=7.3Hz),
5.50(s, 1H), 7.02-7.27(m, 3H), 7.32-7.52(m,
5 8H), 8.17-8.22(m, 2H), 10.30-10.60(m, 1H).

Example 9

N'-Benzoyl-N-{3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-yl}-N,N"-dimethyl-guanidine



The desired compound was obtained by the same
10 procedure as in Example 1.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.70(d, 3H, J=7.3Hz), 2.74-2.76(m, 3H),
3.51(s, 3H), 4.21(q, 1H, J=7.3Hz), 5.49(s,
1H), 7.04-7.16(m, 2H), 7.33-7.55(m, 9H), 8.16-
15 8.22(m, 2H), 10.20-10.55(br, 1H).

IR (neat) [cm⁻¹]: 3260, 3070, 2980, 1622, 1495,
1453, 1418, 1396, 1362.

Example 10

N,N'-Di-(tert-butoxycarbonyl)-N"-{5-[1-(2-
20 fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-

guanidine


The compound (1.12 g) obtained in Reference Example 10 and 1,3-di-(tert-butoxycarbonyl)-2-methyl-isothiourea (Japanese Patent Unexamined Publication No. 2-3661) (2.20 g) were dissolved in pyridine (5 ml), followed by adding thereto 1,8-diazabicyclo[5.4.0]undec-7-ene (636 mg), and the resulting mixture was stirred at room temperature for 24 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (1.24 g).

15 ¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.49(s, 9H), 1.50(s, 9H), 1.69(d, 3H, J=7.1Hz), 4.26(q, 1H, J=7.1Hz), 4.67(d, 2H, J=5.3Hz), 6.05(s, 1H), 7.03-7.12(m, 2H), 7.33-7.55(m, 6H), 8.84(br-s, 1H), 11.47(br-s, 1H).

Example 11

N,N"-Di-(tert-butoxycarbonyl)-N-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N',N'-dimethyl-guanidine



5 The compound (2.38 g) obtained in Reference Example 7, the compound (2.18 g) obtained in Reference Example 11 and tributylphosphine (3.49 g) were dissolved in tetrahydrofuran, followed by adding thereto 1,1'-(azodicarbonyl)dipiperidine (4.36 g) at 0°C, and the

10 resulting mixture was brought back to room temperature and stirred for 24 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the extract solution was washed with water and dried. The insoluble materials were filtered off,

15 after which the mother liquor was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (3.02 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

20 1.46(s, 9H), 1.49(s, 9H), 1.68(d, 3H, J=7.1Hz), 2.98(br-s, 6H), 4.25(q, 1H, J=7.1Hz), 4.26(br-s, 1H), 4.85(br-s, 1H),

131


6.09(s, 1H), 6.98-7.23(m, 2H), 7.28-7.54(m, 6H).

IR (neat) [cm⁻¹]: 2978, 1722, 1680, 1602, 1485, 1417.

5 MS (FD) [m/e]: 566 (M⁺).

Example 12

(tert-Butoxycarbonyl)-{5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-{morpholin-1-yl-[(tert-butoxycarbonyl)-iminol-methyl]-amine



10 By the same procedure as in Example 11, the desired compound was obtained from the compound obtained in Reference Example 7 and the compound obtained in Reference Example 13.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

15 1.46(s, 9H), 1.48(s, 9H), 1.68(d, 3H, J=7.2Hz), 3.41-3.80(br-m, 8H), 4.23(br-s, 1H), 4.24(q, 1H, J=7.2Hz), 4.87(br-s, 1H), 6.06(s, 1H), 6.98-7.10(m, 2H), 7.30-7.63(m, 6H).


IR (neat) [cm⁻¹]: 2978, 1723, 1683, 1595, 1484,

1111.

MS (FD) [m/e]: 608 (M⁺).

Example 13

(tert-Butoxycarbonyl)-{5-[1-(2-fluoro-
 5 biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-{piperidin-1-
 yl-[(tert-butoxycarbonyl)-iminol-methyl]-amine




From the compound obtained in Reference
 Example 7 and the compound obtained in Reference Example
 12, the desired compound was obtained by the same
 10 process as in Example 11 except for using triphenyl-
 phosphine and diethyl azodicarboxylate in place of
 tributylphosphine and 1,1'-(azodicarbonyl)dipiperidine.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.41-1.54(m, 6H), 1.46(s, 9H), 1.49(s, 9H),
 15 1.68(d, 3H, J=7.3Hz), 3.19(br-s, 1H),
 3.35(br-s, 2H), 3.77(br-s, 1H), 4.22(br-s,
 1H), 4.26 (q, 1H, J=7.3Hz), 4.90(br-s, 1H),
 6.12(s, 1H), 6.99-7.11(m, 2H), 7.33-7.54(m,
 6H).

Example 14

N,N'-Di-(tert-butoxycarbonyl)-N''-(5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N-methyl-guanidine



5 The compound (1.50 g) obtained in Reference Example 10 and the compound (2.00 g) obtained in Reference Example 14 were dissolved in acetonitrile (50 ml), and triethylamine (1.54 g) was added, after which a solution of silver nitrate (2.58 g) in acetonitrile (20
10 ml) was added dropwise under ice-cooling over a period of 30 minutes, and the resulting mixture was stirred at room temperature for 2 days. The insoluble materials were filtered off and washed with acetonitrile, after which the mother liquor was concentrated under reduced
15 pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (2.54 g).


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.46(s, 9H), 1.48(s, 9H), 1.69(d, 3H,
20 J=7.1Hz), 3.10(s, 3H), 4.26(q, 1H, J=7.1Hz),
4.49(s, 2H), 6.04(s, 1H), 7.01-7.11(m, 2H),

7.32-7.53(m, 6H).

Example 15

1-(tert-Butoxycarbonyl)-2-[(tert-butoxy-
carbonyl)-iminol-3-{5-[1-(2-fluoro-biphenyl-4-yl)-
 5 ethyl]-isoxazol-3-ylmethyl}-imidazolidin-4-one



By the same procedure as in Example 14, the desired compound was obtained from the compound obtained in Reference Example 10 and the compound obtained in Reference Example 15.

10 $^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

1.51(s, 9H), 1.52(s, 9H), 1.67(d, 3H, $J=7.3\text{Hz}$), 4.24(q, 1H, $J=7.3\text{Hz}$), 4.25(s, 2H), 4.81(s, 2H), 6.08(d, 1H, $J=1.0\text{Hz}$), 7.02-7.11(m, 2H), 7.33-7.55(m, 6H).

15 IR (KBr) [cm^{-1}]: 2980, 1740, 1708, 1659, 1368.


Elementary analysis:

Calculated: C 64.35, H 6.10, N 9.68

Found : C 64.02, H 6.24, N 9.60

Example 16

N-((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylamino)-methylamino-methylene)-4-methyl-benzenesulfonamide



5 5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylamine (1.41 g), a well-known compound was added to a solution of N-dichloromethylene-4-methyl-benzenesulfonamide (Chem. Ber., 99, 2900(1966)) (1.33 g) in acetonitrile (40 ml) under ice-cooling. After 30 minutes,

10 triethylamine (0.73 ml) was slowly dropped thereinto and the resulting mixture was stirred under ice-cooling for another 1 hour. Methylamine (2 ml of a 40% ethanolic solution) was added dropwise thereto and stirred for 1 hour, followed by extraction. The extract was purified

15 by a silica gel column chromatography to obtain the desired compound (735 mg).

Melting point 125 - 127°C.

¹H-NMR (270 MHz, CDCl₃) δ ppm:


1.70(d, 3H, J=7.3Hz), 2.39(s, 3H), 2.95(d, 3H, J=4.6Hz), 4.22(q, 1H, J=7.3Hz), 5.87(d, 1H, J=0.7Hz), 7.01-7.11(m, 2H), 7.25(d, 2H, J=8.4Hz), 7.34-7.55(m, 6H), 7.80(d, 2H,

20

$J=8.4\text{Hz}$), 7.97(m, 1H), 10.12(s, 1H).

Example 17

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine



5 The compound (500 mg) obtained in Reference
Example 1 was dissolved in N,N-dimethylformamide (2 ml),
and ammonium acetate (5.00 g) was added, after which the
resulting mixture was stirred at 120°C, and ammonia gas
was introduced therein for 1.5 hours. A saturated
10 aqueous sodium chloride solution was added to the
reaction mixture, followed by extraction with ethyl
acetate, and the extract solution was washed with water
and dried. The solvent was distilled off under reduced
pressure and the residue was purified by a silica gel
15 column chromatography to obtain the desired compound (316
mg).

¹H-NMR (270 MHz, d₆-DMSO) δ ppm:

1.54(d, 3H, J=7.1Hz), 4.08(q, 1H, J=7.1Hz),

5.32(s, 1H), 6.02(br-s, 4H), 7.21-7.25(m, 2H),

20 7.38-7.54(m, 6H).


IR (KBr) [cm⁻¹]: 3449, 3345, 3106, 1657, 1614,

137

1562, 1472, 1414.

Example 18

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-methyl-guanidine hydrochloride



5 The compound (600 mg) obtained in Reference
Example 1 was dissolved in N,N-dimethylformamide (5 ml),
followed by adding thereto a methylamine-water-acetic
acid solution prepared from a 40% aqueous methylamine
solution (1.31 g) and acetic acid (10 ml), and the
10 resulting mixture was stirred at 120°C for 30 minutes.
Chloroform (50 ml) and a 5 M aqueous sodium hydroxide
solution (300 ml) were added to the reaction mixture,
followed by extraction with chloroform, and the extract
solution was washed with water and dried. The solvent
15 was distilled off under reduced pressure and the residue
was purified by a silica gel column chromatography and
treated with a hydrogen chloride-isopropanol solution to
obtain the desired compound (367 mg).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

20 1.64(d, 3H, J=7.2Hz), 2.85(s, 3H), 4.12(q, 1H,


138

$J=7.2\text{Hz}$), 5.19(s, 1H), 5.30(br-s, 2H),
5.59(br-s, 1H), 7.06-7.15(m, 2H), 7.33-7.53(m,
6H).

IR (KBr) [cm^{-1}]: 3144, 1680, 1637, 1484, 1417.

5 Example 19

N' -{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl}- N,N -dimethyl-guanidine hydrochloride



The compound (1.68 g) obtained in Example 1
was dissolved in methylene chloride (20 ml), followed by
10 adding thereto trifluoroacetic acid (12 ml), and the
resulting mixture was stirred at room temperature for 2
hours and the solvent was distilled off under reduced
pressure. The residue was dissolved in methylene
chloride and treated with a hydrogen-chloride-diethyl
15 ether solution to obtain the desired compound (1.39 g).

Melting point 73 - 81°C (decomp.).


$^1\text{H-NMR}$ (270 MHz, d_6 -DMSO) δ ppm:

1.61(d, 3H, $J=7.0\text{Hz}$), 3.08(s, 6H), 4.29(q, 1H,
 $J=7.0\text{Hz}$), 6.04(s, 1H), 7.26-7.34(m, 2H), 7.37-
20 7.55(m, 6H), 8.27(br-s, 2H).

IR (KBr) [cm^{-1}]: 3132, 1673, 1634, 1484, 1417.

Example 20

N-Ethyl-N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidine hydrochloride



- 5 The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 2.

$^1\text{H-NMR}$ (270 MHz, $\text{d}_6\text{-DMSO}$) δ ppm:


- 10 1.13(t, 3H, $J=7.1\text{Hz}$), 1.60(d, 3H, $J=7.3\text{Hz}$),
 3.31(q, 2H, $J=7.1\text{Hz}$), 4.29(q, 1H, $J=7.3\text{Hz}$),
 6.17(s, 1H), 7.24-7.52(m, 8H), 8.10-8.70(br, 2H), 8.45-8.65(br, 1H), 11.30-11.65(br, 1H).

IR (KBr) [cm^{-1}]: 3600-2400, 2980, 1675, 1623, 1580,
 1482, 1415, 1131.

15 Example 21

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-piperidin-1-yl-methyl)-amine hydrochloride

140



The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 3.


$^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

5 1.55-1.75(m, 9H), 3.52(br, 4H), 4.15(q, 1H, $J=7.3\text{Hz}$), 5.71(s, 1H), 7.02-7.12(m, 2H), 7.31-7.50(m, 6H), 8.30(br, 2H), 11.20(br, 1H).

IR (KBr) [cm^{-1}]: 3600-2500, 2945, 1660, 1633, 1538, 1484, 1447, 1418.

10 Example 22

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine hydrochloride



The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 4.


Melting point 174 - 176°C (decomp.).

5 $^1\text{H-NMR}$ (270 MHz, $\text{d}_6\text{-DMSO}$) δ ppm:

1.60(d, 3H, J=7.1Hz), 3.56(m, 4H), 3.67(m, 4H), 4.28(q, 1H, J=7.1Hz), 6.02(s, 1H), 7.26-7.37(m, 2H), 7.38-7.54(m, 6H), 8.51(br-s, 2H).

Example 23

10 (N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-guanidino)-acetic acid hydrochloride



The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 5.

15 Melting point 62°C (decomp.).

142


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.54(d, 3H, J=7.1Hz), 3.85(d, 2H, J=5.6Hz),
 4.10(q, 1H, J=7.1Hz), 5.40(s, 1H), 6.19(br-s,
 2H), 6.41(t, 1H, J=5.6Hz), 7.21-7.24(m, 2H),
 5 7.36-7.54(m, 6H).

IR (KBr) [cm⁻¹]: 3142, 2978, 1684, 1624, 1484,
 1411.

Example 24

2-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 10 isoxazol-5-ylimino}-1-methyl-imidazolidin-4-one
hydrochloride



The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 6.


15 Melting point 158 - 160°C (decomp.).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.1Hz), 3.07(s, 3H), 3.97(s,
 2H), 4.16(q, 1H, J=7.1Hz), 5.41(s, 1H), 7.05-
 7.15(m, 2H), 7.32-7.54(m, 6H), 8.91(br-s, 1H).
 20 IR (KBr) [cm⁻¹]: 3153, 2972, 1761, 1668, 1603,
 1578, 1484, 1452, 1418.

Example 25

Ethyl (N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidino)-acetate hydrochloride



The desired compound was obtained by the same
5 procedure as in Example 19 except for using the compound
obtained in Example 7.

Melting point 144 - 146°C (decomp.).

¹H-NMR (270 MHz, CDCl₃) δ ppm:


1.26(t, 3H, J=7.1Hz), 1.65(d, 3H, J=7.3Hz),
10 4.16-4.28(m, 3H), 4.38(s, 2H), 5.78(s, 1H),
7.02-7.10(m, 2H), 7.32-7.56(m, 6H), 8.00-
8.30(m, 2H).

IR (KBr) [cm⁻¹]: 3088, 2981, 1736, 1684, 1650,
1589, 1485, 1413.

15 - Example 26

N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-guanidine

144



The compound (1.24 g) obtained in Example 10 was dissolved in trifluoroacetic acid (10 ml), and the solution was stirred at room temperature for 2 hours and then the solvent was distilled off under reduced pressure. The residue was dissolved in ethyl acetate and the resulting solution was neutralized with a 1N aqueous sodium hydroxide solution, after which the organic layer was separated, washed with water, dried and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography to obtain the desired compound (562 mg).


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.50(d, 3H, J=6.9Hz), 4.12(q, 1H, J=6.9Hz),
 4.42(br-s, 2H), 6.08(s, 1H), 6.90-6.97(m, 2H),
 7.19-7.57(m, 9H), 8.21(br-s, 1H).

Example 27

N'-{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl}-N,N-dimethyl-guanidine hydrochloride

145



The compound (2.69 g) obtained in Example 11 was dissolved in a solution of trifluoroacetic acid (10 ml) in water (10 ml), and the resulting solution was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure. The residue was dissolved in methylene chloride and treated with a hydrogen chloride-diethyl ether solution to obtain the desired compound (897 mg).

$^1\text{H-NMR}$ (270 MHz, $\text{d}_6\text{-DMSO}$) δ ppm:

10 1.62(d, 3H, $J=7.0\text{Hz}$), 3.00(s, 6H), 4.47(q, 1H, $J=7.0\text{Hz}$), 4.53(d, 2H, $J=5.9\text{Hz}$), 6.40(s, 1H), 7.22-7.28(m, 2H), 7.37-7.54(m, 6H), 7.69(br-s, 2H), 8.06(t, 1H, $J=5.9\text{Hz}$).


IR (KBr) [cm^{-1}]: 3422, 3228, 1658, 1630, 1562,

15 1485, 1418.

Example 28

((5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino)-morpholin-4-yl-methyl)-amine hydrochloride

146



The desired compound was obtained by the same procedure as in Example 27 except for using the compound obtained in Example 12.

Melting point 161 - 163°C.

5 $^1\text{H-NMR}$ (270 MHz, $\text{d}_6\text{-DMSO}$) δ ppm:

1.63(d, 3H, $J=7.3\text{Hz}$), 3.46(m, 4H), 3.64(m, 4H), 4.48(q, 1H, $J=7.3\text{Hz}$), 4.55(d, 2H, $J=5.8\text{Hz}$), 6.42(s, 1H), 7.22-7.29(m, 2H), 7.37-7.54(m, 6H), 8.00(br-s, 2H), 8.43(t, 1H, $J=5.8\text{Hz}$).


10

IR (KBr) [cm^{-1}]: 3393, 3356, 1655, 1612, 1561, 1485, 1418, 1116.

Example 29

15 {{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethylimino}-piperidin-1-yl-methyl}-amine hydrochloride

147




The desired compound was obtained by the same procedure as in Example 27 except for using the compound obtained in Example 13.

¹H-NMR (270 MHz, d₆-DMSO) δ ppm:

- 5 1.52(br-s, 6H), 1.62(d, 3H, J=7.3Hz),
 3.50(br-s, 4H), 4.47(q, 1H, J=7.3Hz), 4.53(d,
 2H, J=5.6Hz), 6.37(s, 1H), 7.21-7.27(m, 2H),
 7.39-7.53(m, 6H), 7.81(br-s, 2H), 8.25(br-s,
 1H).

10 Example 30

N-(5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-ylmethyl)-N'-methyl-guanidine hydrochloride



The desired compound was obtained by the same procedure as in Example 27 except for using the compound
 15 obtained in Example 14.

148

Melting point 71 - 74°C (decomp.).


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.68(d, 3H, J=7.3Hz), 2.89(d, 3H, J=4.6Hz),
 4.25(q, 1H, J=7.3Hz), 4.42(br-s, 2H), 6.17(s,
 5 1H), 7.00-7.10(m, 2H), 7.36-7.54(m, 6H).

IR (KBr) [cm⁻¹]: 3338, 1646, 1602, 1484, 1418.

Example 31

2-Amino-3-{5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-3-ylmethyl}-3,5-dihydro-imidazol-4-one
 10 hydrochloride



The desired compound was obtained by the same procedure as in Example 27 except for using the compound obtained in Example 15.

Melting point 210 - 232°C (decomp.).

15 ¹H-NMR (270 MHz, d₆-DMSO)-δ ppm:


1.62(d, 3H, J=7.1Hz), 4.31(s, 2H), 4.47(q, 1H,
 J=7.1Hz), 4.94(s, 2H), 6.45(s, 1H), 7.21-
 7.29(m, 2H), 7.37-7.55(m, 6H), 9.53(br-s, 3H).

IR (KBr) [cm⁻¹]: 3061, 2983, 1778, 1706, 1689,

20 1604, 1544, 1485, 1419.

Example 32

Methyl [2-(N'-(tert-butoxycarbonyl)-N"-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidino)-ethoxy]-acetate



5 The desired compound was obtained by the same procedure as in Example 1 except for using the trifluoroacetic acid salt of methyl (2-amino-ethoxy)-acetate.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

10 1.49(s, 9H), 1.67(d, 3H, J=7.3Hz), 3.59-3.64 (m, 2H), 3.70-3.76(m, 2H), 3.79(s, 3H), 4.11-4.18(m, 1H), 4.14(s, 2H), 5.30(s, 1H), 7.07-7.17(m, 2H), 7.32-7.46(m, 4H), 7.51-7.54(m, 2H), 8.28(br-s, 1H), 8.49(br-s, 1H)

15 IR (neat) [cm⁻¹]: 3399, 3349, 2978, 1750, 1732, 1634, 1606, 1556, 1486, 1455, 1416, 1370, 1241, 1151, 770, 670

Example 33

N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N"-[2-(2-hydroxy-ethoxy-ethyl)]-guanidine




The desired compound was obtained by the same procedure as in Example 1 except for using 2-(2-aminoethoxy)-ethanol.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

- 5 1.49(s, 9H), 1.67(d, 3H, J=7.1Hz), 2.40(br-s, 1H), 3.55-3.70(m, 6H), 3.70-3.80(m, 2H), 4.15 (q, 1H, J=7.1Hz), 5.32(s, 1H), 7.07-7.16(m, 2H), 7.32-7.54(m, 6H), 8.36(br-s, 1H), 8.51(s, 1H)

10 Example 34

N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluorobiphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N''-(2-hydroxy-ethyl)-guanidine



The desired compound was obtained by the same procedure as in Example 1 except for using 2-aminoethanol.


151

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.50(s, 9H), 1.67(d, 3H, J=7.1Hz), 3.56-3.60
 (m, 3H), 3.77-3.82(m, 2H), 4.14(q, 1H, J=7.1
 Hz), 5.34(s, 1H), 7.06-7.16(m, 2H), 7.32-7.46
 5 (m, 4H), 7.51-7.54(m, 2H), 8.41(br-s, 1H),
 8.59(br-s, 1H)

Example 35

tert-Butyl [N'-(tert-butoxycarbonyl)-N''-(3-[1-
(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N-(2-
 10 hydroxy-ethyl)-guanidino]-acetate



The desired compound was obtained by the same
 procedure as in Example 1 except for using tert-butyl 3-
 (2-hydroxy-ethylamino)-propionate.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

15 1.33(s, 9H), 1.44(s, 9H), 1.64(d, 3H, J=7.1
 Hz), 3.55-3.65(m, 2H), 3.74-3.82(m, 2H),
 3.86-
 3.94(m, 1H), 4.02-4.17(m, 3H), 5.30(s, 1H),
 7.04-7.15(m, 2H), 7.32-7.46(m, 4H), 7.50-7.53
 20 (m, 2H)

IR (KBr) [cm⁻¹]: 3254, 2979, 2936, 1738, 1614, 1484,
 1459, 1418, 1369, 1249, 1152, 1060, 769, 699

Example 36

4-[(tert-Butoxycarbonyl)-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl]-
morpholin-3-ol




5 The desired compound was obtained by the same
 procedure as in Example 1 except for using piperidin-2-
 ol.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.48(s, 9H), 1.66(d, 3H, J=7.0Hz), 3.44-4.00
 10 (m, 6H), 4.10-4.25(m, 1H), 5.32(s, 1H), 6.47
 (br-s, 0.5H), 6.66(br-s, 0.5H), 6.91-6.96(m,
 1H), 7.07-7.16(m, 2H), 7.32-7.53(m, 6H)

Example 37

(tert-Butoxycarbonyl)-({3-[1-(4-isobutyl-phen-
 15 yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-
amine




The desired compound was obtained by the same procedure as in Example 1 except for using the compound obtained in Reference Example 18.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 0.89(d, 6H, J=6.6Hz), 1.44(s, 9H), 1.62(d, 3H, J=7.3Hz), 1.83(m, 1H, J=6.6Hz), 2.42(d, 2H, J=7.3Hz), 3.54-3.58(m, 4H), 3.72-3.77(m, 4H), 4.09(q, 1H, J=7.2Hz), 5.23(s, 1H), 7.05-7.09(m, 2H), 7.17-7.20(m, 2H)

10 Example 38

(tert-Butoxycarbonyl)-({3-[1-(6-methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine




The desired compound was obtained by the same procedure as in Example 1 except for using the compound obtained in Reference Example 19.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.35(s, 9H), 1.72(d, 3H, J=7.2Hz), 3.54-3.56(m, 4H), 3.71-3.75(m, 4H), 3.91(s, 3H), 4.25(q, 1H, J=7.1Hz), 5.21(s, 1H), 7.10-7.14(m, 2H), 7.37(dd, 1H, J=8.2, 1.5Hz), 7.66-7.70(m, 3H)

Example 39

N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N,N-diethyl-guanidine methanesulfonate



The compound (5.0 g) obtained in Reference
 5 Example 2 was dissolved in acetonitrile (100 ml) and
 triethylamine (3.8 ml) was added thereto, after which a
 40% aqueous dimethylamine solution (2.84 ml) was added
 dropwise thereto under ice-cooling. Thereafter, a
 solution of silver nitrate (2.05 g) in acetonitrile (10
 10 ml) was added dropwise thereto and the resulting mixture
 was stirred at room temperature for 18 hours. The
 insoluble materials were filtered off and, after washing
 with chloroform, the mother liquor was concentrated under
 reduced pressure. The residue was dissolved in a 83%
 15 (V/V) aqueous trifluoroacetic acid solution (100 ml) and
 the solution was stirred at room temperature for 8 hours,
 after which the solvent was removed by azeotropic
 distillation using toluene. A saturated aqueous sodium
 bicarbonate solution was added to the residue and the
 20 resulting mixture was subjected to extraction with ethyl
 acetate. The organic layer was dried over sodium sulfate
 and then concentrated under reduced pressure. The
 residue was purified by a silica gel column

155

chromatography (hexane/ethyl acetate = 4/1). This purified product was dissolved in 1,4-dioxane and treated with methanesulfonic acid (0.56 ml) to obtain the desired compound (3.42 g).


5 Melting point 154 - 155°C

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.21(t, 6H, J=7.1Hz), 1.66(d, 3H, J=7.1Hz),
 2.70(s, 3H), 3.42(q, 4H, J=7.1Hz), 4.17(q, 1H,
 J=7.1Hz), 5.69(s, 1H), 7.02-7.13(m, 2H), 7.26-
 10 7.54(m, 6H), 8.24(br-s, 2H), 10.83(br-s, 1H)

Example 40

N'-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-iso-
xazol-5-yl)-N,N-bis-(2-methoxy-ethyl)-guanidine methane-
sulfonate




15 The desired compound was obtained by the same
 procedure as in Example 39 except for using bis-(2-meth-
 oxy-ethyl)-amine.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.68(d, 3H, J=7.1Hz), 2.80(s, 3H), 3.43(s,
 20 6H), 3.65-3.75(m, 8H), 4.23(q, 1H, J=7.1Hz),
 6.04(s, 1H), 7.07-7.25(m, 2H), 7.32-7.54(m,
 6H), 7.76(br-s, 1H), 8.00(br-s, 2H)

Example 41

((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-pyrrolidin-1-yl-methyl)-amine
methanesulfonate



5 The desired compound was obtained by the same procedure as in Example 39 except for using pyrrolidine.


Melting point 182 - 183°C (decomp.)

¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.68(d, 3H, J=7.1Hz), 2.04-2.15(m, 4H), 2.67
 10 (s, 3H), 3.50-3.65(m, 4H), 4.28(q, 1H, J=7.1
 Hz), 6.03(s, 1H), 7.14-7.26(m, 2H), 7.35-7.57
 (m, 6H)

Example 42

((3-[1-(2-Fluor-biphenyl-4-yl)-ethyl]-isoxa-
 15 zol-5-ylimino}-piperazin-1-yl-methyl)-amine methanesul-
fonate



The desired compound was obtained by the same

157

procedure as in Example 39 except for using piperazine.


Melting point 185°C (decomp.)

¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.68(d, 3H, J=7.1Hz), 2.69(s, 6H), 3.40(t, 4H,
5 J=5.3Hz), 3.86(t, 4H, J=5.3Hz), 4.28(q, 1H,
J=7.1Hz), 5.99(s, 1H), 7.13-7.25(m, 2H), 7.35-
7.51(m, 6H)

Example 43

[(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
10 zol-5-ylimino)-(4-methyl-piperazin-1-yl)-methyl]-amine
methanesulfonate



The desired compound was obtained by the same procedure as in Example 39 except for using 1-methyl-piperazine.


15 Melting point 186 - 187°C (decomp.)

¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.68(d, 3H, J=7.1Hz), 2.69(s, 9H), 2.98(s,
3H), 3.31(br-s, 2H), 3.64(br-s, 4H), 4.15(br-
s, 2H), 4.28(q, 1H, J=7.1Hz), 6.00(s, 1H),
20 7.13-7.25(m, 2H), 7.32-7.52(m, 6H)

Example 44

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine




The desired compound was obtained by the same
5 procedure as in Example 39 except for using 2-morpholin-
4-yl-ethylamine.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.64(d, 3H, J=7.3Hz), 2.49-2.57(m, 6H), 3.30-
3.31(m, 2H), 3.69(t, 4H, J=4.3Hz), 4.41(q, 1H,
10 J=7.3Hz), 5.18(s, 1H), 5.70(s, 1H), 6.13(s,
2H), 7.07-7.17(m, 2H), 7.32-7.54(m, 6H)

Example 45

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl}-N'-(2-methoxy-ethyl)-guanidine



15 The desired compound was obtained by the same
procedure as in Example 39 except for using 2-methoxy-
ethylamine.


159

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.3Hz), 3.38(s, 3H), 3.41(m,
2H), 3.52(t, 2H, J=4.3Hz), 4.14(q, 1H, J=7.3
Hz), 5.19(s, 1H), 5.50-5.70(m, 3H), 7.08-7.16
5 (m, 2H), 7.33-7.54(m, 6H)

Example 46

(({3-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine hydrochloride



The desired compound was obtained by the same
10 procedure as in Example 19 except for using the compound
obtained in Example 37.


Melting point 94 - 99°C

¹H-NMR (300 MHz, CDCl₃) δ ppm:

0.89(d, 6H, J=6.6Hz), 1.60(d, 3H, J=7.1Hz),
1.78-1.88(m, 1H), 2.43(d, 2H, J=7.1Hz), 3.55-
15 3.62(m, 4H), 3.72-3.80(m, 4H), 4.09(q, 1H,
J=7.1Hz), 5.65(s, 1H), 7.08(d, 2H, J=8.3Hz),
7.14(d, 2H, J=8.1Hz), 8.38(br-s, 1H)

Example 47

20 (({3-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine

hydrochloride


The desired compound was obtained by the same procedure as in Example 19 except for using the compound obtained in Example 38.

5 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.70(d, 3H, J=7.1Hz), 3.44-3.48(m, 4H), 3.69-
 3.73(m, 4H), 3.91(s, 3H), 4.24(q, 1H, J=7.2
 Hz), 5.21(s, 1H), 5.31(br-s, 1H), 7.10-7.13
 (m, 2H), 7.39(d, 1H, J=8.6Hz), 7.66-7.70(m,
 10 3H)

Example 48

Methyl [2-(N'-(3-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazol-5-yl)-guanidino)-ethoxy]-acetate



Trifluoroacetic acid (15.0 ml) was added to the
 15 compound (5.74 g) obtained in Example 32 and the
 resulting mixture was stirred at room temperature for one
 hour. A saturated aqueous sodium bicarbonate solution

was added to the reaction mixture, and the solution was thereafter subjected to extraction with ethyl acetate, after which the organic layer was dried over magnesium sulfate and then concentrated under reduced pressure.

- 5 The residue was purified by a silica gel column chromatography (chloroform alone -> chloroform/methanol = 99/1 -> 39/1) to obtain the desired compound (4.32 g).


¹H-NMR (300 MHz, CDCl₃) δ ppm:

10 1.65(d, 3H, J=7.1Hz), 3.44-3.51(m, 2H), 3.64-3.67(m, 2H), 3.74(s, 3H), 4.10(s, 2H), 4.10-4.16(m, 1H), 5.20(s, 1H), 5.60(br-s, 2H), 6.07(br-s, 1H), 7.07-7.17(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H)

15 IR (Neat) [cm⁻¹]: 3374, 2952, 1749, 1624, 1572, 1483, 1457, 1222, 1132, 969, 915, 769, 729, 699

Example 49

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-[2-(2-hydroxy-ethoxy-ethyl)]-guanidine



- 20 Trifluoroacetic acid (10 ml) was added the compound (5.09 g) obtained in Example 33 and the resulting mixture was stirred at room temperature for one


hour. The reaction mixture was subjected to azeotropic distillation using toluene to remove the solvent, and the residue was thereafter dissolved in 1,4-dioxane, after which the solution was treated with 4 N hydrogen chloride/diethyl ether solution and then concentrated under reduced pressure. The concentrated solution was diluted with chloroform, then neutralized with an aqueous sodium hydroxide solution, and thereafter subjected to extraction with chloroform. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (chloroform alone -> chloroform/methane = 30/1) to obtain the desired compound (3.34 g).

15 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.0Hz), 3.42-3.48(m, 2H), 3.57-3.66(m, 4H), 3.73-3.78(m, 2H), 4.13(q, 1H, J=7.1Hz), 5.55(s, 1H), 5.69(br-s, 2H), 7.07-7.16(m, 2H), 7.31-7.55(m, 6H)

20 Example 50

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-(2-hydroxy-ethyl)-guanidine



163

The desired compound was obtained by the same procedure as in Example 49 except for using the compound obtained in Example 34.

¹H-NMR (300 MHz, CD₃OD) δ ppm:


5 1.62(d, 3H, J=7.1Hz), 3.28-3.36(m, 2H), 3.62-
3.66(m, 2H), 4.13(q, 1H, J=7.3Hz), 5.33(s,
1H), 7.10-7.21(m, 2H), 7.30-7.44(m, 6H), 7.49-
7.52(m, 2H)

IR (KBr) [cm⁻¹]: 3433, 1639, 1572, 1478, 1456,
10 1417, 1068, 786, 695

MS (FD) [m/e]: 368 (M⁺)

Example 51

{{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine



15 The compound (4.57 g) obtained in Reference
Example 20 was dissolved in cyanomorpholine (8.64 g), and
potassium carbonate (4.26 g) was added thereto, after
which the resulting mixture was heated under reflux at
130°C for 8 hours. After cooling to room temperature, a
20 saturated aqueous sodium chloride solution was added,
after which the resulting mixture was subjected to
extraction with ethyl acetate. The organic layer was


dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 2/1 → 1/2) to obtain the desired compound (1.53 g).

5 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.71(s, 6H), 3.47-3.50(m, 4H), 3.71-3.74(m, 4H), 5.19(s, 1H), 5.39(s, 2H), 7.11-7.20(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H)

Example 52

10 (Morpholin-4-yl-{3-[1-(3-phenoxy-phenyl)-ethyl]-isoxazol-5-ylimino}-methyl)-amine



The desired compound was obtained by the same procedure as in Example 51 except for using the compound obtained in Reference Example 25.


15 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.61(d, 3H, J=7.3Hz), 3.48(t, 4H, J=4.9Hz),
3.72(t, 4H, J=4.9Hz), 4.08(q, 1H, J=7.3Hz),
5.21(s, 1H), 5.37(br-s, 2H), 6.80-6.84(m, 1H),
6.97-7.12(m, 5H), 7.21-7.35(m, 3H)

20 Example 53

{3-[1-Ethoxy-1-(2-fluoro-biphenyl-4-yl)-ethyl]-eth-

yl-1-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine
methanesulfonate



The compound (5.0 g) obtained in Reference Example 21 was dissolved in cyanomorpholine (7.75 g) and potassium carbonate (4.24 g) was added thereto, after which the mixture was heated under reflux at 130°C for 8 hours. After cooling to room temperature, a saturated aqueous sodium chloride solution was added, and thereafter, the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 2/1 -> 1/2). This purified product was dissolved in 1,4-dioxane and methanesulfonic acid (0.34 ml) was added thereto under ice-cooling, and the resulting mixture was concentrated under reduced pressure. The crude product was purified by a recrystallization method from isopropanol to obtain the desired compound (850 mg).

Melting point 158 - 160°C


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.71(t, 3H, J=6.7Hz), 1.90(s, 3H), 2.71(s, 3H), 3.32-3.57(m, 6H), 3.73-3.75(m, 4H).

5.68(s, 1H), 7.22-7.54(m, 8H), 8.69(br-s, 2H),
11.16(br-s, 1H)

Example 54

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine



- 1) Sodium hydride (25 mg, 60% oily) was added to a tetrahydrofuran solution (4 ml) of the compound (118 mg, 93% e.e.) obtained in Reference Example 26 under a nitrogen atmosphere, and thereafter, the resulting mixture was stirred at 40°C for 10 minutes. It was again cooled under ice-cooling and thereafter cyanomorpholine (0.084 ml) was added thereto, after which the temperature was brought back to room temperature and stirred for 6 hours. The reaction mixture was diluted with ethyl acetate and then neutralized with a saturated aqueous ammonium chloride solution. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 1/1 -> 1/4) to obtain the desired compound (137 mg, 93% e.e.).
- 2) ({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-

zol-5-ylimino}-morpholin-4-yl-methyl)-amine (3 g) was separated using a preparative optical active column (CHIRALCEL OD, a registered trade mark of DAICEL CHEMICAL INDUSTRIES, LTD., 2 cmØ x 25 cm) to obtain the desired
 5 compound (1.5 g).

Separation conditions:

Eluent: Hexane/ethanol = 100/15

Observation wavelength: 254 nm

Flow rate: 20 ml/min

10 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.66(d, 3H, $J=7.1\text{Hz}$), 3.45-3.60(m, 4H), 3.70-3.80(m, 4H), 4.15(q, 1H, $J=7.1\text{Hz}$), 5.25(s, 1H), 5.37(br-s, 2H), 7.05-7.17(m, 2H), 7.33-7.54(m, 6H)

15 $[\alpha]_D^{22} = -20.0^\circ$ (c: 1.00, CHCl_3)

Example 55

(S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine



1) The desired compound was obtained by the same
 20 procedure as in Example 54 except for using the compound obtained in Reference Example 27.

2) The separation was conducted by the same procedure as in Example 54 to obtain the desired compound.

168


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.1Hz), 3.45-3.55(m, 4H), 3.65-
 3.75(m, 4H), 4.15(q, 1H, J=7.1Hz), 5.25(s,
 1H), 5.38(br-s, 2H), 7.05-7.17(m, 2H), 7.33-
 7.54(m, 6H)

[α]_D²² = +19.8° (c: 1.00, CHCl₃)

Example 56

((3-[1-(2-Fluoro-2',3',4',5',6'-pentadeutero-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-
 10 methyl)-amine



The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 29.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

15 1.66(d, 3H, J=7.1Hz), 3.47-3.51(m, 4H), 3.71-
 3.75(m, 4H), 4.15(q, 1H, J=7.1Hz), 5.25(s,
 1H), 5.37(br-s, 2H), 7.07-7.17(m, 2H), 7.37
 (t, 1H, J=8.1Hz)

IR (KBr) [cm⁻¹]: 3454, 3360, 2971, 1629, 1578,
 20 1548, 1444, 1277, 1124, 1110, 975, 872

Example 57

((3-[1-(2-Fluoro-2'-methoxy-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine




The desired compound was obtained by the same
5 procedure as in Example 54 except for using the compound
obtained in Reference Example 30.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.2Hz), 3.47-3.50(m, 4H), 3.71-
3.75(m, 4H), 3.80(s, 3H), 4.15(q, 1H, J=7.2
10 Hz), 5.27(s, 1H), 5.34(br-s, 2H), 6.97-7.13(m,
4H), 7.23-7.38(m, 3H)

Example 58

((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-ylimino)-morpholin-4-yl-methyl)-amine



15 The desired compound was obtained by the same
procedure as in Example 54 except for using the compound
obtained in Reference Example 31.


170

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.67(d, 3H, J=7.1Hz), 3.48(t, 4H, J=4.8Hz),
3.72(t, 4H, J=4.8Hz), 4.16(q, 1H, J=7.1Hz),
5.25(s, 1H), 5.34(br-s, 2H), 7.10-7.51(m, 8H)

5 Example 59

[(3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-
isoxazol-5-ylimino]-morpholin-4-yl-methyl)-amine



The desired compound was obtained by the same
procedure as in Example 54 except for using the compound
10 obtained in Reference Example 22.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.31-1.34(m, 2H), 1.46-1.51(m, 2H), 3.47(t,
4H, J=4.8Hz), 3.73(t, 4H, J=4.8Hz), 5.17(s,
1H), 5.35(br-s, 2H), 7.14-7.25(m, 2H), 7.33-
15 7.55(m, 6H)

Example 60

[(3-Biphenyl-4-ylmethyl-isoxazol-5-ylimino)-
morpholin-4-yl-methyl]-amine

171




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 28.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 3.48(t, 4H, J=5.3Hz), 3.72(t, 4H, J=5.3Hz),
 3.94(s, 2H), 5.24(s, 1H), 5.34(s, 2H), 7.34-
 7.58(m, 9H)

Example 61

10 {[3-(1-Biphenyl-4-yl-ethyl)-isoxazol-5-yl-
 iminol-morpholin-4-yl-methyl]}-amine




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 23.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

15 1.67(d, 3H, J=7.3Hz), 3.48(t, 4H, J=4.3Hz),
 3.72 (t, 4H, J=4.3Hz), 4.16(q, 1H, J=7.3Hz),
 5.24(s, 1H), 5.35(s, 2H), 7.30-7.58(m, 9H)

Example 62

{[3-(1-Biphenyl-4-yl-1-methyl-ethyl)-isoxazol-5-yliminol-morpholin-4-yl-methyl]}-amine



The desired compound was obtained by the same
5 procedure as in Example 54 except for using the compound
obtained in Reference Example 24.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.72(s, 6H), 3.47(t, 4H, J=5.3Hz), 3.72(t, 4H,
J=5.3Hz), 5.18(s, 1H), 5.38(s, 2H), 7.32-7.58
(m, 9H)

10

Example 63

{[3-[1-(2-Fluoro-4'-methoxy-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino]-morpholin-4-yl-methyl}-amine



The desired compound was obtained by the same
15 procedure as in Example 54 except for using the compound
obtained in Reference Example 32.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


173

1.65(d, 3H, J=7.2Hz), 3.46-3.50(m, 4H), 3.70-
3.74(m, 4H), 3.85(s, 3H), 4.13(q, 1H, J=7.2
Hz), 5.25(s, 1H), 5.36(br-s, 2H), 6.94-7.00
(m, 2H), 7.05-7.14(m, 2H), 7.33(t, 1H, J=8.0
Hz), 7.43-7.49(m, 2H)

5

Example 64

4'-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-
isoxazol-3-yl]-ethyl}-2'-fluoro-biphenyl-4-ol



The compound (5.16 g) obtained in Example 63
10 was dissolved in tetrahydrofuran (100 ml) under a nitro-
gen atmosphere and then a methylene chloride solution (40
ml) of boron tribromide (1.6 ml) was added at -78°C,
after which the temperature was elevated to room temper-
ature over one hour and the stirring was further con-
15 ducted at room temperature for 3 hours. The reaction
mixture was neutralized with a 15% aqueous sodium
hydroxide solution and then subjected to extraction with
ethyl acetate and methanol. The organic layer was dried
over sodium sulfate and then concentrated under reduced
20 pressure. The residue was purified by a silica gel
column chromatography (chloroform alone -> chloro-
form/methanol = 50/1 -> 33/1) to obtain the desired

174

compound (2.67 g).


¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

1.52(d, 3H, J=7.2Hz), 3.38-3.44(m, 4H), 3.54-
3.59(m, 4H), 4.06(q, 1H, J=7.2Hz), 5.39(s,
5 1H), 6.43(br-s, 2H), 6.83(d, 2H, J=8.3Hz),
7.13-7.20(m, 2H), 7.30-7.40(m, 3H), 9.61(br-s,
1H)

IR (KBr) [cm⁻¹]: 3335, 3190, 1660, 1568, 1497,
1448, 1274, 1114, 983, 827

10 Example 65

4'-{1-[5-(Amino-morpholin-4-yl-methylene-
amino)-isoxazol-3-yl]-ethyl}-2'-fluoro-biphenyl-2-ol



The desired compound was obtained by the same
procedure as in Example 64 except for using the compound
15 obtained in Example 57.

¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

1.57(d, 3H, J=7.1Hz), 3.21-3.22(m, 2H), 3.46-
3.51(m, 4H), 3.79-3.84(m, 2H), 4.21(q, 1H, J=
7.1Hz), 6.15(s, 1H), 6.84(t, 1H, J=7.5Hz),
20 6.91(d, 1H, J=7.9Hz), 7.12-7.21(m, 4H), 7.26-
7.31(m, 1H), 9.53(br-s, 1H)


IR (KBr) [cm⁻¹]: 3275, 2964, 1659, 1605, 1493,

175

1451, 1419, 1358

Example 66

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl}-N'-[2-hydroxy-ethoxy-ethyl]-guanidine hydro-
5 chloride



The compound (3.34 g) obtained in Example 49 was dissolved in 1,4-dioxane and treated with 4 N hydrochloric acid to obtain the desired compound (521 mg).

Melting point 127 - 128°C

10 ¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.68(d, 3H, J=7.3Hz), 3.48-3.54(m, 2H), 3.54-3.62(m, 2H), 3.63-3.70(m, 4H), 4.27(q, 1H, J=7.1Hz), 5.98(s, 1H), 7.12-7.24(m, 2H), 7.31-7.52(m, 6H)

15 IR (KBr) [cm⁻¹]: 3223, 3121, 2934, 1684, 1644,

1616, 1582, 1532, 1484, 1418, 1353, 1267,


1137, 1108, 1064, 698

MS (FD) [m/e]: 413 (M-HCl)

Example 67

20 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl}-N'-(2-hydroxy-ethyl)-guanidine hydrochloride

176




The desired compound was obtained by the same procedure as in Example 66 except for using the compound obtained in Example 50.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.59(d, 3H, J=7.1Hz), 3.47-3.58(m, 2H), 3.70-3.83(m, 2H), 4.13(q, 1H, J=7.0Hz), 5.78(s, 1H), 7.00-7.07(m, 2H), 7.31-7.49(m, 6H), 7.98 (br-s, 1H)

Example 68

10 4'-[1-[5-(Amino-morpholin-4-yl-methylene-amino)-isoxazol-3-yl]-ethyl]-2'-fluoro-biphenyl-4-ol hydrochloride



The desired compound was obtained by the same procedure as in Example 66 except for using the compound
15 obtained in Example 64.

Melting point 195 - 210°C (decomp.)

177

¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

1.58(d, 3H, J=7.2Hz), 3.40-3.67(m, 8H), 4.24
(q, 1H, J=7.3Hz), 5.99(s, 1H), 6.84(d, 2H,
J=8.4Hz), 7.19-7.45(m, 5H), 8.49(br-s, 2H),
9.67(br-s, 1H)

IR (KBr) [cm⁻¹]: 3215, 3114, 1647, 1614, 1532,
1495, 1418, 1272, 1116, 820


Elementary analysis:

Calculated: C 59.13, H 5.41, N 12.54

Found : C 59.05, H 5.26, N 12.47

Example 69

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl)-N'-(2-morpholin-4-yl-ethyl)-guanidine hydro-
chloride



15 The desired compound was obtained by the same
procedure as in Example 66 except for using the compound
obtained in Example 44.

¹H-NMR (300 MHz, CD₃OD) δ ppm:


1.69(d, 3H, J=7.3Hz), 3.43-3.48(m, 6H), 3.86
(t, 2H, J=7.3Hz), 3.90-4.10(br-s, 6H), 4.30(q,
1H, J=7.3Hz), 6.08(s, 1H), 7.15-7.25(m, 2H),

178

7.36-7.53(m, 6H)

Example 70

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-yl)-N'-(2-methoxy-ethyl)-guanidine hydrochloride



5 The desired compound was obtained by the same
 procedure as in Example 66 except for using the compound
 obtained in Example 45.


¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.65(d, 3H, J=7.3Hz), 3.39(s, 3H), 3.52(t, 2H,
 10 J=4.6Hz), 3.62(t, 2H, J=4.6Hz), 4.28(q, 1H,
 J=7.3Hz), 5.98(s, 1H), 7.15-7.35(m, 2H), 7.38-
 7.52(m, 6H)

Example 71

2-[3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
 15 zol-5-ylimino}-1-(2-hydroxy-ethyl)-imidazolidin-4-one
hydrochloride

179



The compound (3.3 g) obtained in Example 35 was dissolved in tetrahydrofuran (30 ml) and conc. hydrochloric acid was added, after which the solution was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and purified by a recrystallization method from toluene to obtain the desired compound (1.4 g).

Melting point 159 - 167°C (decomp.)

¹H-NMR (300 MHz, CD₃OD) δ ppm:

10 1.73(d, 3H, J=7.3Hz), 3.71-3.76(m, 2H), 3.82-3.86(m, 2H), 4.39(q, 1H, J=7.1Hz), 4.53(s, 2H), 6.65(s, 1H), 7.18-7.27(m, 2H), 7.35-7.52(m, 6H)


IR (KBr) [cm⁻¹]: 3452, 3192, 2939, 1807, 1707,

15 1616, 1526, 1485, 1450, 1417, 1147, 1051, 697

MS (FD) [m/e]: 444 (M⁺), 409 (M-HCl)

Example 72

((3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine
 20 methanesulfonate




The compound (1.53 g) obtained in Example 51 was dissolved in 1,4-dioxane and methanesulfonic acid (0.27 ml) was added under ice-cooling, after which the solution was stirred for 30 minutes. Subsequently, it was purified by a recrystallization method from 1,4-dioxane to obtain the desired compound (1.89 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.71(s, 6H), 2.71(s, 3H), 3.45-3.52(m, 4H),
 3.71-3.78(m, 4H), 5.51(s, 1H), 7.07(dd, 1H,
 10 J=12.3, 1.8Hz), 7.13(dd, 1H, J=8.3, 1.8Hz),
 7.34-7.46(m, 4H), 7.50-7.54(m, 2H), 8.64(br-s,
 2H), 11.10(br-s, 1H)

Example 73

(Morpholin-4-yl-({3-[1-(3-phenoxy-phenyl)-eth-
 15 yl-1-isoxazol-5-ylimino]-methyl})-amine methanesulfonate



181


The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 52.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.62(d, 3H, J=7.2Hz), 2.72(s, 3H), 3.43-3.47
(m, 4H), 3.72-3.76(m, 4H), 4.11(q, 1H, J=7.2
Hz), 5.53(s, 1H), 6.83-7.01(m, 5H), 7.09-7.15
(m, 1H), 7.23-7.37(m, 3H), 8.63(br-s, 2H),
11.10(br-s, 1H)

10 Example 74

((3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-ylimino)-morpholin-4-yl-methyl)-amine methanesul-
fonate




The desired compound was obtained by the same
15 procedure as in Example 72 except for using the compound
obtained in Example 58.

¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

20 1.67(d, 3H, J=7.1Hz), 2.73(s, 3H), 3.46-3.50
(m, 4H), 3.72-3.76(m, 4H), 4.18(q, 1H, J=7.1
Hz), 5.58(s, 1H), 7.11-7.61(m, 8H), 8.56(br-s,
2H)

Example 75

{{3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine methanesulfonate




5 The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 59.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

10 1.36-1.41(m, 2H), 1.47-1.52(m, 2H), 2.74(s, 3H), 3.46-3.50(m, 4H), 3.73-3.78(m, 4H), 5.50 (s, 1H), 7.12-7.23(m, 2H), 7.33-7.48(m, 4H), 7.51-7.56(m, 2H), 8.61(br-s, 2H), 11.10(br-s, 1H)

Example 76

15 [1-(3-Biphenyl-4-ylmethyl-isoxazol-5-ylimino)-morpholin-4-yl-methyl]-amine methanesulfonate




The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 60.

$^1\text{H-NMR}$ (300 MHz, CD_3OD) δ ppm:

5 2.69(s, 3H), 3.60(t, 4H, $J=5.3\text{Hz}$), 3.77(t, 4H, $J=5.3\text{Hz}$), 4.02(s, 2H), 5.92(s, 1H), 7.32-7.45 (m, 5H), 7.56-7.60(m, 4H)

Example 77

10 {[3-(1-Biphenyl-4-yl-ethyl)-isoxazol-5-ylimino]-
no1-morpholin-4-yl-methyl}-amine methanesulfonate




The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 61.

$^1\text{H-NMR}$ (300 MHz, CD_3OD) δ ppm:

15 1.68(d, 3H, $J=7.3\text{Hz}$), 2.69(s, 3H), 3.57(t, 4H, $J=4.3\text{Hz}$), 3.76(t, 4H, $J=4.3\text{Hz}$), 4.23(q, 1H, $J=7.3\text{Hz}$), 5.91(s, 1H), 7.29-7.44(m, 5H), 7.57-7.60(m, 4H)

Example 78

20 {[3-(1-Biphenyl-4-yl-1-methyl-ethyl)-isoxazol-5-ylimino]-

5-yliminol-morpholin-4-yl-methyl)-amine methanesulfonate


The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 62.

5 ¹H-NMR (300 MHz, CD₃OD) δ ppm:

1.75(s, 6H), 2.68(s, 3H), 3.58(t, 4H, J=5.3 Hz), 3.76(t, 4H, J=5.3Hz), 5.83(s, 1H), 7.32-7.45(m, 5H), 7.56-7.60(m, 4H)

Example 79

10 ((3-[1-(2-Fluoro-4'-methoxy-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine methanesulfonate



The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 63.

185

Melting point 187 - 189°C (decomp.)

¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

1.59(d, 3H, J=7.0Hz), 2.29(s, 3H), 3.40-3.53
 (m, 4H), 3.63-3.67(m, 4H), 3.78(s, 3H), 4.26
 5 (q, 1H, J=7.2Hz), 6.00(s, 1H), 7.02(d, 2H,
 J=8.4Hz), 7.19-7.30(m, 2H), 7.41-7.48(m, 3H),
 8.40(br-s, 2H)

IR (KBr) [cm⁻¹]: 3098, 1674, 1634, 1614, 1496,
 1456, 1251, 1182, 1116, 1048, 825


10 Elementary Analysis

Calculated: C 55.37, H 5.62, N 10.76

Found : C 55.32, H 5.60, N 10.77

Example 80

15 [2-(N'-(tert-Butoxycarbonyl)-N"-{3-[1-(2-flu-
 oro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidino)-etho-
 xyl-acetic acid



The compound (52 mg) obtained in Example 32 was
 dissolved in tetrahydrofuran (1 ml) and a 5% aqueous
 sodium hydroxide solution (1 ml) was added, after which
 20 the solution was stirred at room temperature for 3 hours.
 To the reaction mixture was added a saturated aqueous
 ammonium chloride solution and thereafter the resulting

mixture was subjected to extraction with ethyl acetate. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (chloroform/methanol = 9/1) to obtain the desired compound (25 mg).


$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.42(s, 9H), 1.62(d, 3H, $J=7.1\text{Hz}$), 3.50-3.64 (m, 2H), 3.65-3.75(m, 2H), 4.06(s, 2H), 4.06-4.14(m, 1H), 5.31(s, 1H), 7.05-7.13(m, 2H), 7.30-7.42(m, 4H), 7.48-7.51(m, 2H), 8.18(br-s, 1H), 8.44(br-s, 1H)

IR (neat) [cm^{-1}]: 3397, 3348, 2980, 2934, 1731, 1634, 1606, 1562, 1486, 1455, 1418, 1370, 1242, 1150, 912, 770, 733, 699

Example 81

Sodium [2-(N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidino)-ethoxyl]-acetate



The compound (4.32 g) obtained in Example 48 was dissolved in tetrahydrofuran (80 ml) and a 5% aqueous sodium hydroxide solution (80 ml) was added, after which the solution was stirred at room temperature for one hour. The reaction mixture was concentrated under

reduced pressure and then filtered, after which the solid materials were washed with ethyl acetate and water. The filtrate was concentrated and thereafter the solid materials were again separated by filtration and then washed with ethyl acetate and water. The combined crude crystals were purified by a recrystallization method from water to obtain the desired compound (3.08 g).

¹H-NMR (300 MHz, CD₃OD), δ ppm:

1.63(d, 3H, J=7.1Hz), 3.38-3.42(m, 2H), 3.56-3.60(m, 2H), 3.87(s, 2H), 4.13(q, 1H, J=7.2 Hz), 5.35(s, 1H), 7.11-7.21(m, 2H), 7.30-7.43(m, 4H), 7.49-7.52(m, 2H)

R (neat) [cm⁻¹]; 3429, 1573, 1453, 1430, 1330, 694


Elementary analysis

Calculated: C 57.77, H 5.07, N 12.25

Found : C 57.86, H 5.15, N 12.19

Example 82

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine hydrochloride



The desired compound was obtained by the same procedure as in Example 66 except for using the compound

obtained in Example 54.

Melting point 134 - 136°C


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.64(d, 3H, J=7.1Hz), 3.45-3.65(m, 4H), 3.70-
 5 3.80(m, 4H), 4.15(q, 1H, J=7.1Hz), 5.69(s,
 1H), 7.03-7.11(m, 2H), 7.33-7.52(m, 6H), 8.45
 (br-s, 2H), 11.31(br-s, 1H)

[α]_D²²=-16.0° (c: 1.00, CHCl₃)

Example 83

10 (S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine hydro-
chloride



The desired compound was obtained by the same
 procedure as in Example 66 except for using the compound
 15 obtained in Example 55.

Melting point 134 - 136°C


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.64(d, 3H, J=7.3Hz), 3.45-3.60(m, 4H), 3.60-
 3.80(m, 4H), 4.15(q, 1H, J=7.3Hz), 5.69(s,
 20 1H), 7.02-7.12(m, 2H), 7.32-7.52(m, 6H), 8.44
 (br-s, 2H)

[α]_D²²=+14.4° (c: 1.00, CHCl₃)

Example 84

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine phosphate



- 5 The desired compound was obtained by treating the compound obtained in Example 54 with phosphoric acid.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


- 1.54(d, 3H, J=7.3Hz), 3.40-3.43(m, 4H), 3.55-3.58(m, 4H), 4.11(q, 1H, J=7.3Hz), 5.42(s, 1H), 6.46(br-s, 2H), 7.21-7.26(m, 2H), 7.38-7.53(m, 6H)

IR (neat) [cm⁻¹]: 3381, 2973, 2361, 1682, 1618, 1552, 1484, 1456, 1411, 1274, 1113

[α]_D²⁰ = -27.2° (c: 0.60, MeOH)

15 Example 85

(S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine phosphate



The desired compound was obtained by the same procedure as in Example 84 except for using the compound obtained in Example 55.


¹H-NMR (300 MHz, CDCl₃) δ ppm: Same as in Example 84.

IR (neat) [cm⁻¹]: Same as in Example 84.

$[\alpha]_D^{20} = +27.7^\circ$ (c: 0.52, MeOH)

Example 86

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine methanesulfonate



The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 54.

Melting point: 166 - 167°C

¹H-NMR (300 MHz, CDCl₃) δ ppm:

191

1.66(d, 3H, J=7.1Hz), 2.72(s, 3H), 3.46-3.51
(m, 4H), 3.71-3.77(m, 4H), 4.17(q, 1H, J=7.2
Hz), 5.59(s, 1H), 7.02-7.12(m, 2H), 7.33-7.46
(m, 4H), 7.50-7.53(m, 2H), 8.62(br-s, 2H),
11.14(br-s, 1H)


5

IR (neat) [cm⁻¹]: 2974, 1668, 1634, 1548, 1484,
1446, 1270, 1194, 1117, 1043, 776, 699
[α]_D²² = -14.0° (c: 1.00, CHCl₃)

Example 87

10

(S)-((3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-morpholin-4-yl)-amine methanesulfo-
nate



The desired compound was obtained by the same
procedure as in Example 72 except for using the compound
15 obtained in Example 55.

Melting point 162 - 165°C

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.3Hz), 2.72(s, 3H), 3.46-3.51
(m, 4H), 3.71-3.78(m, 4H), 4.17(q, 1H, J=7.1
Hz), 5.59(s, 1H), 7.02-7.12(m, 2H), 7.33-7.46
(m, 4H), 7.50-7.53(m, 2H), 8.62(br-s, 2H),
11.13(br-s, 1H)


20

192

IR (neat) [cm⁻¹]: 2972, 1668, 1634, 1548, 1484,
 1446, 1418, 1198, 1116, 1062, 1010, 768, 699
 [α]_D²²=+12.0° (c: 0.80, CHCl₃)

Example 88

5 (R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl-
 isoxazol-5-ylimino]-morpholin-4-yl-methyl)-amine ben-
 zenesulfonate



The desired compound was obtained by treating
 the compound obtained in Example 54 with benzenesulfonic
 10 acid.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


1.59(d, 3H, J=7.1Hz), 3.50(m, 4H), 3.66(m,
 4H), 4.26(q, 1H, J=7.1Hz), 5.98(s, 1H), 7.25-
 7.59(m, 13H)

15 IR (neat) [cm⁻¹]: 3135, 1679, 1630, 1552, 1484,
 1445, 1418
 [α]_D²⁰=-16.9° (c: 0.53, MeOH)

Example 89

20 (S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-

isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine benzenesulfonate



The desired compound was obtained by the same procedure as in Example 88 except for using the compound 5 obtained in Example 55.


$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm: Same as in Example 88.

IR (neat)[cm^{-1}]: Same as in Example 88.

$[\alpha]_D^{20} = +16.8^\circ$ (c: 0.51, MeOH)

10 Example 90

(R)-((3-((1-(2-Fluoro-biphenyl-4-yl)-ethyl)-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine sulfate



The desired compound was obtained by treating the compound obtained in Example 54 with sulfuric acid.

15 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.53(d, 3H, $J=7.3\text{Hz}$), 3.30-3.80(m, 8H), 4.07 (q, 1H, $J=6.8\text{Hz}$), 5.72(s, 1H), 6.97-7.05(m,


194

2H), 7.28-7.44(m, 6H), 7.95(br-s, 2H)

[α]_D²² = -20.2° (c: 1.00, THF)

Example 91

(S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 5 isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine sulfate



The desired compound was obtained by the same procedure as in Example 90 except for using the compound obtained in Example 55.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


10 1.53(d, 3H, J=6.8Hz), 3.30-3.80(m, 8H), 4.05-
 4.10(m, 1H), 5.72(s, 1H), 6.97-7.05(m, 2H),
 7.28-7.44(m, 6H), 7.95(br-s, 1H)

[α]_D²² = +20.2° (c: 1.00, THF)

Example 92

15 (R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine D-cam-
 phorsulfonate

195



The desired compound was obtained by treating the compound obtained in Example 54 with D-camphor-sulfonic acid.


Melting point 167 - 169°C

5 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

0.76(s, 3H), 0.95(s, 3H), 1.23-1.32(m, 1H),
 1.53-1.62(m, 1H), 1.66(d, 3H, J=7.3Hz), 1.79
 (d, 1H, J=18.1Hz), 1.82-1.88(m, 1H), 1.96-2.00
 (m, 1H), 2.21-2.28(m, 1H), 2.35-2.47(m, 1H),
 10 2.76(d, 1H, J=14.6Hz), 3.26(d, 1H, J=14.6Hz),
 3.48-3.52(m, 4H), 3.73-3.76(m, 4H), 4.17(q,
 1H, J=7.1Hz), 5.63(s, 1H), 7.03-7.53(m, 8H),
 8.35(br-s, 2H), 11.12(br-s, 2H)

Example 93

15 (S)-((3-((1-(2-Fluoro-biphenyl-4-yl)-ethyl)-
isoxazol-5-yl)imino)-morpholin-4-yl-methyl)-amine D-cam-
phorsulfonate




The desired compound was obtained by the same procedure as in Example 92 except for using the compound obtained in Example 55.

Melting point 167 - 168°C

- 5 ¹H-NMR (300 MHz, CDCl₃) δ ppm:
- 0.76(s, 3H), 0.95(s, 3H), 1.24-1.32(m, 1H),
 1.54-1.65(m, 1H), 1.66(d, 3H, J=7.1Hz), 1.79
 (d, 1H, J=18.1Hz), 1.82-1.91(m, 1H), 1.96-
 2.00(m, 1H), 2.21-2.30(m, 1H), 2.35-2.47(m,
 10 1H), 2.75(d, 1H, J=14.6Hz), 3.26(d, 1H, J=
 14.7Hz), 3.48-3.52(m, 4H), 3.73-3.76(m, 4H),
 4.17(q, 1H, J=7.1Hz), 5.66(s, 1H), 7.04-7.14
 (m, 2H), 7.33-7.52(m, 6H), 8.53(br-s, 2H),
 11.11(br-s. 1H)

15 Example 94

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine 3-bro-
mo-(+)-camphor-10-sulfonate



- The desired compound was obtained by treating
 20 the compound obtained in Example 54 with 3-bromo-(+)-

197


camphor-10-sulfonic acid.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

0.97(s, 3H), 1.25(s, 3H), 1.47-1.54(m, 1H),
 1.68(d, 3H, J=7.1Hz), 1.85-2.00(m, 1H), 2.00-
 5 2.10(m, 1H), 2.23-2.26(m, 1H), 2.65-2.69(m,
 1H), 2.83(d, 1H, J=14.8Hz), 3.23-3.28(m, 1H),
 3.55-3.59(m, 4H), 3.74-3.78(m, 4H), 4.27(q,
 1H, J=7.1Hz), 4.76-4.79(m, 1H), 5.91(s, 1H),
 7.13-7.23(m, 2H), 7.34-7.51(m, 6H)

10 Example 95

(S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine 3-bro-
mo-(+)-camphor-10-sulfonate



The desired compound was obtained by the same
 15 procedure as in Example 94 except for using the compound
 obtained in Example 55.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


0.95(s, 3H), 1.23(s, 3H), 1.49-1.59(m, 1H),
 1.67(d, 3H, J=7.4Hz), 1.80-2.15(m, 2H), 2.21-
 20 2.24(m, 1H), 2.62-2.66(m, 1H), 2.83(d, 1H, J=
 15.0Hz), 3.23-3.28(m, 1H), 3.53-3.60(m, 4H),
 3.73-3.77(m, 4H), 4.21(q, 1H, J=7.3Hz), 4.62-

198

4.65(m, 1H), 5.79(s, 1H), 7.06-7.17(m, 2H),
7.30-7.49(m, 6H)

Example 96

(R)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
5 isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine 3-bro-
mo-(+)-camphor-8-sulfonate




The desired compound was obtained by treating the compound obtained in Example 54 with 3-bromo-(+)-camphor-8-sulfonic acid.

10 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

0.90(s, 3H), 1.22(s, 3H), 1.37-1.43(m, 1H),
1.50-1.63(m, 1H), 1.67(d, 3H, J=7.1Hz), 1.90-
2.15(m, 2H), 2.76(d, 1H, J=14.3Hz), 2.94(s,
1H), 3.15(d, 1H, J=14.6Hz), 3.40-3.52(m, 4H),
15 3.72-3.77(m, 4H), 4.17(q, 1H, J=7.1Hz), 4.50
-(d, 1H, J=4.7Hz), 5.50(s, 1H), 7.01-7.12(m,
2H), 7.34-7.53(m, 6H)

Example 97

(S)-({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
20 isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine 3-bro-
mo-(+)-camphor-8-sulfonate




The desired compound was obtained by the same procedure as in Example 96 except for using the compound obtained in Example 54.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 0.90(s, 3H), 1.11(s, 3H), 1.37-1.48(m, 1H),
 1.50-1.63(m, 1H), 1.67(d, 3H, J=7.1Hz), 1.95-
 2.15(m, 2H), 2.76(d, 1H, J=14.3Hz), 2.94(s,
 1H), 3.15(d, 1H, J=14.5Hz), 3.40-3.52(m, 4H),
 3.72-3.77(m, 4H), 4.18(q, 1H, J=7.1Hz), 4.49
 10 (d, 1H, J=4.8Hz), 5.52(s, 1H), 7.02-7.12(m,
 2H), 7.36-7.53(m, 6H)

Example 98

((3-[1-(9H-Carbazol-2-yl)-ethyl]-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine



15 The desired compound was obtained by the same
 procedure as in Example 54 except for using the compound
 obtained in Reference Example 34.

200


Melting point 113°C (decomp.)

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.71(d, 3H, J=7.1Hz), 3.42-3.46(m, 4H), 3.66-
3.71(m, 4H), 4.27(q, 1H, J=7.1Hz), 5.26(s,
1H), 5.35(br-s, 2H), 7.16-7.23(m, 2H), 7.33-
7.42(m, 3H), 7.96-8.04(m, 2H), 8.15(s, 1H)

Example 99

{[3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-yliminol-morpholin-4-yl-methyl]-amine




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 35.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

3.47-3.51(m, 4H), 3.71-3.75(m, 4H), 3.92(s,
2H), 5.26(s, 1H), 5.38(br-s, 2H), 7.04-7.14(m,
2H), 7.33-7.47(m, 4H), 7.50-7.55(m, 2H)

Example 100

{[3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-yliminol-morpholin-4-yl-methyl]-amine methanesulfonate



The desired compound was obtained by the same procedure as in Example 72 except for using the compound obtained in Example 99.


Melting point 71 - 74°C (decomp.)

5 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

2.73(s, 3H), 3.47-3.51(m, 4H), 3.69-3.73(m, 4H), 3.96(s, 2H), 5.63(s, 1H), 7.01-7.11(m, 2H), 7.34-7.47(m, 4H), 7.50-7.54(m, 2H), 8.63(br-s, 2H), 11.2(br-s, 1H)

10 Example 101

(({3-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine



The desired compound was obtained by the same procedure as in Example 54 except for using the compound

15 obtained in Reference Example 37.

¹H-NMR (270 MHz, CDCl₃) δ ppm:


1.58(d, 3H, J=7.3Hz), 3.47(t, 4H, J=4.6Hz), 3.72(t, 4H, J=4.6Hz), 4.00(q, 1H, J=7.3Hz),

202

4.22(s, 4H), 5.20(s, 1H), 5.35(br-s, 2H),
6.77-6.80(m, 3H)

Example 102

((3-[1-(1-Methyl-1H-indol-3-yl)-ethyl]-isoxa-
5 zol-5-ylimino)-morpholin-4-yl-methyl)-amine




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 38.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

10 1.72(d, 3H, J=7.3Hz), 3.43(t, 4H, J=4.6Hz),
3.68(t, 4H, J=4.6Hz), 3.73(s, 3H), 4.40(q, 1H,
J=7.3Hz), 5.24(s, 1H), 5.31(br-s, 2H), 6.92(s,
1H), 7.03-7.28(m, 3H), 7.61(d, 1H, J=7.9Hz)

Example 103

15 ((3-[1-(1H-Indol-3-yl)-ethyl]-isoxazol-5-yl-
imino)-morpholin-4-yl-methyl)-amine



203


The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 39.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

5 1.72(d, 3H, J=7.3Hz), 3.44(t, 4H, J=5.0Hz),
 3.69(t, 4H, J=5.0Hz), 4.41(q, 1H, J=7.3Hz),
 5.23(s, 1H), 5.28(br-s, 2H), 7.04-7.19(m, 3H),
 7.33(d, 1H, J=7.9Hz), 7.63(d, 1H, J=7.9Hz),
 8.03(br-s, 1H)

10 Example 104

((3-[1-(1-Methyl-1H-indol-2-yl)-ethyl]-isoxa-
zol-5-ylimino)-morpholin-4-yl-methyl)-amine



The desired compound was obtained by the same procedure as in Example 54 except for using the compound


15 obtained in Reference Example 41.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

20 1.73(d, 3H, J=7.3Hz), 3.44(t, 4H, J=4.6Hz),
 3.64(s, 3H), 3.70(t, 4H, J=4.6Hz), 4.34(q, 1H,
 J=7.3Hz), 5.12(s, 1H), 5.26(br-s, 2H), 6.45(s,
 1H), 7.04-7.26(m, 3H), 7.56(d, 1H, J=7.3Hz)

Example 105

{[3-(1-Benzofuran-5-yl-ethyl)-isoxazol-5-yl-
iminol-morpholin-4-yl-methyl]-amine}




The desired compound was obtained by the same
5 procedure as in Example 54 except for using the compound
obtained in Reference Example 43.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.67(d, 3H, J=7.3Hz), 3.46(t, 4H, J=4.6Hz),
3.71(t, 4H, J=4.6Hz), 4.19(q, 1H, J=7.3Hz),
10 5.20(s, 1H), 5.34(br-s, 2H), 6.71(d, 1H, J=
2.3Hz), 7.21-7.26(m, 1H), 7.42(d, 1H, J=8.6
Hz), 7.51(d, 1H, J=1.7Hz), 7.59(d, 1H, J=
2.3Hz)

Example 106

15 {[3-(1-Benzofuran-6-yl-ethyl)-isoxazol-5-yl-
iminol-morpholin-4-yl-methyl]-amine}



The desired compound was obtained by the same


procedure as in Example 54 except for using the compound obtained in Reference Example 45.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.68(d, 3H, J=7.3Hz), 3.46(t, 4H, J=4.6Hz),
 3.71(t, 4H, J=4.6Hz), 4.23(q, 1H, J=7.3Hz),
 5.21(s, 1H), 5.33(br-s, 2H), 6.72(d, 1H, J=
 2.3Hz), 7.19(dd, 1H, J=8.3, 1.7Hz), 7.45-7.52
 (m, 2H), 7.58(d, 1H, J=2.3Hz)

Example 107

(3-{1-[5-(Amino-morpholin-4-yl-methyleneami-
 no)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone meth-
 anesulfonate




The desired compound was obtained by the same procedure as in Example 54 and Example 72 except for using (3-[1-(5-amino-isoxazol-3-yl)-ethyl]-phenyl)-phenyl-methanone (Japanese Patent Unexamined Publication No. 63-152,368).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.67(d, 3H, J=7.1Hz), 2.72(s, 3H), 3.45-3.51
 (m, 4H), 3.72-3.76(m, 4H), 4.22(q, 1H, J=7.1
 Hz), 5.57(s, 1H), 7.40-7.51(m, 4H), 7.57-7.65
 (m, 2H), 7.71(s, 1H), 7.77-7.79(m, 2H), 8.61
 (br-s, 2H), 11.13(br-s, 1H)

Example 108

[({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-ylimino}-morpholin-4-yl-methylimino)-morpholine-4-
yl-methyl]-amine




5 A mixture of the free form of the compound
(2.20 g) obtained in Example 22, 4-morpholinecarbonitrile
(2.8 ml) and sodium amide (0.44 g) was stirred at room
temperature for 5 hours. The reaction mixture was poured
into a saturated aqueous ammonium chloride solution and
10 then subjected to extraction with chloroform. The
organic layer was dried over magnesium sulfate and then
concentrated under reduced pressure, after which the
residue was purified by a silica gel column chroma-
tography to obtain the desired compound (1.62 g).

15 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.62(d, 3H, J=7.3Hz), 3.26-3.29(m, 4H), 3.54-
3.57(m, 4H), 3.63-3.66(m, 8H), 4.11(q, 1H,
J=7.2Hz), 4.63(br-s, 2H), 5.01(s, 1H), 7.05-
7.17(m, 2H), 7.33-7.54(m, 6H)

20 Example 109

[({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxa-
zol-5-ylimino}-morpholin-4-yl-methylimino)-morpholin-4-

yl-methyl]-amine hydrochloride


The compound (1.66 g) obtained in Example 108 was dissolved in 1,4-dioxane (20 ml) and thereto was added a 4 N hydrogen chloride/1,4-dioxane solution (1.00 ml), after which the resulting mixture was stirred at room temperature for 2 hours, upon which a white precipitate separated. The reaction mixture was heated to 100°C to dissolve the precipitate and thereafter allowed to slowly cool with stirring. The resulting white precipitate was separated by filtration to obtain the desired compound (1.19 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.1Hz), 3.44-3.56(m, 4H), 3.60-3.68(m, 4H), 3.68-3.83(m, 8H), 4.16(q, 1H, J=7.0Hz), 5.52(s, 1H), 7.03-7.15(m, 4H), 7.35-7.55(m, 6H)

Example 110

{{3-[1-(2-Fluoro-biphenyl-4-yl)-vinyl]-isoxa-
zol-5-ylimino}-morpholin-4-yl-methyl)-amine



Trifluoroacetic acid (4 ml) was added to a solution of the compound (30.0 mg) obtained in Example 53 in methylene chloride (1 ml), and the resulting mixture was stirred at room temperature for 8 hours. After the addition of a saturated aqueous sodium chloride solution, the mixture was subjected to extraction with ethyl acetate, and the organic layer was washed successively with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, thereafter dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography to obtain the desired compound (20 mg).


Melting point 167.5°C (decomp.)

¹H-NMR (300 MHz, CDCl₃) δ ppm:

3.51-3.55(m, 4H), 3.74-3.78(m, 4H), 5.42(br-s, 2H), 5.54(s, 1H), 5.69(s, 1H), 5.84(s, 1H), 7.26-7.59(m, 8H)

Example 111

(Morpholin-4-yl-[3-(1-quinolin-3-yl-ethyl)-isoxazol-5-ylimino]-methyl)-amine




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 47.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

- 5 1.76(d, 3H, J=7.3Hz), 3.48(t, 4H, J=4.6Hz),
 3.72(t, 4H, J=4.6Hz), 4.34(q, 1H, J=7.3Hz),
 5.24(s, 1H), 5.33(br-s, 2H), 7.50-7.79(m, 3H),
 8.02-8.09(m, 2H), 8.89(d, 1H, J=2.3Hz).

Example 112

- 10 {[3-(1-Isoquinolin-4-yl-ethyl)-isoxazol-5-yliminol-morpholin-4-yl-methyl]-amine



The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 48.


- 15 ¹H-NMR (270 MHz, CDCl₃) δ ppm:

210

1.83(d, 3H, J=7.3Hz), 3.45(t, 4H, J=4.6Hz),
 3.68(t, 4H, J=4.6Hz), 4.79(q, 1H, J=7.3Hz),
 5.13(s, 1H), 5.40(br-s, 2H), 7.56-7.72(m, 2H),
 7.97(d, 1H, J=7.6Hz), 8.14(d, 1H, J=8.6Hz),
 8.52(s, 1H), 9.15(s, 1H).

Example 113

{[3-(1-Biphenyl-4-yl-dimethoxy-methyl)-
isoxazol-5-yliminol-morpholin-4-yl-methyl]-amine




The desired compound was obtained by the same
 10 procedure as in Example 54 except for using the compound
 obtained in Reference Example 50.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

3.28(s, 6H), 3.47(t, 4H, J=4.6Hz), 3.71(t, 4H,
 J=4.6Hz), 5.32(s, 1H), 5.36(br-s, 2H), 7.33-
 7.45(m, 3H), 7.54-7.67(m, 6H).

Example 114

{[3-[Dimethoxy-(1-methyl-1H-indol-2-yl)-
methyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine




The desired compound was obtained by the same procedure as in Example 54 except for using the compound obtained in Reference Example 52.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

- 5 3.27(s, 6H), 3.44(t, 4H, J=4.6Hz), 3.66(s, 3H),
 3.69(t, 4H, J=4.6Hz), 5.26(s, 1H), 5.30(br-s,
 2H), 6.87(s, 1H), 7.06-7.28(m, 3H), 7.62(d, 1H,
 J=7.6Hz).

Example 115

- 10 N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluoro-
 biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N''-phenyl-guanidine



The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


- 15 1.54(s, 9H), 1.68(d, 3H, J=7.1Hz), 4.16(q, 1H,
 J=7.1Hz), 5.45(s, 1H), 7.07-7.17(m, 3H), 7.27-

212

7.46(m, 6H), 7.51-7.61(m, 4H), 8.63(br-s, 1H),
10.10(br-s, 1H).

Example 116

N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluoro-
5 biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N"-pyridin-3-yl-
guanidine



The desired compound was obtained by the same
procedure as in Example 1.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

10 1.55(s, 9H), 1.69(d, 3H, J=7.1Hz), 4.18(q, 1H,
J=7.1Hz), 5.45(s, 1H), 7.07-7.25(m, 2H), 7.27-
7.46(m, 4H), 7.51-7.55(m, 2H), 8.14-8.18(m, 1H),
8.32-8.35(m, 1H), 8.69-8.71(m, 2H), 10.22(br-s,
1H).

15 Example 117

(tert-Butoxycarbonyl)-({3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-thiamorpholin-
4-yl-methyl)-amine

213




The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.43(s, 9H), 1.66(d, 3H, J=7.3Hz), 2.68-2.74(m, 4H), 3.84(br-s, 4H), 4.16(q, 1H, J=7.1Hz),
 5.28(s, 1H), 6.81(br-s, 1H), 7.07-7.16(m, 2H),
 7.34-7.46(m, 4H), 7.50-7.54(m, 2H).

Example 118

1-([[(tert-Butoxycarbonyl)-amino]-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-one



The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


1.46(s, 9H), 1.68(d, 3H, J=7.3Hz), 2.60(t, 4H,

214

J=6.2Hz), 3.84(t, 4H, J=6.2Hz), 4.18(q, 1H, J=7.0Hz), 5.34(s, 1H), 7.06(br-s, 1H), 7.07-7.17(m, 2H), 7.33-7.46(m, 4H), 7.50-7.55(m, 2H).

Example 119

5 1-([tert-Butoxycarbonyl]-aminol-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-ol



The desired compound was obtained by the same procedure as in Example 1.


10 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.43(s, 9H), 1.55-1.68(m, 3H), 1.66(d, 3H, J=7.3Hz), 1.85-1.99(m, 2H), 3.25-3.40(m, 2H), 3.84-3.99(m, 3H), 4.12(q, 1H, J=7.1Hz), 5.25(s, 1H), 6.75(br-s, 1H), 7.07-7.16(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H).

Example 120

N-(tert-Butoxycarbonyl)-N'-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N"-hydroxy-guanidine

215




The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.51(s, 9H), 1.66(d, 3H, J=7.1Hz), 4.16(q, 1H, J=7.1Hz), 5.79(s, 1H), 6.20(br-s, 1H), 7.06-7.14(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H), 7.78(br-s, 1H), 9.89(br-s, 1H).

Example 121

N-(tert-Butoxycarbonyl)-N'-{3-[1-(2-fluoro-4-phenyl-ethyl)-isoxazol-5-yl]-N-methoxy-guanidine}



The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


1.51(s, 9H), 1.68(d, 3H, J=7.1Hz), 3.78(s, 3H), 4.19(q, 1H, J=7.1Hz), 5.87(s, 1H), 7.08-7.17(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H),

216

7.70(br-s, 1H), 9.86(br-s, 1H).

Example 122

N-(tert-Butoxycarbonyl)-N'-(2-dimethylamino-ethyl)-N''-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-guanidine




The desired compound was obtained by the same procedure as in Example 1.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.49(s, 9H), 1.67(d, 3H, J=7.1Hz), 2.26(s, 6H),
 2.49(t, 2H, J=6.2Hz), 3.42-3.49(m, 2H), 4.14(q,
 1H, J=7.1Hz), 5.31(br-s, 1H), 7.07-7.17(m, 2H),
 7.32-7.46(m, 4H), 7.50-7.54(m, 2H), 8.18(br-s,
 1H), 8.48(br-s, 1H).

Example 123

N-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-N'-phenyl-guanidine



217


The desired compound was obtained by the same procedure as in Example 48 except for using the compound obtained in Example 115.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.64(d, 3H, J=7.1Hz), 4.14(q, 1H, J=7.1Hz),
 5.18(s, 1H), 5.48(br-s, 2H), 7.05-7.15(m, 2H),
 7.23-7.47(m, 3H), 7.32-7.47(m, 6H), 7.51-7.55(m,
 3H).

Example 124

10 N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
 isoxazol-5-yl}-N'-pyridin-3-yl-guanidine




The desired compound was obtained by the same procedure as in Example 48 except for using the compound obtained in Example 116.

15 ¹H-NMR (300 MHz, CDCl₃) δ ppm:

 1.64(d, 3H, J=7.1Hz), 4.14(q, 1H, J=7.1Hz),
 5.33(s, 1H), 5.75(br-s, 2H), 7.04-7.11(m, 2H),
 7.13-7.26(m, 1H), 7.31-7.45(m, 5H), 7.49-7.52(m,
 2H), 7.90(d, 1H, J=8.3Hz), 8.28(d, 1H,
 20 J=4.2Hz), 8.46(br-s, 1H).

Example 125

(({3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-thiamorpholin-4-yl-methyl)-amine




The desired compound was obtained by the same
 5 procedure as in Example 48 except for using the compound
 obtained in Example 117.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.1Hz), 2.62-2.66(m, 4H), 3.80-
 3.85(m, 4H), 4.14(q, 1H, J=7.1Hz), 5.24(s, 1H),
 10 5.35(br-s, 1H), 7.07-7.20(m, 2H), 7.32-7.46(m,
 4H), 7.50-7.54(m, 2H).

Example 126

1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-methyl)-piperidin-4-one



219


The desired compound was obtained by the same procedure as in Example 48 except for using the compound obtained in Example 118.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.67(d, 3H, J=7.1Hz), 2.55(t, 4H, J=6.2Hz),
 3.83(t, 4H, J=6.2Hz), 4.16(q, 1H, J=7.1Hz),
 5.28(s, 1H), 5.47(br-s, 2H), 7.07-7.18(m, 2H),
 7.32-7.46(m, 4H), 7.50-7.54(m, 2H).

Example 127

10 1-(Amino-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-
 isoxazol-5-ylimino}-methyl)-piperidin-4-ol




The desired compound was obtained by the same procedure as in Example 48 except for using the compound
 15 obtained in Example 119.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

20 1.50-1.64(m, 3H), 1.65(d, 3H, J=7.1Hz), 1.81-
 1.94(m, 2H), 3.18-3.28(m, 2H), 3.81-3.96(m, 3H),
 4.14(q, 1H, J=7.1Hz), 5.22(s, 1H), 5.34(br-s,
 2H), 7.07-7.17(m, 2H), 7.33-7.45(m, 4H), 7.50-
 7.54(m, 2H).

Example 128

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-hydroxy-guanidine




The desired compound was obtained by the same
5 procedure as in Example 48 except for using the compound
obtained in Example 120.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.63(d, 3H, J=7.1Hz), 4.12(q, 1H, J=7.1Hz),
5.34(s, 1H), 5.59(br-s, 2H), 7.04-7.12(m, 2H),
10 7.33-7.45(m, 6H), 7.49-7.54(m, 2H).

Example 129

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-methoxy-guanidine



The desired compound was obtained by the same
15 procedure as in Example 48 except for using the compound

221


obtained in Example 121.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.1Hz), 3.73(s, 3H), 4.14(q, 1H,
J=7.1Hz), 5.32(br-s, 2H), 5.41(s, 1H), 7.06-
5 7.15(m, 2H), 7.32-7.46(m, 4H), 7.50-7.54(m, 2H).

Example 130

N-(2-Dimethylamino-ethyl)-N'-{3-[1-(2-fluoro-
biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-guanidine



The desired compound was obtained by the same
10 procedure as in Example 48 except for using the compound
obtained in Example 122.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.1Hz), 2.29(s, 6H), 2.50-2.55(m,
2H), 3.26-3.32(m, 2H), 4.14(q, 1H, J=7.1Hz),
15 5.19(s, 1H), 5.98(br-s, 1H), 6.34(br-s, 1H),
7.07-7.17(m, 2H), 7.33-7.46(m, 4H), 7.50-7.54(m,
2H).

Example 131

[(3-{1-Methyl-1-[3-(2-phenyl-[1,3]dioxolan-2-yl)-phenyl]-

ethyl)-isoxazol-5-ylimino)-morpholin-4-yl-methyl)-amine




The desired compound was obtained by the same procedure as in Example 54 using the compound obtained in Reference Example 53.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.66(s, 6H), 3.44-3.48(m, 4H), 3.70-3.73(m, 4H),
 4.05(s, 4H), 5.07(s, 1H), 5.31(br-s, 2H), 7.20-
 7.35(m, 6H), 7.47-7.58(m, 3H)

Example 132

10 (3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-
 isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone



The compound (8.8 mg) obtained in Example 131 was dissolved in 90% aqueous acetic acid solution (2 ml), followed by stirring for 40 hours. The reaction solution
15 was extracted with ethyl acetate, and the extract solution was washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate and

223


thereafter concentrated under reduced pressure. The resulting residue was purified by a silica gel column chromatography to obtain the desired compound (8.3 mg).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.72(s, 6H), 3.46-3.50(m, 4H), 3.70-3.74(m, 4H),
 5.14(s, 1H), 5.39(br-r, 2H), 7.35-7.61(m, 6H),
 7.76-7.84(m, 3H)

Example 133

(Morpholin-4-yl-{3-[1-(6-phenyl-pyridin-3-yl)-
 10 ethyl]-isoxazol-5-ylimino}-methyl)-amine




By the same procedure as in Example 54, the desired compound was obtained from the compound obtained in Reference Example 55.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

15 1.69(d, 3H, J=7.3Hz), 3.48(t, 4H, J=5.0Hz),
 3.72(t, 4H, J=5.0Hz), 4.18(q, 1H, J=7.3Hz),
 5.23(s, 1H), 5.36(br-s, 2H), 7.39-7.50(m, 3H),
 7.67(m, 2H), 7.95(dd, 2H, J=8.3, 1.7Hz), 8.64(s,
 1H)

20 Example 134

(Morpholin-4-yl-{3-[1-(5-phenyl-pyridin-2-yl)-

ethyl-1-isoxazol-5-ylimino-methyl)-amine


By the same procedure as in Example 54, the desired compound was obtained from the compound obtained in Reference Example 57.

5 $^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

1.74(d, 3H, $J=7.3\text{Hz}$), 3.48(t, 4H, $J=5.3\text{Hz}$),
 3.72(t, 4H, $J=5.3\text{Hz}$), 4.34(q, 1H, $J=7.3\text{Hz}$),
 5.20-5.45(m, 3H), 7.32-7.57(m, 6H), 7.80(dd, 1H,
 $J=7.9, 2.3\text{Hz}$), 8.78(d, 1H, $J=2.3\text{Hz}$)

10 Reference Example 1

1-(3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-5-yl)-2-methyl-isothiouraea



3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl-thiourea (Japanese Patent Unexamined Publication


15 No. 63-152368) (3.03 g) was dissolved in N,N-dimethyl-

formamide (90 ml), followed by adding thereto methyl iodide (1.51 g) and potassium carbonate (0.86 g), and the resulting mixture was stirred at 40°C for 2 hours. Water was added to the reaction mixture, followed by
 5 extraction with ethyl acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (2.67 g).

- 10 ¹H-NMR (270 MHz, CDCl₃) δ ppm:
 1.67(d, 3H, J=7.2Hz), 2.44(s, 3H), 4.17(q, 1H, J=7.2Hz), 5.50(s, 1H), 5.92(br-s, 2H), 7.06-7.15(m, 2H), 7.32-7.54(m, 6H).

Reference Example 2

- 15 1-(tert-Butoxycarbonyl)-3-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-2-methyl-isothiourea



- In tetrahydrofuran (80 ml) was suspended sodium hydride (4.22 g, 60% oily), and a solution in
 20 tetrahydrofuran (100 ml) of the compound obtained in Reference Example 1 (25.0 g) was added dropwise under

ice-cooling, after which a solution of tert-butyl azidoformate ("Organic Syntheses" Coll. Vol. 5, John Wiley and Sons, Inc., New York (1973), p 157) (15.1 g) in tetrahydrofuran (50 ml) was slowly dropped thereinto over
5 a period of 65 minutes, and the resulting mixture was stirred under ice-cooling for 1 hour and then at room temperature overnight. Water was added to the reaction mixture, followed by extraction with diethyl ether, and the extract solution was washed with water and dried.
10 The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (21.1 g).

Melting point 124 - 126°C (decomp.).


¹H-NMR (270 MHz, CDCl₃) δ ppm:

15 1.49(s, 9H), 1.68(d, 3H, J=7.1Hz), 2.37(s, 3H), 4.18(q, 1H, J=7.1Hz), 5.63(s, 1H), 7.06-7.15(m, 2H), 7.35-7.53(m, 6H), 8.93(br-s, 1H).

IR (KBr) [cm⁻¹]: 3382, 2980, 1750, 1588.

20 Reference Example 3

3-Benzoyl-1-(3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl)-1-methyl-thiourea



227

A solution consisting of {3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-methyl-amine (4.06 g), pyridine (40 ml) and benzoyl isothiocyanate (2.5 g) was stirred overnight at room temperature. The solution
5 was concentrated and the residue was purified by a silica gel column chromatography to obtain the desired compound (5.28 g).

Melting point 115 - 116°C.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

10 1.59(d, 3H, J=7.3Hz), 3.79(s, 3H), 4.14(q, 1H,
 J=7.3Hz), 5.83(s, 1H), 6.92-6.97(m, 2H),
 7.16(t, 1H, J=8.2Hz), 7.34-7.52(m, 8H), 7.68-
 7.73(m, 2H), 8.79(s, 1H).

IR (KBr) [cm⁻¹]: 3440, 3275, 3125, 2980, 1690,
15 1612, 1515, 1488, 1424, 1360, 1266, 1230,
 1168.

Reference Example 4

3-Benzoyl-1-{3-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-1,2-dimethyl-isothiourea



20 Potassium carbonate (4.1 g) and methyl iodide
(1.25 ml) were added to a solution in N,N-dimethylform-

amide (60 ml) of 5.22 g of the compound obtained in Reference Example 3, and the resulting mixture was stirred at room temperature for 5 hours. The reaction solution was diluted with ethyl acetate and water was added thereto, followed by extraction. The extract was purified by a silica gel column chromatography to obtain the desired compound (4.87 g).


Melting point 124 - 126°C (decomp.).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

10 1.66(d, 3H, J=7.3Hz), 2.28(s, 3H), 3.56(s, 3H), 4.19(q, 1H, J=7.3Hz), 6.06(s, 1H), 7.00-7.10(m, 2H), 7.33-7.52(m, 9H), 9.03(d, 2H, J=7.7Hz).

Reference Example 5

15 Ethyl 5-(2-fluoro-biphenyl-4-yl)-2-hydroxy-4-oxo-hex-2-enoate



3-(2-Fluoro-biphenyl-4-yl)-butan-2-one

(Japanese Patent Unexamined Publication No. 54-144347)

(116 mg) was dissolved in toluene (2 ml), followed by adding thereto sodium hydride (29 mg, 60% oily), and the mixture was stirred at room temperature for 1 hour.

229

Then, diethyl oxalate (105 mg) was added and the resulting mixture was stirred at 40°C for 3 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (163 mg).

¹H-NMR (270 MHz, CDCl₃) δ ppm:


10 1.35(t, 3H, J=7.2Hz), 1.54(d, 3H, J=7.1Hz),
 3.86(q, 1H, J=7.1Hz), 4.32(q, 2H, J=7.2Hz),
 6.37(s, 1H), 7.04-7.12(m, 2H), 7.31-7.55(m, 7H).

IR (KBr) [cm⁻¹]: 2925, 1734, 1636, 1484.

15

Reference Example 6

Ethyl 5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-3-carboxylate



The compound (163 mg) obtained in Reference
20 Example 5 and hydroxylamine hydrochloride (40 mg) were dissolved in ethanol (2 ml) and the resulting solution was stirred at 60°C for 9 hours. Water was added to the reaction solution, followed by extraction with ethyl

230

acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (143 mg).


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.41(t, 3H, J=7.1Hz), 1.73(d, 3H, J=7.3Hz),
4.34(q, 1H, J=7.3Hz), 4.43(q, 2H, J=7.1Hz),
6.45(s, 1H), 7.02-7.12(m, 2H), 7.33-7.55(m,
6H).

IR (KBr) [cm⁻¹]: 2983, 1733, 1625, 1584, 1484,
1418.

Reference Example 7

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-yl}-methanol



The compound (2.45 g) obtained in Reference Example 6 was dissolved in tetrahydrofuran (20 ml), and lithium aluminum hydride (300 mg) was added at 0°C and the resulting solution was stirred for 1.5 hours. Water was added to the reaction mixture, followed by extraction with methylene chloride, and the extract solution was

washed with water and dried. The solvent was distilled off under reduced pressure and the residue was recrystallized from methylene chloride to obtain the desired compound (2.09 g).

5 Melting point 127 - 127.5°C.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.70(d, 3H, J=7.3Hz), 4.28(q, 1H, J=7.3Hz),
4.74(s, 2H), 6.09(s, 1H), 7.03-7.13(m, 2H),
7.33-7.55(m, 6H).

10 IR (KBr) [cm⁻¹]: 3308, 1603, 1485, 1418.


Elementary analysis;

Calculated: C 72.71, H 5.42, N 4.71

Found : C 72.61, H 5.45, N 4.88

15 Reference Example 8

3-Bromomethyl-5-[1-(2-fluoro-biphenyl-4-yl)-
ethyl]-isoxazole



reaction mixture, followed by extraction with methylene chloride, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel
5 column chromatography to obtain the desired compound (6.83 g).

Melting point 102 - 103°C.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.71(d, 3H, J=7.3Hz), 4.27(q, 1H, J=7.3Hz),
10 4.39(s, 2H), 6.12(d, 1H, J=0.7Hz), 7.03-
7.13(m, 2H), 7.33-7.55(m, 6H).

IR (KBr) [cm⁻¹]: 1600, 1484, 1417.


Elementary analysis;

Calculated: C 60.02, H 4.20, N 3.89

15 Found : C 59.86, H 4.17, N 4.04

Reference Example 9

3-Azidomethyl-5-[1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazole



The compound (2.08 g) obtained in Reference
20 Example 8 and sodium azide (749 mg) were dissolved in
N,N-dimethylformamide (20 ml) and the resulting solution

233

was stirred at 50°C for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced
5 pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (1.85 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.71(d, 3H, J=7.3Hz), 4.28(q, 1H, J=7.3Hz),
10 4.39(s, 2H), 6.07(s, 1H), 7.02-7.12(m, 2H),
7.33-7.55(m, 6H).


IR (neat) [cm⁻¹]: 2978, 2933, 2104, 1596, 1485.

Elementary analysis;

Calculated: C 67.07, H 4.69, N 17.38
15 Found : C 66.93, H 4.78, N 17.56

Reference Example 10

{5-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-
isoxazol-3-ylmethyl}-amine



The compound (1.82 g) obtained in Reference
20 Example 9 was dissolved in tetrahydrofuran (15 ml),
followed by adding thereto sodium borohydride (641 mg),


and the resulting mixture was stirred under reflux. Methanol (3 ml) was added dropwise over a period of 1 hour and stirred for 3 hours, after which the resulting mixture was cooled to room temperature. A 1N aqueous HCl solution (6 ml) was added thereto and separated. The aqueous layer was washed with hexane, adjusted to pH 11 with a 15% aqueous sodium hydroxide solution, and then extracted with methylene chloride, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (1.13 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.70(d, 3H, J=7.2Hz), 3.91(s, 2H), 4.26(q, 1H, J=7.2Hz), 6.01(s, 1H), 7.03-7.13(m, 2H), 7.33-7.55(m, 6H).

Reference Example 11

N',N''-Di-(tert-butoxycarbonyl)-N,N-dimethyl-guanidine



1,3-Di-(tert-butoxycarbonyl)-2-methyl-isothio-urea (Japanese Patent Unexamined Publication No. 2-3661) (3.00 g) was dissolved in a 50% aqueous dimethylamine

235


solution (40 ml) and the resulting solution was stirred at room temperature for 18 hours. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain
5 the desired compound (2.58 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.50(s, 18H), 3.07(s, 6H).

Reference Example 12

((tert-Butoxycarbonyl)-[((tert-butoxycarbonyl)-
10 imino-piperidin-1-yl-methyl]-amine



The desired compound was obtained by the same procedure as in Reference Example 11.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.49(s, 18H), 1.64(br-s, 6H), 3.52(br-s, 4H),
15 10.13(br-s, 1H).


Elementary analysis;

Calculated: C 58.69, H 8.93, N 12.83

Found : C 58.46, H 8.86, N 12.79

Reference Example 13

20 ((tert-Butoxycarbonyl)-[((tert-butoxycarbonyl)-
imino-morpholin-4-yl-methyl]-amine



The desired compound was obtained by the same procedure as in Reference Example 11.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.48(s, 9H), 1.50(s, 9H), 3.59(br-s, 4H),

5 3.72-3.76(m, 4H), 10.21(br-s, 1H).

Reference Example 14

1,3-Di-(tert-butoxycarbonyl)-1,2-dimethyl- isothiourea



1,3-Di-(tert-butoxycarbonyl)-2-methyl-isothio-
10 urea (Japanese Patent Unexamined Publication No. 2-3661)
(2.00 g) was dissolved in N,N-dimethylformamide (20 ml),
followed by adding thereto 60% sodium hydride (331 mg),
and the resulting mixture was stirred at 50°C for 2
hours. After the mixture was cooled to 0°C, methyl
15 iodide (1.96 g) was added and the resulting mixture was
stirred at room temperature for 2 hours. Water was added
to the reaction mixture, followed by extraction with

237

ethyl acetate, and the extract solution was washed with water and dried. The solvent was distilled off under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound
5 (2.07 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.48(s, 9H), 1.51(s, 9H), 2.39(s, 3H), 3.12(s, 3H).

IR (neat) [cm⁻¹]: 2979, 1720, 1624.


10 Elementary analysis;

Calculated: C 51.29, H 7.95, N 9.20

Found : C 51.06, H 8.08, N 9.31

Reference Example 15

Ethyl [1,3-di-(tert-butoxycarbonyl)-2-methyl-
15 isothioureidol-acetate



The desired compound was obtained by the same procedure as in Reference Example 14.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.29(t, 3H, J=7.1Hz), 1.48(s, 9H), 1.51(s,
20 9H), 2.45(s, 3H), 4.22(q, 2H, J=7.1Hz),
4.30(s, 2H).

238

IR (neat) [cm⁻¹]: 2981, 1725, 1615, 1369, 1315.


Elementary analysis;

Calculated: C 51.05, H 7.50, N 7.44

Found : C 50.76, H 7.56, N 7.50

5 Reference Example 16

1-(3-[1-(4-Isobutyl-phenyl)-ethyl]-isoxazol-5-yl)-2-methyl-isothiourea



Under a nitrogen atmosphere, 2-(4-isobutyl-phenyl)-propionic acid (15.0 g) was dissolved in ethanol (200 ml), and conc. sulfuric acid (1 ml) was added, after which the solution was stirred with heating under reflux for 15 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with ethyl acetate, and thereafter neutralized with a saturated aqueous sodium bicarbonate solution. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain ethyl 2-(4-isobutyl-phenyl)-propionate.

Tetrahydrofuran (100 ml) was added to sodium

hydride (4.34 g, 60% oily) and then a solution obtained by dissolving the above ester (about 17.0 g) and acetonitrile (7.56 ml) in tetrahydrofuran (150 ml) was added dropwise with heating under reflux over one hour. After
5 stirring with heating under reflux for 6 hours, the resulting mixture was cooled to room temperature and thereto was added a small amount of water, after which the mixture was diluted with ethyl acetate and thereto was added a saturated aqueous sodium bicarbonate solu-
10 tion. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from hexane to obtain 4-(4-isobutyl-phenyl)-3-oxo-pentanitrile (10.2 g).

15 This cyanoketone (10.2 g) was dissolved in ethanol (150 ml) and thereafter pyridine (30 ml) and hydroxylamine hydrochloride (6.17 g) were added, after which the resulting mixture was stirred at room temperature for 24 hours. The reaction mixture was concen-
20 trated under reduced pressure, diluted with ethyl acetate, and thereafter neutralized with a saturated aqueous sodium bicarbonate solution, after which the neutralized solution was subjected to extraction with ethyl acetate. The organic layer was dried over sodium sul-
25 fate and then concentrated under reduced pressure, to obtain 3-[1-(4-isobutyl-phenyl)-ethyl]-isoxazol-5-yl-amine (11.35 g).

This isoxazol (11.35 g) was dissolved in ethy-

lene dichloride (200 ml) and then benzoyl isothiocyanate (11.9 ml) was added, after which the resulting mixture was stirred at 60°C for 5 hours. The reaction mixture was concentrated under reduced pressure and a small amount of water was added, after which the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was isolated by a silica gel column chromatography (hexane/ethyl acetate = 2/1) and then purified by a recrystallization method from toluene, to obtain 1-benzoyl-3-{3-[1-(4-isobutyl-phenyl)-ethyl]-isoxazol-5-yl}-thiourea (4.65 g).

This thiourea (4.65 g) was dissolved in tetrahydrofuran (50 ml) and then methanol (50 ml) and potassium carbonate (3.15 g) were added, after which the mixture was stirred at 50°C for 5 hours. To the reaction mixture was added a small amount of water, and the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried over sodium sulfate and thereafter concentrated under reduced pressure, to obtain 3-[1-(4-isobutyl-phenyl)-ethyl]-isoxazol-5-yl-thiourea (15.52 g).

The desired compound was obtained by the same procedure as in Reference Example 1 except for using this thiourea.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

241

0.89(d, 6H, J=6.6Hz), 1.63(d, 3H, J=7.3Hz),
 1.83(m, 1H), 2.43(d, 2H, J=6.1Hz), 2.44(s,
 3H), 4.11(q, 1H, J=7.2Hz), 5.45(s, 1H), 5.91
 (br-s, 2H), 7.06-7.09(m, 2H), 7.17-7.20(m, 2H)

5 Reference Example 17

1-(3-[1-(6-Methoxy-naphthalen-2-yl)-ethyl]-
isoxazol-5-yl)-2-methyl-isothiourea



The desired compound was obtained by the same
 procedure as in Reference Example 16 except for using 2-
 10 (6-methoxy-naphthalen-2-yl)-propionic acid.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.72(d, 3H, J=7.2Hz), 2.42(s, 3H), 3.91(s,
 3H), 4.27(q, 1H, J=7.2Hz), 5.46(s, 1H), 5.90
 (br-s, 2H), 7.10-7.15(m, 2H), 7.37(dd, 1H,
 15 J=8.4, 1.8Hz), 7.65-7.71(m, 3H)

Reference Example 18

1-(tert-Butylcarbonyl)-3-{3-[1-(4-isobutyl-
phenyl)-ethyl]-isoxazol-5-yl}-2-methyl-isothiourea

242




The desired compound was obtained by the same procedure as in Reference Example 2 except for using the compound obtained in Reference Example 16.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

- 5 0.89(d, 6H, J=6.6Hz), 1.50(s, 9H), 1.65(d, 3H, J=7.3Hz), 1.84(m, 1H, J=6.6Hz), 2.36(s, 3H), 2.44(d, 2H, J=7.1Hz), 4.12(q, 1H, J=7.3Hz), 5.58(s, 1H), 7.08-7.11(m, 2H), 7.17-7.20(m, 2H), 8.95(br-s, 1H)

10 Reference Example 19

1-(tert-Butoxycarbonyl)-3-(3-[1-(6-methoxy-naphthalen-2-yl)-ethyl]-isoxazol-5-yl)-2-methyl-isothio-urea



The desired compound was obtained by the same procedure as in Reference Example 2 except for using the compound obtained in Reference Example 17.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


- 15 1.50(s, 9H), 1.74(d, 3H, J=7.2Hz), 2.34(s, 3H), 3.91(s, 3H), 4.29(q, 1H, J=7.3Hz), 5.59

243

(s, 1H), 7.10-7.16(m, 2H), 7.36(dd, 1H, J=8.4, 1.6Hz), 7.65(s, 1H), 7.68-7.71(m, 2H), 8.95 (br-s, 1H)

Reference Example 20

5 3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylamine



Under a nitrogen atmosphere, 2-(2-fluoro-bi-phenyl-4-yl)-propionic acid (15.0 g) was dissolved in N,N-dimethylformamide (150 ml) and then sodium hydride (6.14 g, 60% oily) was added, after which the resulting mixture was stirred for one hour. Subsequently, iodomethane (9.5 ml) was added and the mixture was stirred for 12 hours. A small amount of water was added to the reaction mixture and the resulting mixture was then subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from hexane, to obtain methyl 2-(2-fluoro-biphenyl-4-yl)-2-methyl-propio-
nate (14.2 g).

Tetrahydrofuran (100 ml) was added to sodium hydride (2.70 g, 60% oily), and thereafter, a solution obtained by dissolving the above ester (12.2 g) and ace-

tonitrile (4.66 ml) in tetrahydrofuran (100 ml) was dropwise added with heating under reflux over one hour. The resulting mixture was stirred for 8 hours with heating under reflux and then cooled to room temperature, and
5 a small amount of water was thereafter added thereto, after which the mixture was diluted with ethyl acetate and then a saturated aqueous sodium bicarbonate solution was added. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then
10 concentrated under reduced pressure. The residue was purified by a recrystallization method from ethanol, to obtain 4-(2-fluoro-biphenyl-4-yl)-4-methyl-3-oxo-pentanitrile (6.27 g).


This cyanoketone (9.98 g) was dissolved in
15 ethanol (200 ml) and then pyridine (40 ml) and hydroxylamine hydrochloride (2.47 g) were added, after which the resulting mixture was stirred at 50°C for 5 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, neutralized with a
20 saturated aqueous sodium bicarbonate solution and thereafter subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from ethanol, to
25 obtain the desired compound (7.00 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.69(s, 6H), 4.37(br-s, 2H), 4.86(s, 1H),
7.10-7.34(m, 2H), 7.32-7.46(m, 4H), 7.50-7.55

(m, 2H)

Reference Example 21

3-[1-Ethoxy-1-(2-fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine

5 Under a nitrogen atmosphere, ethyl 2-(2-fluoro-biphenyl-4-yl)-2-hydroxy-propionate (Japanese Patent Unexamined Publication No. 52-105,144) (15.0 g) was dissolved in N,N-dimethylformamide (300 ml) and then sodium hydride (4.16 g, 60% oily) was added under ice-
10 cooling, after which the resulting mixture was stirred for one hour. Subsequently, iodoethane (10.4 ml) was added and the resulting mixture was stirred for 12 hours. To the reaction mixture were added a small amount of water and ethanol, and thereafter, the solvent was
15 removed by azeotropic distillation using toluene. To the residue was added ethyl acetate and the resulting mixture was neutralized with a saturated aqueous sodium bicarbonate solution and then subjected to extraction with ethyl acetate. The organic layer was dried over
20 sodium sulfate and then concentrated under reduced pressure to obtain ethyl 2-ethoxy-2-(2-fluoro-biphenyl-4-yl)-propionate.

To a mixture of sodium hydride (4.16 g, 60% oily) and tetrahydrofuran (100 ml) was then added dropwise a solution obtained by dissolving the above ester and acetonitrile (5.43 ml) in tetrahydrofuran (200 ml), with heating under reflux over one hour. After stirring with heating under reflux for 4 hours, the mixture was cooled to room temperature, and a small amount of ethanol was added, after which the mixture was diluted with ethyl acetate and then a saturated aqueous sodium bicarbonate solution was added. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure, to obtain 4-ethoxy-4-(2-fluoro-biphen-yl-4-yl)-3-oxo-pentanitrile which was a cyanoketone derivative.

This cyanoketone was dissolved in ethanol (300 ml) and then pyridine (60 ml) and hydroxylamine hydrochloride (5.42 g) were added, after which the resulting mixture was stirred at 50°C for 5 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, neutralized with an aqueous sodium bicarbonate solution, and thereafter subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 3/1) to obtain the desired compound (11.3 g).


¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.26(t, 3H, J=7.0Hz), 1.86(s, 3H), 3.35-3.60

(m, 2H), 4.39(br-s, 2H), 5.03(s, 1H), 7.25-7.46(m, 6H), 7.51-7.55(m, 2H)

Reference Example 22

3-[1-(2-Fluoro-biphenyl-4-yl)-cyclopropyl]-
5 isoxazol-5-ylamine



Under a nitrogen atmosphere, methyl (2-fluoro-biphenyl-4-yl)-acetate (5.0 g) was dissolved in tetrahydrofuran (50 ml) and then sodium hydride (8.29 g, 60% oily) was added under ice-cooling, after which the resulting mixture was stirred for 30 minutes. Subsequently, N,N-dimethylformamide (100 ml) was added and then 1,2-dibromoethane (17.6 ml) was added, after which the resulting mixture was stirred for 1.5 hours. To the reaction mixture was added 4 N hydrochloric acid-1,4-dioxane solution (60 ml) and the solution was then neutralized with a saturated aqueous ammonium chloride solution and thereafter subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 20/1), to obtain methyl 1-(2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylate (4.28 g).

248


From this ester, the desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.30(q, 2H, J=3.7Hz), 1.48(q, 2H, J=3.7Hz),
 4.34(br-s, 2H), 4.88(s, 1H), 7.13-7.23(m, 2H),
 7.35-7.47(m, 4H), 7.52-7.55(m, 2H)

Reference Example 23

3-(1-Biphenyl-4-yl-ethyl)-isoxazol-5-ylamine



10 After monomethylation with ethyl 4-biphenyl-acetoacetate, the desired compound was obtained by the same procedure as stated in the half of Reference Example 20.

¹H-NMR (300 MHz, CDCl₃) δ ppm:


15 1.65(d, 3H, J=7.3Hz), 4.12(q, 1H, J=7.3Hz),
 4.40(s, 2H), 4.92(s, 1H), 7.30-7.45(m, 5H),
 7.52-7.59(m, 4H)

Reference Example 24

3-(1-Biphenyl-4-yl-1-methyl-ethyl)-isoxazol-5-

20 ylamine

249



After dimethylation with ethyl 4-biphenylacetate, the desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20.


5 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.70(s, 6H), 4.32(s, 2H), 4.84(s, 1H), 7.33-7.59(m, 9H)

Reference Example 25

3-[1-(3-Phenoxy-phenyl)-ethyl]-isoxazol-5-

10 ylamine



Using calcium 2-(3-phenoxyphenyl)-propionate, the desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20.


$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

15

1.59(d, 3H, $J=7.1\text{Hz}$), 4.12(q, 1H, $J=7.1\text{Hz}$),
4.41(br-s, 2H), 4.87(s, 1H), 6.81-6.86(m, 1H),
6.96-7.11(m, 5H), 7.21-7.36(m, 3H)

Reference Example 26

(R)-3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine



Under a nitrogen atmosphere, tert-butyl cyano-
5 acetate (0.57 ml) was added dropwise to a mixture of
tetrahydrofuran (5 ml) and sodium hydride (160 mg, 60%
oily) with stirring under ice-cooling. The resulting
mixture was stirred for 10 minutes under ice-cooling,
then stirred at room temperature for 20 minutes, and
10 again stirred at 0°C. Separately, isobutyl chloroformate
(0.26 ml) was added dropwise to a tetrahydrofuran
solution (20 ml) of (R)-2-(2-fluoro-biphenyl-4-yl)-
propionic acid (449 mg, 93% e.e.) and N-methylmorpholine
(0.22 ml) at -15°C with stirring. After 5 minutes, this
15 solution was added dropwise to the previous mixture.
After 20 minutes, this was poured into a saturated
aqueous sodium bicarbonate solution and the resulting
mixture was subjected to extraction with ethyl acetate.
The organic layer was dried over sodium sulfate and then
20 concentrated under reduced pressure. To the viscous
residue thus obtained were added hydroxylamine
hydrochloride (278 mg) and ethanol (10 ml), and the
resulting mixture was stirred for 4 hours with heating


under reflux. After cooling to room temperature, ethanol was removed by distillation, and a saturated aqueous sodium bicarbonate solution was added to the residue and the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 3/2), to obtain the desired compound (226 mg, 93% e.e.).

10 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.63(d, 3H, $J=7.1\text{Hz}$), 4.09(q, 1H, $J=7.1\text{Hz}$),
4.46(br-s, 2H), 4.91(s, 1H), 7.05-7.18(m, 2H),
7.31-7.47(m, 4H), 7.50-7.76(m, 2H)

Reference Example 27

15 (S)-3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine




The desired compound was obtained by the same procedure as in Reference Example 26 except for using (S)-2-(2-fluoro-biphenyl-4-yl)-propionic acid.

20 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ ppm:

1.61(d, 3H, $J=7.1\text{Hz}$), 4.08(q, 1H, $J=7.1\text{Hz}$),
4.55(br-s, 2H), 4.89(s, 1H), 7.05-7.17(m, 2H),
7.31-7.44(m, 4H), 7.50-7.76(m, 2H)

Reference Example 28

3-Biphenyl-4-ylmethyl-isoxazol-5-ylamine


Using 4-biphenyl-acetoacetic acid, the desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

3.89(s, 2H), 4.36(s, 2H), 4.94(s, 1H), 7.31-7.59(m, 9H)

Reference Example 29

10 3-[1-(2-Fluoro-2',3',4',5',6'-pentadeuterio-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine



Under a nitrogen atmosphere, benzene deuteride

(56 ml) and water (6 ml) were added to sodium nitrite (4.87 g) and the resulting mixture was stirred at 60°C. To this solution was added dropwise with stirring over 3 hours a solution obtained by dissolving dimethyl 2-(4-amino-3-fluorophenyl)-2-methyl-malonate (Japanese Patent Unexamined Publication No. 2-223,542) (10.0 g) and glacial acetic acid (4.24 g) in benzene deuteride (19 ml). After stirring for 2 hours, the resulting solution was washed with an aqueous sodium sulfate solution and then concentrated under reduced pressure. The residue was dissolved in a 85% aqueous sulfuric acid solution (17.7 ml), and the resulting solution was subjected to extraction with toluene-hexane. It was washed with a 1 N aqueous sodium carbonate solution and then with a saturated aqueous sodium chloride solution and thereafter concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 13/1), to obtain diethyl 2-(2-fluoro-2',3',4', 5',6'-pentadeuterio-biphenyl-4-yl)-2-methyl-malonate (5.99 g).

This ester (5.98 g) was dissolved in ethanol (39 ml) and then a 50% aqueous sodium hydroxide solution (3.42 ml) was added at -15°C, after which the resulting mixture was stirred at room temperature for 6 hours. A small amount of water was added to the reaction mixture and the pH of the solution was adjusted to 8 with 3 N hydrochloric acid, after which the mixture was subjected to extraction with chloroform. The aqueous layer was

adjusted to pH 1 and then subjected to extraction with ethyl acetate, after which the organic layer was dried over sodium sulfate and then concentrated under reduced pressure. Glacial acetic acid (4.24 g) was added to the
5 residue and the resulting mixture was heated under reflux for 17 hours. It was cooled under ice-cooling and then water (12 ml) was added, after which the resulting mixture was filtered and the residue was washed with 50% acetic acid, to obtain 2-(2-fluoro-2',3',4',5',6'-penta-
10 deuterio-biphenyl-4-yl)-propionic acid (3.84 g).

This carboxylic acid (3.84 g) was dissolved in ethanol (20 ml) and then toluene (10 ml) and conc. sulfuric acid (50 mg) were added, after which the resulting mixture was stirred at 60-80°C for 4 hours. The reac-
15 tion mixture was diluted with ethyl acetate, then neutralized with sodium carbonate and thereafter subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure, to obtain ethyl 2-(2-fluoro-
20 2',3',4',5',6'-pentadeuterio-biphenyl-4-yl)-propionate (4.26 g).

Tetrahydrofuran (30 ml) was added to sodium
hydride (1.11 g, 60% oily), and then to the solution was
added dropwise over 40 minutes with heating under reflux
25 a solution obtained by dissolving the above ester (4.26 g) and acetonitrile (1.14 g) in tetrahydrofuran (10 ml). After stirring with heating under reflux for 2 hours, the solution was cooled to room temperature, and then,


isopropanol (15 ml) was added, after which the resulting mixture was neutralized with 3 N hydrochloric acid under ice-cooling and then subjected to extraction with chloroform. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was dissolved in ethanol (20 ml) and then pyridine (7 ml) and hydroxylamine hydrochloride (2.13 g) were added, after which the resulting mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure and then a small amount of water was added, after which the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from chloroform to obtain the desired compound (3.24 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.64(d, 3H, J=7.1Hz), 4.11(q, 1H, J=7.1Hz),
4.39(br-s, 2H), 4.94(s, 1H), 7.06-7.19(m, 2H),
7.38(t, 1H, J=7.9Hz)

Reference Example 30

3-[1-(2-Fluoro-2'-methoxy-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine



The desired compound was obtained by the same procedure as in Reference Example 29 except for using methoxybenzene.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

5 1.64(d, 3H, J=7.1Hz), 3.81(s, 3H), 4.11(q, 1H, J=7.1Hz), 4.37(br-s, 2H), 4.95(s, 1H), 6.96-7.13(m, 5H), 7.23-7.48(m, 2H)

Reference Example 31

3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-

10 5-ylamine



Under a nitrogen atmosphere, methylene chloride (100 ml) was added to aluminum chloride (20.1 g) and then, to thereto was added dropwise at room temperature a solution obtained by dissolving 2-fluorobiphenyl (20.0 g) and acetyl chloride (10.7 ml) in methylene chloride (100 ml). After stirring for 4 hours, a small amount of water was added to the reaction mixture, and then the mixture was subjected to extraction with chloroform. The organic layer was dried over sodium sulfate and then concentrated

under reduced pressure. The residue was purified by a recrystallization method from ethanol, to obtain 1-(2'-fluoro-biphenyl-4-yl)-ethanone (17.53 g).

This ketone (17.53 g) was dissolved in morpho-
5 line (130 ml) and then sulfur (5.25 g) was added, after which the resulting mixture was stirred with heating under reflux for 10 hours. The mixture was cooled to room temperature and thereafter 1 N hydrochloric acid (500 ml) was added, after which the resulting mixture was
10 subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from ethanol, to obtain 2-(2'-fluoro-biphenyl-4-yl)-1-morpholin-4-yl-ethanethione
15 (21.69 g).

This compound was dissolved in ethanol (200 ml) and then a 15% aqueous sodium hydroxide solution (50 ml) was added, after which the resulting mixture was stirred with heating under reflux for 4 hours. After cooling to
20 room temperature, the solvent was concentrated under reduced pressure, and diluted hydrochloric acid was added, after which the resulting mixture was subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under
25 reduced pressure. The residue was purified by a recrystallization method from ethanol, to obtain (2'-fluoro-biphenyl-4-yl)-acetic acid (13.46 g).

Diisopropylamine (16.4 ml) was dissolved in

tetrahydrofuran (100 ml) and then a hexane solution (30.3 ml, 1.66 M) of n-butyllithium was added under ice-cooling, after which the resulting mixture was stirred for 15 minutes. Subsequently, thereto was added under ice-cooling a solution obtained by dissolving the above carboxylic acid (13.44 g) in tetrahydrofuran (100 ml), and thereafter, hexamethylphosphorus triamide (40 ml) was added, after which the resulting mixture was stirred under ice-cooling for one hour. Further, iodomethane (3.63 ml) was added and the resulting mixture was stirred for 3 hours. To the reaction mixture was added 10% hydrochloric acid (500 ml) and then the solution was subjected to extraction with ethyl acetate. The organic layer was washed with a saturated sodium chloride solution, then dried over sodium sulfate and thereafter concentrated under reduced pressure, to obtain 2-(2'-fluoro-biphenyl-4-yl)-propionic acid (16.64 g).

This carboxylic acid was dissolved in ethanol (100 ml) and conc. sulfuric acid (2 ml) was added to the solution, after which the solution was stirred with heating under reflux for 4 hours. The reaction mixture was diluted with ethyl acetate, neutralized with a saturated aqueous sodium bicarbonate solution, and thereafter subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 4/1), to obtain ethyl 2-(2'-

fluoro-biphenyl-4-yl)-propionate (9.26 g).

Tetrahydrofuran (100 ml) was added to sodium hydride (2.12 g, 60% oily) and thereto was added dropwise with heating under reflux over one hour a solution
5 obtained by dissolving the above ester (9.62 g) and acetonitrile (3.67 ml) in tetrahydrofuran (100 ml). After heating under reflux for 5 hours, the resulting mixture was cooled to room temperature, and then a small amount of water was added, after which the resulting mix-
10 ture was diluted with ethyl acetate and an aqueous sodium bicarbonate solution was added. After extraction with ethyl acetate, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column
15 chromatography (hexane/ethyl acetate = 3/1), to obtain 4-(2'-fluoro-biphenyl-4-yl)-3-oxo-pentanitrile (7.33 g).

This cyanoketone was dissolved in ethanol (120 ml) and then pyridine (20 ml) and hydroxylamine hydrochloride (2.86 g) were added, after which the resulting
20 mixture was stirred at 60°C for 8 hours. The reaction mixture was concentrated under reduced pressure, then diluted with ethyl acetate and thereafter neutralized with an aqueous sodium bicarbonate solution, after which the mixture was subjected to extraction with ethyl
25 acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 4/1) to obtain the desired


compound (6.31 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.1Hz), 4.12(q, 1H, J=7.1Hz),
4.36(br-s, 2H), 4.92(s, 1H), 7.10-7.53(m, 8H)

5 Reference Example 32

3-[1-(2-Fluoro-4'-methoxy-biphenyl-4-yl)-ethyl]-isoxazol-5-ylamine



2-(2-Fluoro-biphenyl-4-yl)-propionic acid

(104.2 g) was dissolved in methanol (410 ml) and then

- 10 conc. sulfuric acid (60.2 g) was added, after which the resulting mixture was stirred at 40°C for 2.5 hours. The mixture was cooled to room temperature, diluted with toluene, then neutralized with a saturated aqueous sodium bicarbonate solution, and thereafter subjected to
- 15 extraction with ethyl acetate. The organic layer was

dried over sodium sulfate and then concentrated under reduced pressure, to obtain methyl 2-(2-fluoro-biphenyl-4-yl)-propionate (110.2 g).

Under a nitrogen atmosphere, ethylene dichloride (700 ml) was added to aluminum chloride (125.1 g) and then 2-fluorobiphenyl (20.0 g) was added. A solution obtained by dissolving acetyl chloride (73.7 g) in ethylene dichloride (300 ml) was dropwise added under ice-cooling over 2 hours. After stirring at 20-30°C for 2 hours, the temperature was elevated to 40-60°C and stirring was conducted for 3 hours. After cooling to room temperature, a small amount of water was added to the reaction mixture and then hydrochloric acid was added, after which the resulting mixture was subjected to extraction with ethylene dichloride. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/ethyl acetate = 10/1 → 7/1), to obtain methyl 2-(4'-acetyl-2-fluoro-biphenyl-4-yl)-propionate (107.6 g).

This ester (109.6 g) was dissolved in methylene chloride (670 ml) and then m-chloroperbenzoic acid (110.3 g) was added at room temperature, after which the resulting mixture was stirred with heating under reflux for 20 hours. After cooling to room temperature, m-chloroperbenzoic acid was removed by filtration and the residue was washed with a 20% aqueous sodium thiosulfate solution and then with a saturated aqueous sodium bicar-

bonate solution. The mother liquor was extracted with chloroform, and thereafter, the organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The residue was purified by a recrystallization method from hexane-ethyl acetate (130/1), to obtain methyl 2-(4'-acetoxy-2-fluoro-biphenyl-4-yl)-propionate (97.0 g).

This compound was dissolved in methanol (1,000 ml) and then a 20% aqueous sodium hydroxide solution (200 ml) was added, after which the resulting mixture was stirred at 35°C for 3 hours. After cooling to room temperature, the solvent was concentrated under reduced pressure, water (1,500 ml) was added and then 4 N hydrochloride acid was added to adjust the pH to 1. The deposit was washed with water and thereafter vacuum dried at 60°C, to obtain 2-(2-fluoro-4'-hydroxy-biphenyl-4-yl)-propionic acid (68.6 g).

This carboxylic acid (67.6 g) was dissolved in acetone (1,300 ml) and then potassium carbonate (100.9 g) and dimethyl sulfate (92.1 g) were added, after which the resulting mixture was stirred with heating under reflux for 5 hours. The reaction mixture was filtered and the filtrate obtained was concentrated under reduced pressure.

To this residue were added methanol (1,000 ml) and then a 20% aqueous sodium hydroxide solution (150 ml), after which the resulting mixture was stirred at 35°C for 2 hours. After cooling to room temperature, the

solvent was concentrated under reduced pressure and then water (1,000 ml) was added, after which 4 N hydrochloric acid was added to adjust the pH to 1 and extraction with chloroform was conducted. The organic layer was dried
5 over sodium sulfate and then concentrated under reduced pressure.

This residue was dissolved in ethanol (300 ml) and then conc. sulfuric acid (34.4 g) was added, after which the resulting mixture was stirred with heating
10 under reflux for 2 hours. The reaction mixture was cooled to room temperature, diluted with toluene, neutralized with a saturated aqueous sodium bicarbonate solution and thereafter subjected to extraction with toluene. The organic layer was dried over sodium sul-
15 fate and then concentrated under reduced pressure, to obtain ethyl 2-(2-fluoro-4'-methoxy-biphenyl-4-yl)-propionate (82.9 g).

After tetrahydrofuran (300 ml) was added to sodium hydride (19.7 g, 60% oily), a solution obtained by
20 dissolving the above ester (82.9 g) and acetonitrile (20.3 g) in tetrahydrofuran (100 ml) was added dropwise over 45 minutes thereto. After stirring with heating under reflux for 1.5 hours, the resulting mixture was cooled to room temperature, and isopropanol (50 ml) was
25 added, after which the mixture was neutralized with 3 N hydrochloric acid and then subjected to extraction with chloroform. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure, to

264

obtain 4-(2-fluoro-4'-methoxy-biphenyl-4-yl)-3-oxo-pentanitrile (89.1 g).


After this cyanoketone was dissolved in ethanol (200 ml), pyridine (60 ml) and hydroxylamine hydrochloride (38.1 g) were added, and the resulting mixture was stirred at 70°C for 4 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, thereafter neutralized with a saturated aqueous sodium bicarbonate solution, and then subjected to extraction with ethyl acetate. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to obtain the desired compound (79.36 g).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.63(d, 3H, J=7.3Hz), 3.85(s, 3H), 4.09(q, 1H, J=7.3Hz), 4.38(br-s, 2H), 4.93(s, 1H), 6.94-7.00(m, 2H), 7.04-7.13(m, 2H), 7.31-7.38(m, 2H), 7.44-7.49(m, 2H)

Reference Example 33

Methyl 2-(9H-carbazol-2-yl)-propionate



The desired compound was obtained in the same manner as in the known method [P.S. Manchand et al., Heterocycles, 39,833 (1994)] except for using carbazole.


¹H-NMR (300 MHz, CDCl₃) δ ppm:

265

1.59(d, 3H, J=7.1Hz), 3.67(s, 3H), 3.89(q, 1H, J=7.1Hz), 7.15-7.25(m, 2H), 7.36-7.43(m, 3H), 7.98-8.10(m, 3H)

Reference Example 34

5 3-[1-(9H-Carbazol-2-yl)-ethyl]-isoxazol-5-yl-
amine




The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using the compound obtained in
10 Reference Example 33.

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.71(d, 3H, J=7.1Hz), 4.24(q, 1H, J=7.1Hz), 4.90(s, 1H), 7.15-7.25(m, 2H), 7.34-7.44(m, 3H), 7.98-8.05(m, 3H)

15 Reference Example 35

3-(2-Fluoro-biphenyl-4-ylmethyl)-isoxazol-5-
ylamine




The desired compound was obtained by the same procedure as in Reference Example 26 except for using (2-fluoro-biphenyl-4-yl)-acetic acid.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

5 3.88(s, 2H), 4.97(s, 1H), 7.04-7.14(m, 2H),
 7.33-7.47(m, 4H), 7.51-7.55(m, 2H)

Reference Example 36

Ethyl 2-(2,3-dihydro-benzof[1,4]dioxin-6-yl)-
propionate



10 Under a nitrogen atmosphere, 60% sodium hydride
 (1.13 g) was added to a solution in N,N-dimethylf-
 ormamide (65 ml) of ethyl 3,4-ethylenedioxyphenylacetate
 [M. Sasamoto, Chem. Pharm. Bull., 8, 324 (1969)] (6.00 g)
 in an ice bath. Thereafter, methyl iodide (1.76 ml) was
15 added dropwise and the resulting mixture was stirred
 under ice-cooling for 4 hours. To the reaction mixture
 was added 1 N-hydrochloric acid and the resulting mixture
 was subjected to extraction with diethyl ether, after
 which the extraction solution was washed with water and
20 then dried. The solvent was removed by distillation
 under reduced pressure and the residue was purified by a
 silica gel column chromatography to obtain the desired
 compound (5.57 g).


267

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.22(t, 3H, J=7.3Hz), 1.44(d, 3H, J=7.3Hz),
3.59(q, 1H, J=7.3Hz), 4.05-4.17(m, 2H), 4.24
(s, 4H), 6.74(m, 3H)

5 Reference Example 37

3-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-isoxazol-5-ylamine



The desired compound was obtained by the same procedure as stated in the latter half of Reference


10 Example 20 except for using the compound obtained in Reference Example 36.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.56(d, 3H, J=7.3Hz), 3.97(q, 1H, J=7.3Hz),
4.23(s, 4H), 4.33(br-s, 2H), 4.88(s, 1H),
15 6.73-6.82(m, 3H)

~~Reference Example 38~~

3-[1-(1-Methyl-1H-indol-3-yl)-ethyl]-isoxazol-5-ylamine



268


The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using ethyl 2-(1-methyl-1H-indol-3-yl)-propionate [L.K. Mehta et al., J. Chem. Soc., Perkin Trans. 2, 1488 (1997)].

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.69(d, 3H, J=7.3Hz), 3.74(s, 3H), 4.26(br-s, 2H), 4.36(q, 1H, J=7.3Hz), 4.88(s, 1H), 6.91(s, 1H), 7.04-7.29(m, 3H), 7.62(d, 1H, J=7.9Hz)

Reference Example 39

3-[1-(1H-Indol-3-yl)-ethyl]-isoxazol-5-ylamine




The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using ethyl 2-(1H-indol-3-yl)-propionate [M. Julia et al., Bull. Soc. Chim. Fr. 2291 (1966)].

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.70(d, 3H, J=7.3Hz), 4.25(br-s, 2H), 4.37(q, 1H, J=7.3Hz), 4.87(s, 1H), 7.05-7.21(m, 3H), 7.34(d, 1H, J=8.2Hz), 7.62(d, 1H, J=7.9Hz), 8.04(br-s, 1H)

Reference Example 40


Methyl 2-(1-methyl-1H-indol-2-yl)-propionate

A mixture of 1-methyl-2-(2'-carboxymethoxy-vinyl)indole [F.E. Ziegler et al., J. Am. Chem. Soc., 95,
5 7146 (1973)] (335 mg), 10% palladium/active carbon (50 mg) and tetrahydrofuran (4 ml) was subjected to hydrogenation at room temperature for 30 minutes. The reaction mixture was filtered to remove the catalyst, and thereafter concentrated under reduced pressure, after
10 which the residue was purified by a silica gel column chromatography to obtain the desired compound (168 mg).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.65(d, 3H, J=7.3Hz), 3.69(s, 3H), 3.72(s, 3H), 3.97(q, 1H, J=7.3Hz), 6.43(s, 1H), 7.05-
15 7.31(m, 3H), 7.57(d, 1H, J=7.9Hz)

Reference Example 41

3-((1-methyl-1H-indol-2-yl)-ethyl)-isoxazol-5-ylamine

The desired compound was obtained by the same

270


procedure as stated in the latter half of Reference Example 20 except for using the compound obtained in Reference Example 40.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

5 1.72(d, 3H, J=7.3Hz), 3.64(s, 3H), 4.30-4.33
 (m, 3H), 4.81(s, 1H), 6.44(s, 1H), 7.05-7.28
 (m, 3H), 7.57(d, 1H, J=7.9Hz)

Reference Example 42

Ethyl 2-benzofuran-5-yl-propionate



10 To a solution of 5-benzofurancarbonitrile
 (Japanese Patent Unexamined Publication No. 9-124,631)
 (1.30 g) in tetrahydrofuran (5 ml) was added 0.87 M
 methyl magnesium bromide-tetrahydrofuran solution (21
 ml), and the resulting mixture was heated under reflux
15 for 4 hours under a nitrogen atmosphere. The reaction
 mixture was acidified with conc. sulfuric acid and water
 ~~was added thereto, after which the resulting mixture was~~
 subjected to extraction with diethyl ether. The extract
 solution was washed with water, dried and then distilled
20 under reduced pressure to remove the solvent. The
 residue was purified by a silica gel column
 chromatography to obtain 1-benzofuran-5-yl-ethanone (1.21
 g).

271

¹H-NMR (270 MHz, CDCl₃) δ ppm:

2.67(s, 3H), 6.86(d, 1H, J=2.3Hz), 7.55(d, 1H, J=8.9Hz), 7.70(d, 1H, J=2.3Hz), 7.97(dd, 1H, J=8.9, 1.7Hz), 8.26(d, 1H, J=1.7Hz)

5 A mixture of 1-benzofuran-5-yl-ethanone (850 mg), trimethylsilyl cyanide (0.85 ml), zinc iodide (34 mg) and chloroform (21 ml) was heated under reflux for 3.5 hours under a nitrogen atmosphere. The solvent was removed by distillation under reduced pressure, and the
10 residue was purified by a silica gel column chromatography to obtain the desired cyano compound (1.21 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

0.18(s, 9H), 1.91(s, 3H), 6.80(m, 1H), 7.45-
7.54(m, 2H), 7.67(d, 1H, J=2.0Hz), 7.81(s,
15 1H)

To a solution of this cyano compound (1.21 g) in acetic acid (10 ml) was added tin chloride (II) dihydrate and the resulting mixture was stirred at room temperature for 10 minutes, after which conc. hydrochloric acid (20 ml) was added and the mixture was stirred at
20 room temperature overnight. The reaction mixture was further heated and stirred at 100°C for 2.5 hours and water was added, after which the resulting mixture was subjected to extraction with diethyl ether. The
25 extraction solution was washed with water and dried. The solvent was removed by distillation under reduced pressure and to the residue were added ethanol (4 ml) and conc. sulfuric acid (0.05 ml), after which the resulting

272


mixture was heated and stirred at 80°C for 2.5 hours. The solvent was removed by distillation under reduced pressure and water was added to the residue, after which the resulting mixture was subjected to extraction with diethyl ether. The extract solution was washed with water and dried. The solvent was removed by distillation under reduced pressure and the residue was purified by a silica gel column chromatography to obtain the desired compound (601 mg).

10 ¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.20(t, 3H, J=7.3Hz), 1.54(d, 3H, J=7.3Hz),
3.80(q, 1H, J=7.3Hz), 4.05-4.19(m, 2H), 6.74
(d, 1H, J=2.3Hz), 7.24(d, 1H, J=8.6Hz), 7.45
(d, 1H, J=8.6Hz), 7.54(s, 1H), 7.61(d, 1H,
15 J=2.3Hz)

Reference Example 43

3-(1-Benzofuran-5-yl-ethyl)-isoxazol-5-ylamine



The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using the compound obtained in Reference Example 42.


¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.3Hz), 4.17(q, 1H, J=7.3Hz),

273

4.32(br-s, 2H), 4.86(s, 1H), 6.72(d, 1H, J=2.3Hz), 7.22(dd, 1H, J=8.6, 1.7Hz), 7.43(d, 1H, J=8.6Hz), 7.51(d, 1H, J=1.7Hz), 7.60(d, 1H, J=2.3Hz)

5 Reference Example 44


Ethyl 2-benzofuran-6-yl-propionate

The desired compound was obtained by the same procedure as in Reference Example 42.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

10 1.21(t, 3H, J=7.3Hz), 1.55(d, 3H, J=7.3Hz),
3.82(q, 1H, J=7.3Hz), 4.06-4.18(m, 2H), 6.74
(d, 1H, J=2.3Hz), 7.20(d, 1H, J=7.9Hz), 7.47
(s, 1H), 7.53(d, 1H, J=7.9Hz), 7.6(d, 1H, J=2.3Hz)

15 Reference Example 45

3-(1-Benzofuran-6-yl-ethyl)-isoxazol-5-ylamine

The desired compound was obtained by the same procedure as stated in the latter half of Reference


Example 20 except for using the compound obtained in Reference Example 44.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.66(d, 3H, J=7.3Hz), 4.19(q, 1H, J=7.3Hz),
 4.32(br-s, 2H), 4.87(s, 1H), 6.73(d, 1H, J=
 2.3Hz), 7.18(d, 1H, J=8.3Hz), 7.44(s, 1H),
 7.52(d, 1H, J=8.3Hz), 7.59(d, 1H, J=2.3Hz)

Reference Example 46

(S)-3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-iso-
xazol-5-ylamine



As a different method for producing the compound of Reference Example 27, the following method was carried out: Under a nitrogen atmosphere, a mixture of tetrahydrofuran (73 ml) and lithium amide (1.61 g) was heated to 68°C and tert-butyl cyanoacetate (11.1 g) was added dropwise. Thereafter, the solution was concentrated until the amount of the contents became 30 g while nitrogen was blown into the mixture, and then cooled to room temperature. Tetrahydrofuran was added thereto to adjust the amount of the contents to 50 g and then the resulting mixture was cooled to -10°C. In a separate reaction vessel, under a nitrogen atmosphere, (S)-2-(2-


fluoro-biphenyl-4-yl)-propionic acid (10.1 g, 99% e.e.) and a tetrahydrofuran solution (27 ml) of N-methylmorpholine (5.2 ml) were added dropwise to a tetrahydrofuran solution (27 ml) of isobutyl chloroformate (5.57 g) at -10°C. After 10 minutes, this solution was added dropwise to the previous mixture, and after one hour, water (202 ml) was added, after which the resulting mixture was stirred at room temperature overnight. The crystals precipitated were separated by filtration and dried under reduced pressure to obtain the desired lithium salt (13.4 g).

¹H-NMR (300 MHz, d₆-DMSO) δ ppm:

1.31(d, 3H, J=6.8Hz), 1.37(s, 9H), 4.21(q, 1H, J=6.8Hz), 7.15-7.22(m, 2H), 7.35-7.52(m, 6H).

Na₂HPO₄ (826 ml) was dissolved in water (11.6 g) and the resulting solution was adjusted to pH 8.0 with 1 N phosphoric acid, after which hydroxylamine hydrochloride (78.1 g) was added thereto. To the resulting mixture was added dropwise a solution of the lithium salt (1.40 g) obtained above in isopropanol (11.7 ml) at 80°C, and the resulting mixture was stirred for one hour, after which the temperature was returned to room temperature and water (27 ml) was added to the mixture to crystallize the desired compound. The crystals were separated by filtration and dried under reduced pressure to obtain the desired amine (875 mg, 98% e.e.).

Reference Example 47

3-(1-Quinolin-3-yl-ethyl)-isoxazol-5-ylamine


The desired compound was obtained by the same procedure as stated in the latter half of Reference

- 5 Example 20 except for using 2-quinolin-3-yl-propionic acid methyl ester [T. Sakamoto et al., Heterocycles, 36, 2509(1997)].

¹H-NMR (270 MHz, CDCl₃) δ ppm:

- 10 1.71(d, 3H, J=7.3Hz), 4.27(q, 1H, J=7.3Hz),
4.61(br-s, 2H), 4.87(s, 1H), 7.49-7.79(m, 3H),
8.01-8.09(m, 2H), 8.84(d, 1H, J=2.0Hz).

Reference Example 48

3-(1-Isoquinolin-4-yl-ethyl)-isoxazol-5-ylamine

- 15 The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using 2-isoquinolin-4-yl-propionic acid methyl ester [T. Sakamoto et al., Heterocycles, 36, 2509(1997)].


277

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.81(d, 3H, J=7.3Hz), 4.52(br-s, 2H), 4.71-
4.78(m, 2H), 7.57-7.74(m, 2H), 7.98(d, 1H,
J=7.6Hz), 8.14(d, 1H, J=8.2Hz), 8.50(s, 1H),
5 9.16(s, 1H).

Reference Example 49

Biphenyl-4-yl-dimethoxy-acetic acid methyl
ester



10 A mixture of biphenyl-4-yl-oxo-acetic acid
methyl ester (A. T. Jeffries, et al., J. Org. Chem., 46,
2885(1981)) (10 g), triethyl orthoformate (43 ml),
methanol (60 ml) and conc. sulfuric acid (3 ml) was
heated under reflux for 8.5 hours under a nitrogen
15 atmosphere. The resulting mixture was poured into a
saturated aqueous sodium bicarbonate solution and the
resulting mixture was subjected to extraction with
diethyl ether. The organic layer was washed with a
saturated aqueous sodium chloride solution, then dried
20 over sodium sulfate and thereafter concentrated under
reduced pressure, to obtain the desired compound (10.5 g).

¹H-NMR (270 MHz, CDCl₃) δ ppm:


3.31(s, 6H), 3.75(s, 3H), 7.35-7.47(m, 3H),

278

7.58-7.69(m, 6H).

Reference Example 50

3-(Biphenyl-4-yl-dimethoxy-methyl)-isoxazol-5-
ylamine




The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using the compound obtained in Reference Example 49.

10 ¹H-NMR (270 MHz, CDCl₃) δ ppm:
3.27(s, 6H), 4.38(br-s, 2H), 5.02(s, 1H), 7.31-
7.46(m, 3H), 7.56-7.67(m, 6H).

Reference Example 51

15 Dimethoxy-(1-methyl-1H-indol-2-yl)-acetic acid
methyl ester




The desired compound was obtained by the same procedure as in Reference Example 49 except for using (1-methyl-1H-indol-2-yl)-oxo-acetic acid methyl ester [F. E. Ziegler, et al., J. Amer. Chem. Soc., 95, 7146(1973)].

5 $^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

3.32(s, 6H), 3.77(s, 3H), 3.78(s, 3H), 6.85(s, 1H), 7.10-7.35(m, 3H), 7.63(d, 1H, $J=7.9\text{Hz}$).

Reference Example 52

10 3-[Dimethoxy-(1-methyl-1H-indol-2-yl)-methyl]-isoxazol-5-ylamine



The desired compound was obtained by the same procedure as stated in the latter half of Reference Example 20 except for using the compound obtained in


15 Reference Example 51.

$^1\text{H-NMR}$ (270 MHz, CDCl_3) δ ppm:

3.27(s, 6H), 3.68(s, 3H), 4.38(br-s, 2H), 4.92(s, 1H), 6.86(s, 1H), 7.08-7.31(m, 3H), 7.63(d, 1H, $J=7.9\text{Hz}$).

20 Reference Example 53

3-[1-Methyl-1-[3-(2-phenyl-[1,3]dioxolan-2-yl))-

phenyl-ethyl}-isoxazol-5-ylamine

Ketoprofen (10 g) was dissolved in N,N-dimethylformamide (50 ml) under a nitrogen atmosphere. To the solution was added sodium hydride (3.95 g, 60% oily), followed by stirring. Thirty minutes after the stirring, methyl iodide (6.1 ml) was added thereto, followed by stirring for 10 hours. To the reaction solution were added an ice water and a saturated aqueous sodium hydrogencarbonate solution, followed by extraction with ethyl acetate. The extract solution was washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate and then concentrated under reduced pressure to obtain the residue (12.78 g).

The part of the residue was dissolved in benzene (100 ml), and to the resulting solution were added ethyleneglycol (10 ml) and p-toluenesulfonic acid (10 g), followed by dehydration under reflux for 200 hours. To the resulting solution was added a saturated aqueous sodium hydrogencarbonate, followed by extraction with ethyl acetate. The extract solution was washed with

a saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure to obtain the residue (9.30 g).

The part (1.0 g) of the residue was dissolved
5 in methanol (10 ml), and to the resulting solution was added 10% aqueous potassium hydroxide solution (10 ml), followed by stirring for 10 hours. The reaction solution was concentrated to distill off methanol. To the resulting product was added 2N hydrochloric acid,
10 followed by extraction with ethyl acetate. The extract solution was washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated under reduced pressure to obtain the residue (0.56 g).

15 On the other hand, tetrahydrofuran (10 ml) was added to sodium hydride (220 mg, 60% oily), and then tert-butyl cyanoacetate (0.76 ml) was added dropwise thereto under ice-cooling under a nitrogen atmosphere. Then, the resulting mixture was stirred under ice-cooling
20 to obtain the sodium salt of tert-butyl cyanoacetate.

On the other hand, a solution of the residue
(0.56 g) obtained hereinbefore and N-methylmorpholine
(0.24 ml) in tetrahydrofuran (5 ml) was added dropwise to a solution of isopropyl chloroformate (0.26 ml) in
25 tetrahydrofuran (5 ml) under stirring at -15°C. Thirty minutes after the stirring, to the resulting solution was added dropwise the sodium salt of tert-butyl cyanoacetate obtained hereinbefore. One hour after, to the resulting

mixture was added a saturated aqueous sodium hydrogencarbonate solution, followed by extraction with ethyl acetate. The extract solution was dried over sodium sulfate, and concentrated under reduced pressure
5 to obtain the viscous residue.

To the residue were added hydroxylamine hydrochloride (500 mg), ethanol (16 ml) and pyridine (4 ml), followed by stirring for 4 hours at 50°C. After the reaction solution was cooled to the room temperature,
10 ethanol was distilled off to obtain the residue. To the residue was added a saturated aqueous sodium hydrogencarbonate solution, followed by extraction with ethyl acetate. The extract was dried over sodium sulfate, and concentrated under reduced pressure to obtain the
15 residue.


The residue was purified by a silica gel column chromatography to obtain the desired compound (37.9 mg).

¹H-NMR (300 MHz, CDCl₃) δ ppm:

1.66(s, 6H), 4.05(s, 4H), 4.26(br-s, 2H),
20 4.73(s, 1H), 7.21-7.60(m, 9H)

Reference Example 54

2-(6-Phenyl-pyridin-3-yl)-propionic acid methyl ester




The desired compound was obtained from 5-bromo-2-phenylpyridine (J. W. Tilley, et al., J. Org. Chem., 53,386 (1988)) by the known method described in T. Sakamoto, et al., Heterocycles, 36, 2509 (1993).

5 ¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.57(d, 3H, J=7.3Hz), 3.67(s, 3H), 3.80(q, 1H, J=7.3Hz), 7.41-7.50(m, 3H), 7.71-7.72(m, 2H), 7.97(d, 2H, J=6.6Hz), 8.61(s, 1H)

Reference Example 55

10 3-[1-(6-Phenyl-pyridin-3-yl)-ethyl]-isoxazol-5-ylamine



The desired compound was obtained from the compound obtained in Reference Example 54 by the same procedure as that described in the latter half of


15 reference Example 20.

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.67(d, 3H, J=7.3Hz), 4.14(q, 1H, J=7.3Hz), 4.43(br-s, 2H), 4.91(s, 1H), 7.40-7.49(m, 3H), 7.70(m, 2H), 7.96(dd, 2H, J=8.3, 1.7Hz), 8.63(s, 1H)

Reference Example 56

2-(5-Phenyl-pyridin-2-yl)-propionic acid methyl

ester

The desired compound was obtained from 2-bromo-5-phenylpyridine (M.G. Knize, et al., Heterocycles, 24, 1815 (1986)) by the known method described in T.


5 Sakamoto, et al., Heterocycles, 36, 2509 (1993).

¹H-NMR (270 MHz, CDCl₃) δ ppm:

1.61(d, 3H, J=7.3Hz), 3.72(s, 3H), 4.01(q, 1H, J=7.3Hz), 7.34-7.59(m, 6H, 7.85 (dd, 1H, J=8.2, 2.3Hz), 8.78(d, 1H, J=2.3Hz)

10 Reference Example 57

3-[1-(5-Phenyl-pyridin-2-yl)-ethyl]-isoxazol-5-ylamine



The desired compound was obtained from the compound obtained in Reference Example 56 by the same procedure as that described in the latter half of Reference Example 20.

¹H-NMR (270 MHz, CDC₃) δ mmp:

1.71(d, 3H, J=7.3Hz), 4.30(q, 1H, J=7.3Hz), 4.39(br-s, 2H), 5.08(s, 1H), 7.32-7.57(m, 6H),

7.81(dd, 1H, J=8.3Hz, 2.3Hz), 8.79(d, 1H, J=2.3Hz).

Test Example 1

Inhibition of adjuvant-induced arthritis

Male SD rats were used as test subjects. Heat-killed *Mycobacterium butyricum* suspended in liquid paraffin in a concentration of 0.5% was subcutaneously injected into the right hind paw of each rat. After 17 days, animals showing the clear onset of secondary inflammation also in the left hind paw were selected, and each compound of the present invention suspended in a 0.5% methyl cellulose solution was orally administered to these animals for 5 consecutive days. The volume of each hind paw at the completion of the administration was compared with that at the beginning of the administration, and the swelling-inhibitory effect was evaluated by the difference between them. The results are shown in Table 1, Table 2 and Table 3.

Table 1

Compound administered	Oral dose (mg/kg)	Number of animals	Increase of edema volume (ml)	
			Injected paw	Non-injected paw
Control	-	8	0.29	0.39
Compound of Example 19	25	8	-1.05	-0.55
Compound of Example 20	25	9	-0.63	-0.40
Indomethacin	0.5	9	-1.19	-0.77

Table 2

Compound administered	Oral dose (mg/kg)	Number of animals	Increase of edema volume (ml)	
			Injected paw	Non-injected paw
Control	-	9	0.86	0.33
Compound of Example 17	25	9	-0.01	-0.24
Compound of Example 18	25	9	-0.48	-0.49
Indomethacin	0.5	9	-1.51	-1.05

Table 3

Compound administered	Oral dose (mg/kg)	Number of animals	Increase of edema volume (ml)	
			Injected paw	Non-injected paw
Control	-	10	0.01	0.00
Compound of Example 87	25	10	-0.35	-0.24
Indomethacin	0.5	10	-0.45	-0.40

Test Example 2

Inhibition of allergic reaction type III

Male BALB/c mice were used as test subjects. A suspension prepared by suspending sheep red blood cells in physiological saline to a concentration of 20% was intravenously injected into the tail of each mouse, and after 14 days, this procedure was repeated to immunize the animal. After another 5 days, a 100% sheep red blood cell suspension was subcutaneously injected into the right hind paw of each mouse to cause type III allergy, and 3 hours after the injection, the thicknesses of the right and left hind paws were

measured. The efficacy of drugs was evaluated by taking the difference between the thicknesses of the right and left hind paws as edema volume. Each compound of the present invention was suspended in a 0.5% methyl cellulose solution and orally administered 24 hours before and 1 hour after the induction of inflammatory reaction. Table 4 shows the edema inhibition rate calculated by comparing the edema volume of a group to which the compound was administered with that of a control group.

Table 4

Compound administered	Oral dose (mg/kg)	Number of animals	Edema inhibition rate (%)
Compound of Example 17	10	13	13.6
Compound of Example 18	50	13	18.4
Levamisole	50	13	28.9

Test Example 3

Action on experimental allergic
encephalomyelitis

The medical effect of a compound was evaluated
5 using experimental allergic encephalomyelitis in mice,
which is one of animal models of multiple sclerosis.
Experimental allergic encephalomyelitis was caused
according to the method described by Bell et al. (J.
Immunology, 150: 4085 - 4092, 1993). Briefly, 200 µg of
10 a myelin basic protein (prepared from rabbit brain,
sigma) mixed with the Freund's complete adjuvant was
subcutaneously injected into the thigh of a 8-week older,
female (PL x SJL) F1 mouse (Jackson Laboratories, Bar
Harbor, ME). On the sensitization day and 2 days
15 thereafter, 200 ng of pertussis toxin (List Biological
Laboratories, Campbell, CA) was intraperitoneally
injected. The degree of grave-ness of symptom is
indicated by score according to the following criterion:

- 1: tail paralysis
- 20 2: mild hind limb weakness
- 3: hind limb paralysis and/or mild
forelimb weakness
- 4: complete hind limb paralysis and/or moderate
to severe forelimb weakness
- 25 5: quadriplegia or moribund
- 6: Death

The compound of this invention was suspended in
a 0.5% methylcellulose solution and orally administered

in a proportion of 0.1 ml/10 g of body weight. The control group was orally administered only a 0.5% methyl cellulose solution. The administration was started from the sensitization day and effected once per day
5 successively for 42 days.

The results obtained are shown in Fig. 1. In the mice in the control group, severe experimental allergic encephalomyelitis was caused and all animals (10 mice) were died owing to neuroparalysis during the test
10 period. On the other hand, in the mice treated with the compound of Example 22 (50 mg/kg), experimental allergic encephalomyelitis was also caused, though the symptom was light, and 3 mice of the 10 mice were died.

As described above, the isoxazole derivatives
15 and the like of the present invention are markedly effective in test systems including animal models of chronic inflammation (e.g. rat adjuvant-induced arthritis, etc.), animal models of immune disorder (e.g. mouse allergic reaction type III, etc.), experimental
20 allergic encephalomyelitis mice (e.g. multiple sclerosis, etc.), etc. Therefore, the isoxazole derivatives and the like of the present invention are clearly effective
against chronic inflammation and moreover act on immune disorders responsible for the chronic inflammation.
25 Thus, the isoxazole derivatives and the like of the present invention are effective also against autoimmune diseases such as rheumatoid arthritis and inflammatory diseases.

Preparation Example 1

Production of tablet

Tablets can be produced by mixing all the ingredients and, if necessary, after subjecting the mixture to granulation, tableting the same.

		Amount (mg/tablet)
	Compound of Example 85	20
	Lactose	70
	Corn starch	17
10	Low substituted hydroxypropylcellulose	8
	Hydroxypropylcellulose	4
	Magnesium stearate	1
	Total	120 mg

Preparation Example 2

15 Production of tablet

Tablets can be produced by mixing all the ingredients, and, if necessary, after subjecting the mixture to granulation, tableting the same.

		Amount (mg/tablet)
20	Compound of Example 43	20
	D-Mannitol	60
	Dibasic calcium phosphate	25
	Carmellose calcium	8
	Hydroxypropylmethylcellulose	4
25	Talc	3
	Total	120 mg

Preparation Example 3

Production of capsule

A capsule preparation can be produced by mixing all the ingredients and, if necessary, after granulating the mixture, filling a capsule with the same.

	Amount (mg/capsule)
Compound of Example 69	20
Lactose	150
Corn starch	40
10 Low substituted hydroxypropylcellulose	8
Magnesium stearate	2
Total	220 mg

Preparation Example 4

Production of capsule

15 A capsule preparation can be produced by mixing all the ingredients and, if necessary, after granulating the mixture, filling a capsule with the same.

	Amount (mg/capsule)
Compound of Example 72	20
20 D-Mannitol	123.5
Carmellose calcium	5
Magnesium stearate	1.5
Total	150 mg

Preparation Example 5

25 Production of powder

A powder was produced by mixing all the

ingredients and, if necessary, granulating the mixture.

	Amount (mg/1 g)
Compound of Example 74	40
Lactose	750
5 Corn starch	200
Magnesium stearate	10
Total	1,000 mg

Preparation Example 6

Production of powder

- 10 A powder can be produced by mixing all the ingredients and, if necessary, granulating the mixture.


	Amount (mg/1 g)
Compound of Example 107	40
D-Mannitol	700
15 Corn starch	200
Magnesium stearate	10
Total	1,000 mg

- The isoxazole derivatives and pharmaceutically acceptable salts thereof of the present invention are
-
- 20 useful as therapeutic or prophylactic drugs for autoimmune diseases [e.g. rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, Sjögren's syndrome, Hashimoto's disease, myasthenia gravis, Basedow's disease, Addison's disease, juvenile diabetes
- 25 (type I diabetes), autoimmune hemodyscrasias (e.g. hypoplastic anemia, hemolytic anemia, and idiopathic

thrombocytopenia, etc.), ulcerative colitis, active
chronic hepatitis, glomerular nephritis, interstitial
pulmonary fibrosis, multiple sclerosis, etc.] and
inflammatory diseases (e.g. osteoarthritis, gout, atopic
5 dermatitis, and psoriasis, etc.).

CLAIMS


1. An isoxazole derivative represented by the formula 1:



wherein D is a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxyl-amino group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a sulfo group, $-R^5$, $-OR^5$, $-CO_2R^6$, $-SR^7$, $-(CO)SR^7$, $-(CS)OR^7$ or $-CS_2R^7$ wherein R^5 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, or an acyl group, R^6 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and R^7 is a substituted or unsubstituted alkyl group, or a substituted

or unsubstituted aryl group;

one of A and B is a group represented by the formula:



wherein E is a single bond or an alkylene group;

one of the two broken lines represents a double bond together with the solid line, while the other represents a single bond together with the other solid line. R¹ is bonded to the nitrogen atom bonded through the single bond represented by the broken line and the solid line; and

R¹, R², R³ and R⁴ are independently a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a sulfo group, a protecting group for NH group, -R⁵, -OR⁵, -CO₂R⁶, -SR⁷, -(CO)SR⁷, -(CS)OR⁷ or -CS₂R⁷ wherein R⁵, R⁶ and R⁷ are as defined above, any two of R¹, R², R³ and R⁴ may be taken together with the nitrogen atom(s) to form a substituted or unsubstituted heterocyclic ring; and the

formula: $-NR^3R^4$ may be a group represented by the following formula: $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined in (1) or (2)

(1) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms; $-(CH_2)_n-COCH_3$, wherein n represents an integer of 1 to 3; $-(CH_2)_n-CO_2R^{32}$ wherein n is as defined above and R^{32} represents an alkyl group having 1 to 3 carbon atoms; $-(CH_2)_n-CONR^{33}R^{34}$ wherein n is as defined above and R^{33} and R^{34} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms; $-(CH_2)_m-OR^{35}$ wherein m represents 2 or 3 and R^{35} represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms or $-(CH_2)_m-OR^{36}$ wherein m is as defined above and R^{36} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; $-(CH_2)_m-NR^{37}R^{38}$ wherein m is as defined above and R^{37} and R^{38} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms, or when taken together with the nitrogen atom, represent pyrrolidine, piperidine, azepane, morpholine or N-methylpiperazine wherein said pyrrolidine, piperidine, azepane, morpholine and N-methylpiperazine may be substituted with one or two methyl groups; a phenyl group; a pyridyl group; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a hydroxyl group; an alkoxy group

having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} represent independently hydrogen atoms, alkyl groups having 1 to 3 carbon atoms, phenyl groups or pyridyl groups;

(2) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; and

the other of A and B is a group represented by the formula: $-J-G$

wherein G is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and J is $-C(R^8R^9)-$ or $-C(=CR^8R^9)-$ wherein R^8 and R^9 are independently a hydrogen atom, a substituted or unsubstituted lower alkoxy group, or a substituted or unsubstituted lower alkyl group. R^8 and R^9 may be taken together with the carbon atom to form a substituted or unsubstituted hydrocarbon ring, a substituted or unsubstituted 1,3-dioxane, or a substituted or unsubstituted 1,3-dioxalane, or a pharmaceutically acceptable salt thereof.

2. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein E is a single bond or a lower alkylene.

3. An isoxazole derivative or a pharmaceutically

acceptable salt thereof according to claim 1 or 2, wherein D is a hydrogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxyl-amino group, a substituted or unsubstituted carbamoyl group, $-R^5$ or $-CO_2R^6$ wherein R^5 and R^6 are as defined in claim 1.

4. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to claim 3, wherein D is a hydrogen atom, a carboxyl group, $-R^5$ or $-CO_2R^6$ wherein R^5 and R^6 are as defined in claim 1.

5. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to any of claims 1 to 4, wherein R^1 , R^2 , R^3 and R^4 are independently a hydrogen atom, a hydroxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; and the formula: $-NR^3R^4$ may be a group represented by the following formula: $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined in Claim 1; or any two of R^1 , R^2 , R^3 and R^4 may be taken together with the nitrogen atom(s) to form a


substituted or unsubstituted heterocyclic ring.

6. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to claim 5, wherein R^1 , R^2 , R^3 and R^4 are independently a hydrogen atom, a hydroxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydroxylamino group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, or a substituted or unsubstituted cycloalkyl group; and the formula: $-NR^3R^4$ may be a group represented by the following formula: $-N=C(NH_2)NR^{43}R^{44}$ wherein R^{43} and R^{44} are as defined in Claim 1; or any two of R^1 , R^2 , R^3 and R^4 may be taken together with the nitrogen atom(s) to form a substituted or unsubstituted heterocyclic ring.

7. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to any of claims 1 to 6, wherein G is a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, a substituted or unsubstituted furyl, a substituted or unsubstituted thienyl, a substituted or unsubstituted indolyl, a substituted or unsubstituted isothiazolyl, a substituted or unsubstituted benzothienyl, a substituted or unsubstituted isobenzofuranyl, a substituted or unsubstituted pyrrolyl, a substituted or unsubstituted benzofuryl, a substituted or unsubstituted imidazolyl, a substituted or unsubstituted pyrazolyl, a

substituted or unsubstituted isoxazolyl, a substituted or unsubstituted isothiazolyl, a substituted or unsubstituted thiazolyl, a substituted or unsubstituted oxazolyl, a substituted or unsubstituted benzimidazolyl, a substituted or unsubstituted benzothiazolyl, a substituted or unsubstituted benzoxazolyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted pyrazinyl, a substituted or unsubstituted pyrimidinyl, a substituted or unsubstituted pyridazinyl, a substituted or unsubstituted triazinyl, a substituted or unsubstituted quinolyl, a substituted or unsubstituted isoquinolyl, a substituted or unsubstituted quinazolinyl, a substituted or unsubstituted quinoxalinyl, a substituted or unsubstituted 2,3-dihydrobenzo[1,4]dioxinyl, or a substituted or unsubstituted carbazolyl.

8. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to Claim 1, which is represented by the formula:



wherein G¹ represents phenyl, biphenyl-4-yl, 3-benzoylphenyl, 4-benzoylphenyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-indol-2-yl, 1-methyl-1H-indol-3-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, quinolyl, isoquinolyl, phen-ylpyridyl,

phenylpyrimidinyl, phenylpyridazinyl or phen-ylpyrazinyl wherein said phenyl, biphenyl-4-yl, 3-benzoylphenyl, 4-benzoylphenyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-indol-2-yl, 1-methyl-1H-indol-3-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, quinolyl, isoquinolyl, phenylpyridyl, phenylpyrimidinyl, phenylpyridazinyl and phenylpyrazinyl may be substituted with one or two groups arbitrarily selected from the group consisting of fluorine atom, chlorine atom, bromine atom, acetyl, cyano, $-\text{CO}_2\text{R}^{29}$ wherein R^{29} represents an alkyl group having 1 to 3 carbon atoms and $-\text{CONR}^{30}\text{R}^{31}$ wherein R^{30} and R^{31} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms;

R^{23} and R^{24} represent independently hydrogen atoms, alkyl groups having 1 to 4 carbon atoms, methoxy or ethoxy, or when taken together, form a methylene group; and the formula: $=\text{C}(\text{NR}^{25}\text{R}^{26})\text{NR}^{27}\text{R}^{28}$ is as defined in the following (1), (2) or (3):

(1) R^{25} and R^{26} are as defined in the following (a) or (b) and R^{27} and R^{28} are as defined in the following (c) or (d):

(a) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms; $-(\text{CH}_2)_n-\text{COCH}_3$ wherein n is as defined in Claim 1; $-(\text{CH}_2)_n-\text{CO}_2\text{R}^{32}$ wherein n and R^{32} are as defined in Claim 1; $-(\text{CH}_2)_n-\text{CONR}^{33}\text{R}^{34}$ wherein n, R^{33} and R^{34} are as defined in Claim 1; $-(\text{CH}_2)_m-\text{OR}^{35}$ wherein m and R^{35} are as defined in

Claim 1; $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined in Claim 1; a phenyl; a pyridyl; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined in Claim 1;

(b) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;


(c) each represents independently a hydrogen atom; an alkyl group having 1 to 4 carbon atoms; $-(CH_2)_n-COCH_3$ wherein n is as defined above; $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above; $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above; $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above; $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above; a phenyl group; a pyridyl group; a pyrimidinyl group; a pyridazinyl group; a pyrazinyl group; a tetrazolyl group; a benzyl group; a pyridylmethyl group; a pyrimidinylmethyl group; a pyridazinylmethyl group; a pyrazinylmethyl group; a tetrazolylmethyl group; a

hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

(d) when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

(2) when taken together, R^{26} and R^{27} form with the two nitrogen atoms and the one carbon atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; and R^{25} and R^{28} represent independently hydrogen atoms, alkyl groups having 1 to 3 carbon atoms, acetyl or $-(CH_2)_m-OR^{36}$ wherein m and R^{36} are as defined above, R^{36} is as defined in Claim 1;

(3) the formula: $=C(NR^{25}R^{26})NR^{27}R^{28}$ is a group—
represented by the following formula:



wherein R^{41} and R^{42} are as defined in the following (a') or (b'); and R^{43} and R^{44} are as defined in the following (c') or (d'):

(a') each represents independently a


hydrogen atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-COCH_3$, wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a tetrazolyl group, a benzyl group, a pyridylmethyl group, a pyrimidinylmethyl group, a pyridazinylmethyl group, a pyrazinylmethyl group, a tetrazolylmethyl group, a hydroxyl group, an alkoxy group having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

(b') when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

(c') each represents independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-COCH_3$, wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above, a phenyl

group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a tetrazolyl group, a benzyl group, a pyridylmethyl group, a pyrimidinylmethyl group, a pyridazinylmethyl group, a pyrazinylmethyl group, a tetrazolylmethyl group, a hydroxyl group, an alkoxy group having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

(d') when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; or represented by the formula:



wherein G^1 , R^{23} and R^{24} are as defined above; the formula:

$-N(R^{45})C(NR^{46}R^{47})=NR^{48}$ is as defined in the following (1')

or (2'):

(1') R^{45} represents an alkyl group having 1 to 3 carbon atoms or an acetyl group; R^{48} represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms or an acetyl group; and R^{46} and R^{47} are as defined in the

following (a") or (b"):


(a") each represents independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, $-(CH_2)_n-COCH_3$, wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n, R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, $-(CH_2)_m-NR^{37}R^{38}$ wherein m, R^{37} and R^{38} are as defined above, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a tetrazolyl group, a benzyl group, a pyridylmethyl group, a pyrimidinylmethyl group, a pyridazinylmethyl group, a pyrazinylmethyl group, a tetrazolylmethyl group, a hydroxyl group, an alkoxy group having 1 to 3 carbon atoms or $-NR^{39}R^{40}$ wherein R^{39} and R^{40} are as defined above;

(b") when taken together, they form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group;

(2') when taken together, R^{45} and R^{46} form with the nitrogen atom a 5- to 7-membered saturated nitrogen-containing heterocyclic group wherein said 5- to 7-membered saturated nitrogen-containing heterocyclic group may be substituted with one or two substituents

arbitrarily selected from the group consisting of alkyl group, amino group, hydroxyl group, alkoxy group and oxo group; and R^{47} and R^{48} represent independently alkyl groups having 1 to 3 carbon atoms, acetyl groups or $-(CH_2)_m-OR^{36}$ wherein m and R^{36} are as defined above;

9. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to Claim 1, which is represented by the formula:



wherein G^2 represents 2-fluoro-biphenyl-4-yl, 2'-fluoro-biphenyl-4-yl or 3-benzoyl-phenyl; R^{49} represents methyl; R^{50} represents hydrogen, methyl, methoxy or ethoxy; and the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is as defined in the following (1''), (2'') or (3''):

(1'') R^{51} and R^{52} are as defined in the following (a''), (b'') or (c'') and R^{53} and R^{54} are as defined in the following (d''), (e'') or (f''):

(a'') each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(b'') one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$, wherein n is as defined in Claim 1, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined in Claim 1, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined in Claim 1, $-(CH_2)_m-OR^{35}$ wherein m and

R^{35} are as defined in Claim 1, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined in Claim 1;

(c'") when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups;

(d'") each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;


(e'") one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are

as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above;

(f'") when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups;


(2") the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is a group represented by the following formula:

312



wherein R^{55} represents an alkyl group having 1 to 3 carbon atom, acetyl or $-(CH_2)_m-OR^{56}$ wherein m is as defined above and R^{56} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms;

(3") the formula: $=C(NR^{51}R^{52})NR^{53}R^{54}$ is a group represented by the following formula:



wherein R^{57} and R^{58} are as defined in the following (a""), (b""), or (c ""); and R^{59} and R^{60} are as defined in the following (d""), (e""), or (f ""):

(a "") each represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(b "") one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$, wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n , R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m , R^{37} and R^{38} are as defined above;

(c "") when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperi-

dine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups;


(d'') each represents independently a hydrogen atom or an alkyl group having 1 to 4 carbon atoms;

(e'') one of them represents a hydrogen atom and the other represents $-(CH_2)_n-COCH_3$ wherein n is as defined above, $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined above, $-(CH_2)_n-CONR^{33}R^{34}$ wherein n, R^{33} and R^{34} are as defined above, $-(CH_2)_m-OR^{35}$ wherein m and R^{35} are as defined above, or $-(CH_2)_m-NR^{37}R^{38}$ wherein m, R^{37} and R^{38} are as defined above;

(f'') when taken together, they form with the nitrogen atom pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position

with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, or piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms wherein said pyrrolidine, azepane, morpholine, thiazoline, piperidin-2-one, piperidin-4-one, thiamorpholine, piperazine which may be substituted in the 4-position with an alkyl group having 1 to 3 carbon atoms, piperidine which may be substituted in the 4-position with an alkoxy group having 1 to 3 carbon atoms, 4-hydroxy-piperidine, and piperidine substituted in the 4-position with an amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, may be substituted with one or two methyl groups.

10. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to Claim 1, which is represented by the formula:



wherein G^2 , R^{49} and R^{50} are as defined in Claim 9; the formula: $=C(NR^{61}R^{62})NR^{63}R^{64}$ is as defined in the following (1'"), (2'") or (3'"):

(1'") R^{63} and R^{64} both represent hydrogen atoms; and R^{61}


and R^{62} are as defined in the following (a^v), (b^v) or (c^v):

(a^v) each represents independently a hydrogen atom or an alkyl group having 1 to 3 carbon atoms;

(b^v) one of them represents a hydrogen atom and the other represents $-(CH_2)_n-CO_2R^{32}$ wherein n and R^{32} are as defined in Claim 1; $-(CH_2)_m-OR^{65}$ wherein m is 2 or 3 and R^{65} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, 2-hydroxyethyl or 3-hydroxypropyl; or $-(CH_2)_m-NR^{66}R^{67}$ wherein m is as defined above and R^{66} and R^{67} represent independently hydrogen atoms or alkyl groups having 1 to 3 carbon atoms or, when taken together, form with the nitrogen atom pyrrolidine, piperidine, morpholine, or N-methylpiperazine wherein said pyrrolidine, piperidine, morpholine and N-methylpiperazine may be substituted with one or two methyl groups;

(c^v) when taken together, they form with the nitrogen atom pyrrolidine, piperidine, morpholine or N-methylpiperazine wherein said pyrrolidine, piperidine, morpholine and N-methylpiperazine may be substituted with one or two methyl groups;

(2'") the formula: $=C(NR^{61}R^{62})NR^{63}R^{64}$ is a group represented by the following formula:



wherein R^{68} represents an alkyl group having 1 to 3

carbon atoms, 2-hydroxyethyl or 3-hydroxypropyl.

(3'") when taken together, R⁶¹ and R⁶² form morpholine with the nitrogen atom; and when taken together, R⁶³ and R⁶⁴ form amino-morpholin-4-yl-methylene.

11. An isoxazole derivative or a pharmaceutically acceptable salt thereof according to Claim 1, which is selected from the group consisting of the following compounds:

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl)-amine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl)-amine;

N-{3-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl)-amine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(({3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-morpholin-4-yl-methyl)-amine;

[{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-ylimino}-(4-methyl-piperazin-1-yl)-methyl]-amine;

N-{3-[1-(2'-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-ethyl}-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl}-ethyl)-phenyl]-phenyl-methanone;

N-{3-[1-(3-Benzoyl-phenyl)-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine;

(3-{1-[5-(Amino-morpholin-4-yl-methyleneamino)-isoxazol-3-yl]-1-methyl-ethyl}-phenyl)-phenyl-methanone;

[3-(1-{5-[Amino-(4-methyl-piperazin-1-yl)-methyleneamino]-isoxazol-3-yl}-1-methyl-ethyl)-phenyl]-phenyl-methane;

N-{3-[1-(3-Benzoyl-phenyl)-1-methyl-ethyl]-isoxazol-5-yl}-N'-(2-morpholin-4-yl-ethyl)-guanidine.

12. A pharmaceutical composition comprising as an active ingredient an isoxazole derivative or a pharmaceutically acceptable salt thereof according to any one of claim 1 to 11, together with a pharmaceutically

acceptable carrier.

13. A pharmaceutical composition according to claim 12, which is for the treatment or prophylaxis of autoimmune diseases.

14. A pharmaceutical composition according to claim 12, which is for the treatment or prophylaxis of inflammatory diseases.

15. A pharmaceutical composition according to claim 12, which is an antirheumatic drug.


16. A pharmaceutical composition according to claim 12, which is an anti-inflammatory drug.

17. A method for treating or preventing autoimmune diseases or inflammatory diseases, which comprises administering an isoxazole derivative or a pharmaceutically acceptable salt according to any one of according to claims 1 to 11 in an effectively amount to a human body.

18. Use of an isoxazole derivative or a pharmaceutically acceptable salt according to any one of according to claims 1 to 11 in the manufacture of a medicament for the treatment or prophylaxis of autoimmune diseases or inflammatory diseases.

1 / 1

FIG. 1



INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/01770

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D261/14 C07D261/08 C07D413/12 C07D417/12 C07D413/14 A61K31/42		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 248 399 A (SUMITOMO PHARMA) 9 December 1987 cited in the application see page 3, lines 1-3; pages 15, 24, 43-45.	1-16, 18
Y	FR 2 478 634 A (EGYT GYOGYSZERVEGYESZETI GYAR) 25 September 1981 see page 4, compound Ic; page 7, compound If; page 24, lines 1-4.	1-16, 18
Y	FR 2 068 418 A (INNOTHERA LAB SA) 27 August 1971 see page 12; claims	1-16, 18
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
16 July 1998		27.07.98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Frelon, D

INTERNATIONAL SEARCH REPORT

II. International Application No
PCT/JP 98/01770

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PATENT ABSTRACTS OF JAPAN vol. 017, no. 462 (C-1101), 24 August 1993 & JP 05 112564 A (OTSUKA PHARMACEUT. FACTORY INC.) see abstract -& JP 05 112 564 A see page 16 ---	1-16,18
A	EP 0 091 726 A (SUMITOMO CHEMICAL CO) 19 October 1983 see abstract; claims ---	1-16,18
A	EP 0 188 333 A (SYNTEX INC) 23 July 1986 see abstract ---	1-16,18
A	FR 2 100 914 A (SQUIBB & SONS INC) 24 March 1972 see page 3; claims ---	1-16,18
A	DE 23 41 507 A (THOMAE GMBH DR K) 27 February 1975 see page 11, compounds VIII; page 31 ---	1-16,18
A	PATENT ABSTRACTS OF JAPAN vol. 004, no. 007 (C-070), 19 January 1980 & JP 54 144347 A (NIKKEN KAGAKU K.K.) see abstract ---	1-16,18
A	FR 2 128 505 A (SMITH KLINE FRENCH LAB) 20 October 1972 see claims -----	1-16,18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 98/01770

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 17
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds defined by the general definition in the claims, and considering the unclear and/or unlimited expressions like "substituted", "alkyl", "alkenyl", "alkynyl", "aryl", "heterocyclic", "acyl", etc, and derivatives thereof, which do not allow to specify the scope for which a protection is sought, the search had to be restricted to the scope as illustrated by the prepared compounds and to the general idea underlying the application (i.e., compounds of formula 1 wherein D is a hydrogen atom and E is a single bond or a methylene link which form the common concept of the invention as presently claimed) (see Guidelines, Chapter III, paragraph 2.3).

INTERNATIONAL SEARCH REPORT

Information on patent family members

h. International Application No

PCT/JP 98/01770

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0248399 A	09-12-1987	JP 1791563 C	14-10-1993
		JP 4080035 B	17-12-1992
		JP 63152368 A	24-06-1988
		JP 5247014 A	24-09-1993
		US 4914112 A	03-04-1990
		US 5066666 A	19-11-1991
		US 5180731 A	19-01-1993
FR 2478634 A	25-09-1981	BE 887954 A	16-09-1981
		CA 1163631 A	13-03-1984
		CH 646157 A	15-11-1984
		DE 3110817 A	04-03-1982
		DK 23087 A,B,	16-01-1987
		DK 23187 A,B,	16-01-1987
		DK 122581 A,B,	20-09-1981
		FI 810838 A,B,	20-09-1981
		FI 852926 A,B,	26-07-1985
		FI 852927 A,B,	26-07-1985
		GB 2075009 A,B	11-11-1981
		JP 56158774 A	07-12-1981
		SE 454695 B	24-05-1988
		SE 8101703 A	20-09-1981
		SU 1053750 A	07-11-1983
		SU 1152518 A	23-04-1985
		SU 1158044 A	23-05-1985
FR 2068418 A	27-08-1971	NONE	
EP 0091726 A	19-10-1983	JP 58150576 A	07-09-1983
		AU 560436 B	09-04-1987
		AU 1148383 A	08-09-1983
		CA 1293249 A	17-12-1991
		DE 3378534 A	29-12-1988
		US 4618617 A	21-10-1986
EP 0188333 A	23-07-1986	US 4680300 A	14-07-1987
		AU 5216586 A	17-07-1986
		DK 10086 A	11-07-1986
		JP 61191668 A	26-08-1986

INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/JP 98/01770

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2100914 A	24-03-1972	CA 918158 A CH 522670 A DE 2124907 A GB 1322451 A US 3720685 A	02-01-1973 15-05-1972 20-01-1972 04-07-1973 13-03-1973
DE 2341507 A	27-02-1975	AT 338771 B AT 338772 B AT 335430 B AT 334888 B AT 334889 B AT 335431 B AT 336003 B AT 335432 B AT 335433 B AT 336590 B AT 335434 B AT 335435 B AT 335436 B AT 336591 B AT 335437 B AT 336004 B AT 331235 B AU 7243074 A BE 818952 A DD 114590 A DK 433674 A FI 238974 A FR 2240722 A GB 1445283 A JP 50049262 A NL 7410292 A SE 7410436 A ZA 7405257 A	12-09-1977 12-09-1977 10-03-1977 10-02-1977 10-02-1977 10-03-1977 12-04-1977 10-03-1977 10-03-1977 10-05-1977 10-03-1977 10-03-1977 10-03-1977 10-05-1977 10-03-1977 12-04-1977 10-08-1976 19-02-1976 17-02-1975 12-08-1975 28-04-1975 17-02-1975 14-03-1975 11-08-1976 01-05-1975 18-02-1975 17-02-1975 28-04-1976
FR 2128505 A	20-10-1972	GB 1338169 A GB 1395929 A US 3950333 A US 4022797 A AR 197080 A	21-11-1973 29-05-1975 13-04-1976 10-05-1977 15-03-1974

INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/JP 98/01770

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2128505 A		AR 197093 A	15-03-1974
		AU 460353 B	24-04-1975
		AU 3900972 A	16-08-1973
		BE 779775 A	24-08-1972
		CA 949967 A	25-06-1974
		CH 576478 A	15-06-1976
		CH 578583 A	13-08-1976
		CH 578584 A	13-08-1976
		CS 168580 B	29-06-1976
		CY 856 A	10-09-1976
		DE 2211454 A	05-10-1972
		DE 2265369 B	26-04-1979
		DK 139870 B	07-05-1979
		DK 349776 A,B,	03-08-1976
		DK 580278 A,B,	22-12-1978
		EG 10876 A	31-07-1976
		FI 60393 B	30-09-1981
		FI 763443 A,B,	30-11-1976
		FI 791116 A,B,	04-04-1979
		HK 55176 A	17-09-1976
		JP 1177631 C	14-11-1983
		JP 57009765 A	19-01-1982
		JP 58007631 B	10-02-1983
		JP 54059275 A	12-05-1979
		JP 50105664 A	20-08-1975
		JP 52043832 B	02-11-1977
		JP 917249 C	15-08-1978
		JP 50105665 A	20-08-1975
		JP 52043833 B	02-11-1977
		JP 1144670 C	26-04-1983
		JP 53119867 A	19-10-1978
		JP 57032063 B	08-07-1982
		JP 1211275 C	12-06-1984
		JP 53119868 A	19-10-1978
		JP 57042068 B	07-09-1982
		JP 1181997 C	09-12-1983
		JP 53119869 A	19-10-1978
		JP 58011948 B	05-03-1983
		KE 2625 A	28-05-1976
		NL 7203145 A,B,	12-09-1972

International Application No
PCT/JP 98/01770

Form PCT/ISA/210 (patent family annex) (July 1992)